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is important that the medical profession play a significant role
critically evaluating the use of diagnostic procedures and
erapies as they are introduced and tested in the detection,
anagement, or prevention of disease states. Rigorous and pepert analysis of the available data documenting absolute and
lative benefits and risks of those procedures and therapies can
oduce helpful guidelines that improve the effectiveness of care,
timize patient outcomes, and favorably affect the overall cost
care by focusing resources on the most effective strategies.
The American College of Cardiology Foundation (ACCF)
d the American Heart Association (AHA) have jointly en-
ged in the production of such guidelines in the area of
rdiovascular disease since 1980. The ACC/AHA Task Force
Practice Guidelines, whose charge is to develop, update, or
vise practice guidelines for important cardiovascular diseases
d procedures, directs this effort. The Task Force is pleased to
ve this guideline developed in conjunction with the European
ociety of Cardiology (ESC). Writing committees are charged
ith the task of performing an assessment of the evidence and
ting as an independent group of authors to develop or update
ritten recommendations for clinical practice.
Experts in the subject under consideration have been selected
om all 3 organizations to examine subject-specific data and
rite guidelines. The process includes additional representatives
om other medical practitioner and specialty groups when
propriate. Writing committees are specifically charged to
rform a formal literature review, weigh the strength of
idence for or against a particular treatment or procedure, and
clude estimates of expected health outcomes where data exist.
atient-specific modifiers, comorbidities, and issues of patient
eference that might influence the choice of particular tests or
erapies are considered as well as frequency of follow-up and
st-effectiveness. When available, information from studies on
st will be considered; however, review of data on efficacy and
inical outcomes will constitute the primary basis for preparing
commendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines and the
SC Committee for Practice Guidelines make every effort to
oid any actual, potential, or perceived conflict of interest that
ight arise as a result of an outside relationship or personal
terest of the writing committee. Specifically, all members of
e Writing Committee and peer reviewers of the document are
ked to provide disclosure statements of all such relationships
at might be perceived as real or potential conflicts of interest.
riting committee members are also strongly encouraged to
clare a previous relationship with industry that might be
rceived as relevant to guideline development. If a writing
mmittee member develops a new relationship with industry
ring their tenure, they are required to notify guideline staff in
riting. The continued participation of the writing committee
ember will be reviewed. These statements are reviewed by the
rent Task Force, reported orally to all members of the writing
mmittee at each meeting, and updated and reviewed by the
riting committee as changes occur. Please refer to the meth-
ology manuals for further description of the policies used in
ideline development, including relationships with industry,
ailable online at the ACC, AHA, and ESC World Wide
eb sites (http://www.acc.org/clinical/manual/manual_
troltr.htm, http://circ.ahajournals.org/manual/, and http://
ww.escardio.org/knowledge/guidelines/Rules/). Please see
ppendix I for author relationships with industry and Appen-
x II for peer reviewer relationships with industry that are
rtinent to these guidelines.
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March 15, 2011:e101–98 ACC/AHA/ESC Practice GuidelinesThese practice guidelines are intended to assist healthcare
oviders in clinical decision making by describing a range of
nerally acceptable approaches for the diagnosis, manage-
ent, and prevention of specific diseases and conditions.
hese guidelines attempt to define practices that meet the
eds of most patients in most circumstances. These guide-
ne recommendations reflect a consensus of expert opinion
ter a thorough review of the available, current scientific
idence and are intended to improve patient care. If these
idelines are used as the basis for regulatory/payer deci-
ons, the ultimate goal is quality of care and serving the
tient’s best interests. The ultimate judgment regarding care
a particular patient must be made by the healthcare
ovider and the patient in light of all of the circumstances
esented by that patient. There are circumstances in which
viations from these guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/AHA
ask Force on Practice Guidelines and the ESC Committee for
ractice Guidelines and will be considered current unless they
e updated, revised, or sunsetted and withdrawn from distribu-
n. The executive summary and recommendations are pub-
hed in the August 15, 2006, issues of the Journal of the
merican College of Cardiology and Circulation and the August
, 2006, issue of the European Heart Journal. The full-text
idelines are published in the August 15, 2006, issues of the
urnal of the American College of Cardiology and Circulation
d the September 2006 issue of Europace, as well as posted on
e ACC (www.acc.org), AHA (www.americanheart.org), and
SC (www.escardio.org) World Wide Web sites. Copies of the
ll-text guidelines and the executive summary are available
om all 3 organizations.
Sidney C. Smith Jr, MD, FACC, FAHA, FESC, Chair,
ACC/AHA Task Force on Practice Guidelines
Silvia G. Priori, MD, PhD, FESC, Chair,
ESC Committee for Practice Guidelines
. Introduction
.1. Organization of Committee and
vidence Review (UPDATED)
or new or updated text, view the 2011
ocused Update and the 2011 Update on
abigatran. Text supporting unchanged
commendations has not been updated.
trial fibrillation (AF) is the most common sustained cardiac
ythm disturbance, increasing in prevalence with age. AF is
ten associated with structural heart disease, although a
bstantial proportion of patients with AF have no detectable
art disease. Hemodynamic impairment and thromboem-
lic events related to AF result in significant morbidity,
ortality, and cost. Accordingly, the American College of
ardiology (ACC), the American Heart Association (AHA),
d the European Society of Cardiology (ESC) created a
mmittee to establish guidelines for optimum management
this frequent and complex arrhythmia.
The committee was composed of members representing theCC, AHA, and ESC, as well as the European Heart Rhythm lossociation (EHRA) and the Heart Rhythm Society (HRS).
his document was reviewed by 2 official reviewers nomi-
ted by the ACC, 2 official reviewers nominated by the
HA, and 2 official reviewers nominated by the ESC, as well
by the ACCF Clinical Electrophysiology Committee, the
HA ECG and Arrhythmias Committee, the AHA Stroke
eview Committee, EHRA, HRS, and numerous additional
ntent reviewers nominated by the writing committee. The
cument was approved for publication by the governing
dies of the ACC, AHA, and ESC and officially endorsed by
e EHRA and the HRS.
The ACC/AHA/ESC Writing Committee to Revise the
01 Guidelines for the Management of Patients With Atrial
ibrillation conducted a comprehensive review of the rele-
nt literature from 2001 to 2006. Literature searches were
nducted in the following databases: PubMed/MEDLINE
d the Cochrane Library (including the Cochrane Database
Systematic Reviews and the Cochrane Controlled Trials
egistry). Searches focused on English-language sources and
udies in human subjects. Articles related to animal experi-
entation were cited when the information was important to
derstanding pathophysiological concepts pertinent to pa-
ent management and comparable data were not available
om human studies. Major search terms included atrial
rillation, age, atrial remodeling, atrioventricular conduc-
on, atrioventricular node, cardioversion, classification,
inical trial, complications, concealed conduction, cost-
fectiveness, defibrillator, demographics, epidemiology, ex-
rimental, heart failure (HF), hemodynamics, human, hy-
rthyroidism, hypothyroidism, meta-analysis, myocardial
farction, pharmacology, postoperative, pregnancy, pulmo-
ry disease, quality of life, rate control, rhythm control,
sks, sinus rhythm, symptoms, and tachycardia-mediated
rdiomyopathy.The complete list of search terms is beyond
e scope of this section.
Classification of Recommendations and Level of Evidence
e expressed in the ACC/AHA/ESC format as follows and
scribed in Table 1. Recommendations are evidence based
d derived primarily from published data.
lassification of Recommendations
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure/therapy is ben-
eficial, useful, and effective.
Class II: Conditions for which there is conflicting evidence
and/or a divergence of opinion about the usefulness/
efficacy of performing the procedure/therapy.
X Class IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
X Class IIb: Usefulness/efficacy is less well established by
evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that a procedure/therapy is not useful or
effective and in some cases may be harmful.
evel of Evidence
he weight of evidence was ranked from highest (A) to
west (C), as follows:
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ized clinical trials or meta-analyses.
Level of Evidence B: Data derived from a single random-
ized trial, or nonrandomized studies.
Level of Evidence C: Only consensus opinion of experts,
case studies, or standard-of-care.
.2. Contents of These Guidelines
hese guidelines first present a comprehensive review of the
test information about the definition, classification, epide-
iology, pathophysiological mechanisms, and clinical char-
BLE 1. Applying Classification of Recommendations and Leve
11 Focused Update on Dabigatran)
*Data available from clinical trials or registries about the usefulness/efficacy
yocardial infarction, history of heart failure, and prior aspirin use. A recommend
any important clinical questions addressed in the guidelines do not lend them
a very clear clinical consensus that a particular test or therapy is useful or
†In 2003, the ACC/AHA Task Force on Practice Guidelines developed a
commendations have been written in full sentences that express a complete
e rest of the document (including headings above sets of recommendations),
crease readers’ comprehension of the guidelines and will allow queries at theteristics of AF. The management of this complex and oftentially dangerous arrhythmia is then reviewed. This
cludes prevention of AF, control of heart rate, prevention of
romboembolism, and conversion to and maintenance of
nus rhythm. The treatment algorithms include pharmaco-
gical and nonpharmacological antiarrhythmic approaches,
well as antithrombotic strategies most appropriate for
rticular clinical conditions. Overall, this is a consensus
cument that attempts to reconcile evidence and opinion
om both sides of the Atlantic Ocean. The pharmacological
d nonpharmacological antiarrhythmic approaches may in-
ude some drugs and devices that do not have the approval
dence† (UPDATED) (see the 2011 Focused Update and the
nt subpopulations, such as gender, age, history of diabetes, history of prior
th Level of Evidence B or C does not imply that the recommendation is weak.
o clinical trials. Even though randomized trials are not available, there may
.
suggested phrases to use when writing recommendations. All guideline
, such that a recommendation, even if separated and presented apart from
still convey the full intent of the recommendation. It is hoped that this will
ual recommendation level.l of Evi
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device has been approved for the stated indication.
Because atrial flutter can precede or coexist with AF,
ecial consideration is given to this arrhythmia in each
ction. There are important differences in the mechanisms of
F and atrial flutter, and the body of evidence available to
pport therapeutic recommendations is distinct for the 2
rhythmias. Atrial flutter is not addressed comprehensively
these guidelines but is addressed in the ACC/AHA/ESC
uidelines on the Management of Patients with Supraven-
icular Arrhythmias (1).
.3. Changes Since the Initial Publication of
hese Guidelines in 2001
developing this revision of the guidelines, the Writing
ommittee considered evidence published since 2001 and
afted revised recommendations where appropriate to incor-
rate results from major clinical trials such as those that
mpared rhythm-control and rate-control approaches to
ng-term management. The text has been reorganized to
flect the implications for patient care, beginning with
cognition of AF and its pathogenesis and the general
iorities of rate control, prevention of thromboembolism,
d methods available for use in selected patients to correct
e arrhythmia and maintain normal sinus rhythm. Advances
catheter-based ablation technologies have been incorpo-
ted into expanded sections and recommendations, with the
cognition that that such vital details as patient selection,
timum catheter positioning, absolute rates of treatment
ccess, and the frequency of complications remain incom-
etely defined. Sections on drug therapy have been con-
nsed and confined to human studies with compounds that
ve been approved for clinical use in North America and/or
urope. Accumulating evidence from clinical studies on the
erging role of angiotensin inhibition to reduce the occur-
nce and complications of AF and information on ap-
oaches to the primary prevention of AF are addressed
mprehensively in the text, as these may evolve further in
e years ahead to form the basis for recommendations
fecting patient care. Finally, data on specific aspects of
anagement of patients who are prone to develop AF in
ecial circumstances have become more robust, allowing
rmulation of recommendations based on a higher level of
idence than in the first edition of these guidelines. An
ample is the completion of a relatively large randomized
ial addressing prophylactic administration of antiarrhythmic
edication for patients undergoing cardiac surgery. In devel-
ing the updated recommendations, every effort was made to
aintain consistency with other ACC/AHA and ESC practice
idelines addressing, for example, the management of pa-
ents undergoing myocardial revascularization procedures.
. Definition
.1. Atrial Fibrillation
F is a supraventricular tachyarrhythmia characterized by
coordinated atrial activation with consequent deterioration
atrial mechanical function. On the electrocardiogramCG), AF is characterized by the replacement of consistent nuwaves by rapid oscillations or fibrillatory waves that vary in
plitude, shape, and timing, associated with an irregular,
equently rapid ventricular response when atrioventricular
V) conduction is intact (2) (Fig. 1). The ventricular
sponse to AF depends on electrophysiological (EP) prop-
ties of the AV node and other conducting tissues, the level
vagal and sympathetic tone, the presence or absence of
cessory conduction pathways, and the action of drugs (3).
egular cardiac cycles (R-R intervals) are possible in the
esence of AV block or ventricular or AV junctional
chycardia. In patients with implanted pacemakers, diagno-
s of AF may require temporary inhibition of the pacemaker
expose atrial fibrillatory activity (4). A rapid, irregular,
stained, wide-QRS-complex tachycardia strongly suggests
F with conduction over an accessory pathway or AF with
derlying bundle-branch block. Extremely rapid rates (over
0 beats per minute) suggest the presence of an accessory
thway or ventricular tachycardia.
.2. Related Arrhythmias
F may occur in isolation or in association with other
rhythmias, most commonly atrial flutter or atrial tachycar-
a. Atrial flutter may arise during treatment with antiarrhyth-
ic agents prescribed to prevent recurrent AF. Atrial flutter in
e typical form is characterized by a saw-tooth pattern of
gular atrial activation called flutter (ƒ) waves on the ECG,
rticularly visible in leads II, III, aVF, and V1 (Fig. 2). In the
treated state, the atrial rate in atrial flutter typically ranges
om 240 to 320 beats per minute, with ƒ waves inverted in
CG leads II, III, and aVF and upright in lead V1. The
rection of activation in the right atrium (RA) may be
versed, resulting in ƒ waves that are upright in leads II, III,
d aVF and inverted in lead V1. Atrial flutter commonly
curs with 2:1 AV block, resulting in a regular or irregular
ntricular rate of 120 to 160 beats per minute (most
aracteristically about 150 beats per minute). Atrial flutter
ay degenerate into AF and AF may convert to atrial flutter.
he ECG pattern may fluctuate between atrial flutter and AF,
flecting changing activation of the atria. Atrial flutter is
ually readily distinguished from AF, but when atrial activ-
y is prominent on the ECG in more than 1 lead, AF may be
isdiagnosed as atrial flutter (5).
Focal atrial tachycardias, AV reentrant tachycardias, and
V nodal reentrant tachycardias may also trigger AF. In other
rial tachycardias, P waves may be readily identified and are
parated by an isoelectric baseline in 1 or more ECG leads.
he morphology of the P waves may help localize the origin
the tachycardias.
. Classification
arious classification systems have been proposed for AF.
ne is based on the ECG presentation (2–4). Another is
sed on epicardial (6) or endocavitary recordings or non-
ntact mapping of atrial electrical activity. Several clinical
assification schemes have also been proposed, but none
lly accounts for all aspects of AF (7–10). To be clinically
eful, a classification system must be based on a sufficient
mber of features and carry specific therapeutic implications.
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98Assorted labels have been used to describe the pattern of
F, including acute, chronic, paroxysmal, intermittent, con-
ant, persistent, and permanent, but the vagaries of defini-
ons make it difficult to compare studies of AF or the
fectiveness of therapeutic strategies based on these desig-
tions. Although the pattern of the arrhythmia can change
er time, it may be of clinical value to characterize the
rhythmia at a given moment. The classification scheme
gure 1. Electrocardiogram showing atrial fibrillation with a contro
aves and the ventricular response is completely irregular.
gure 2. Electrocardiogram showing typical atrial flutter with varia
rticularly visible in leads II, III, and aVF, without an isoelectric baselinecommended in this document represents a consensus driven
a desire for simplicity and clinical relevance.
The clinician should distinguish a first-detected episode of
F, whether or not it is symptomatic or self-limited, recog-
zing that there may be uncertainty about the duration of the
isode and about previous undetected episodes (Fig. 3).
hen a patient has had 2 or more episodes, AF is considered
current. If the arrhythmia terminates spontaneously, recur-
te of ventricular response. P waves are replaced by fibrillatory
ioventricular conduction. Note the saw-tooth pattern, F waves,lled rable atr
between deflections.
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinesnt AF is designated paroxysmal; when sustained beyond
d, AF is designated persistent. Termination with pharma-
logical therapy or direct-current cardioversion does not
ange the designation. First-detected AF may be either
roxysmal or persistent AF. The category of persistent AF
so includes cases of long-standing AF (e.g., greater than
y), usually leading to permanent AF, in which cardioversion
s failed or has not been attempted.
These categories are not mutually exclusive in a particular
tient, who may have several episodes of paroxysmal AF
d occasional persistent AF, or the reverse. Regarding
roxysmal and persistent AF, it is practical to categorize a
ven patient by the most frequent presentation. The defini-
on of permanent AF is often arbitrary. The duration of AF
fers both to individual episodes and to how long the patient
s been affected by the arrhythmia. Thus, a patient with
roxysmal AF may have episodes that last seconds to hours
curring repeatedly for years.
Episodes of AF briefer than 30 s may be important in
rtain clinical situations involving symptomatic patients,
e-excitation or in assessing the effectiveness of therapeutic
terventions. This terminology applies to episodes of AF that
st more than 30 s without a reversible cause. Secondary AF
at occurs in the setting of acute myocardial infarction (MI),
rdiac surgery, pericarditis, myocarditis, hyperthyroidism,
lmonary embolism, pneumonia, or other acute pulmonary
sease is considered separately. In these settings, AF is not
e primary problem, and treatment of the underlying disorder
ncurrently with management of the episode of AF usually
rminates the arrhythmia without recurrence. Conversely,
cause AF is common, it may occur independently of a
ncurrent disorder like well-controlled hypothyroidism, and
en the general principles for management of the arrhythmia
ply.
The term “lone AF” has been variously defined but
nerally applies to young individuals (under 60 y of age)
ithout clinical or echocardiographic evidence of cardiopul-
onary disease, including hypertension (11). These patients
ve a favorable prognosis with respect to thromboembolism
gure 3. Patterns of atrial fibrillation (AF). 1, Episodes that gen-
ally last 7 d or less (most less than 24 h); 2, episodes that
ually last longer than 7 d; 3, cardioversion failed or not at-
mpted; and 4, both paroxysmal and persistent AF may be
current.d mortality. Over time, patients may move out of the lone AF category due to aging or development of cardiac abnor-
alities such as enlargement of the left atrium (LA. Then, the
sks of thromboembolism and mortality rise accordingly. By
nvention, the term “nonvalvular AF” is restricted to cases
which the rhythm disturbance occurs in the absence of
eumatic mitral valve disease, a prosthetic heart valve, or
itral valve repair.
. Epidemiology and Prognosis
F is the most common arrhythmia in clinical practice,
counting for approximately one-third of hospitalizations for
rdiac rhythm disturbances. Most data regarding the epide-
iology, prognosis, and quality of life in AF have been
tained in the United States and western Europe. It has been
timated that 2.2 million people in America and 4.5 million
the European Union have paroxysmal or persistent AF
2). During the past 20 y, there has been a 66% increase in
spital admissions for AF (13–15) due to a combination of
ctors including the aging of the population, a rising preva-
nce of chronic heart disease, and more frequent diagnosis
rough use of ambulatory monitoring devices. AF is an ex-
emely costly public health problem (16,17), with hospitaliza-
ns as the primary cost driver (52%), followed by drugs (23%),
nsultations (9%), further investigations (8%), loss of work
%), and paramedical procedures (2%). Globally, the annual
st per patient is close to €3000 (approximately U.S. $3600)
6). Considering the prevalence of AF, the total societal burden
huge, for example, about €13.5 billion (approximately U.S.
5.7 billion) in the European Union.
.1. Prevalence
he estimated prevalence of AF is 0.4% to 1% in the general
pulation, increasing with age (18,19). Cross-sectional stud-
s have found a lower prevalence in those below the age of
y, increasing to 8% in those older than 80 y (Fig. 4)
0–22). The age-adjusted prevalence of AF is higher in men
2,23), in whom the prevalence has more than doubled from
e 1970s to the 1990s, while the prevalence in women has
gure 4. Estimated age-specific prevalence of atrial fibrillation
F) based on 4 population-based surveys. Prevalence, age,
stribution, and gender of patients with AF analysis and impli-
tions. Modified with permission from Feinberg WM, Blacks-
ar JL, Laupacis A, et al. Prevalence, age distribution, and
nder of patients with atrial fibrillation. Analysis and implica-
ns. Arch Intern Med 1995;155:469–73 (19). Copyright © 1995,
merican Medical Association. All rights reserved.
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98mained unchanged (24). The median age of AF patients is
out 75 y. Approximately 70% are between 65 and 85 y old.
he overall number of men and women with AF is about
ual, but approximately 60% of AF patients over 75 y are
male. Based on limited data, the age-adjusted risk of
veloping AF in blacks seems less than half that in whites
8,25,26). AF is less common among African-American
an Caucasian patients with heart failure (HF).
In population-based studies, patients with no history of
rdiopulmonary disease account for fewer than 12% of all
ses of AF (11,22,27,28). In some series, however, the
served proportion of lone AF was over 30% (29,30).
These differences may depend on selection bias when
cruiting patients seen in clinical practice compared with
pulation-based observations. In the Euro Heart Survey on
F (31), the prevalence of idiopathic AF amounted to 10%,
ith an expected highest value of 15% in paroxysmal AF,
% in first-detected AF, 10% in persistent AF, and only 4%
permanent AF. Essential hypertension, ischemic heart
sease, HF (Table 2), valvular heart disease, and diabetes are
e most prominent conditions associated with AF (14).
.2. Incidence
prospective studies, the incidence of AF increases from
ss than 0.1% per year in those under 40 y old to exceed 1.5%
r year in women and 2% in men older than 80 (Fig. 5)
5,32,33). The age-adjusted incidence increased over a 30-y
riod in the Framingham Study (32), and this may have
plications for the future impact of AF (34). During 38 y of
llow-up in the Framingham Study, 20.6% of men who devel-
ed AF had HF at inclusion versus 3.2% of those without AF;
e corresponding incidences in women were 26.0% and 2.9%
5). In patients referred for treatment of HF, the 2- to 3-y
cidence of AF was 5% to 10% (25,36,37). The incidence of
F may be lower in HF patients treated with angiotensin
hibitors (38–40). Similarly, angiotensin inhibition may be
BLE 2. Prevalence of AF in Patients With Heart Failure as
eflected in Several Heart Failure Trials
edominant
HA Class
Prevalence of
AF (%) Study
4 SOLVD–Prevention (1992)(14a)
III 10 to 26 SOLVD–Treatment (1991) (14b)
CHF-STAT (1995) (14c)
MERIT-HF (1999) (14d)
DIAMOND-CHF (1999) (501)
IV 12 to 27 CHARM (2003) Val-HeFT (2003) (848)
IV 20 to 29 Middlekauff (1991) (14e)
Stevenson (1996) GESICA (1994) (14f)
50 CONSENSUS (1987) (14g)
AF indicates atrial fibrillation; NYHA, New York Heart Association; SOLVD,
udies Of Left Ventricular Dysfunction; CHF-STAT, Survival Trial of Antiarrhyth-
ic Therapy in Congestive Heart Failure; MERIT-HF, Metropolol CR/XL Ran-
mized Intervention Trial in Congestive Heart Failure; DIAMOND-CHF, Danish
vestigations of Arrhythmia and Mortality on Dofetilide–Congestive Heart
ilure; CHARM, Candesartan in Heart failure, Assessment of Reduction in
ortality and morbidity; Val-HeFT, Valsartan Heart Failure Trial; GESICA, Grupo
tudio de la Sobrevida en la Insufficienca Cardiaca en Argentina (V); and
NSENSUS, Co-operative North Scandinavian Enalapril Survival Study. Msociated with a reduced incidence of AF in patients with
pertension (41,42), although this may be confined to those
ith left ventricular hypertrophy (LVH) (43–45).
.3. Prognosis
F is associated with an increased long-term risk of stroke
7), HF, and all-cause mortality, especially in women (48).
he mortality rate of patients with AF is about double that of
tients in normal sinus rhythm and linked to the severity of
derlying heart disease (20,23,33) (Fig. 6). About two-thirds
the 3.7% mortality over 8.6 mo in the Etude en Activité
ibérale sur la Fibrillation Auriculaire Study (ALFA) was
tributed to cardiovascular causes (29). Table 3 shows a list
associated heart diseases in the population of the ALFA
udy (29).
gure 5. Incidence of atrial fibrillation in 2 American epidemio-
gical studies. Framingham indicates the Framingham Heart
tudy. Data are from Wolf PA, Abbott RD, Kannel WB. Atrial
rillation: a major contributor to stroke in the elderly. The Fra-
ingham Study. Arch Intern Med 1987;147:1561–4 (32). CHS
dicates the Cardiovascular Health Study. Data are from Psaty
M, Manolio TA, Kuller LH, et al. Incidence of and risk factors
r atrial fibrillation in older adults. Circulation 1997;96:2455–61
5); and Furberg CD, Psaty BM, Manolio TA, et al. Prevalence
atrial fibrillation in elderly subjects (the Cardiovascular Health
tudy). Am J Cardiol 1994;74:236–41 (22), and Farrell B, God-
in J, Richards S, et al. The United Kingdom transient isch-
mic attack (UK-TIA) aspirin trial: final results. J Neurol Neuro-
rg Psychiatry 1991;54:1044–54 (46).
gure 6. Relative risk of stroke and mortality in patients with
rial fibrillation (AF) compared with patients without AF. Source
ta from the Framingham Heart Study (Kannel WB, Abbott RD,
avage DD, et al. Coronary heart disease and atrial fibrillation:
e Framingham Study. Am Heart J 1983;106:389–96) (23), the
egional Heart Study and the Whitehall study (Flegel KM, Shi-
ey MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrilla-
n), and the Manitoba study (Krahn AD, Manfreda J, Tate RB,
al. The natural history of atrial fibrillation: incidence, risk fac-
rs, and prognosis in the Manitoba Follow-Up Study. Am J
ed 1995;98:476–84) (33).
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March 15, 2011:e101–98 ACC/AHA/ESC Practice GuidelinesMortality in the Veterans Administration Heart Failure
rials (V-HeFT) was not increased among patients with
ncomitant AF (49), whereas in the Studies of Left Ventric-
ar Dysfunction (SOLVD), mortality was 34% for those with
F versus 23% for patients in sinus rhythm (p less than
001) (50). The difference was attributed mainly to deaths
e to HF rather than to thromboembolism. AF was a strong
dependent risk factor for mortality and major morbidity in
rge HF trials. In the Carvedilol Or Metoprolol European
rial (COMET), there was no difference in all-cause mortality
those with AF at entry, but mortality increased in those
ho developed AF during follow-up (51). In the Val-HeFT
hort of patients with chronic HF, development of AF was
sociated with significantly worse outcomes (40). HF pro-
otes AF, AF aggravates HF, and individuals with either
ndition who develop the alternate condition share a poor
ognosis (52). Thus, managing the association is a major
allenge (53) and the need for randomized trials to investi-
BLE 3. Demographics and Associated Conditions Among
tients With Atrial Fibrillation in the ALFA Study
Total
Population
Paroxysmal
AF
Chronic
AF
Recent-
Onset
AF
. of patients 756 167 389 200
e, y 69 66 70 68
ale/female ratio 1 1 2 1
me from first episode
AF (mo)
47 39 66 NA
derlying heart disease (%)
Coronary artery disease 17 12 18 19
Hypertensive heart disease 21 17 22 25
Valvular (rheumatic) 15 10 20 12
Dilated cardiomyopathy 9 2 13 9
Hypertrophic cardiomyopathy 5 3 4 9
Other 9 14 9 7
None 29 46 23 28
her predisposing or
sociated factors (%)
Hyperthyroidism 3 4 2 5
Hypertension 39 35 38 46
Bronchopulmonary disease 11 10 13 10
Diabetes 11 7 13 9
Congestive HF 30 14 43 18
Prior embolic events 8 8 11 4
ft atrial size (mm) 44 40 47 42
ft ventricular ejection
ction (%)
59 63 57 58
Persistent atrial fibrillation (AF) includes both recent-onset and chronic AF.
cent-onset AF was defined as persistent AF lasting greater than or equal to
and less than 30 d. Chronic AF was defined as persistent AF of more than
-d duration. Patients in whom the diagnosis was definite and those in whom
was probable were included. Modified with permission from Levy S, Maarek
, Coumel P, et al. Characterization of different subsets of atrial fibrillation in
neral practice in France: the ALFA Study, The College of French Cardiolo-
sts. Circulation 1999;99:3028–35 (29). © 1999 American Heart Association.
ALFA indicates Etude en Activité Libérale sur la Fibrillation Auriculaire; HF,
art failure; and NA, not applicable or unavailable.te the impact of AF on the prognosis in HF is apparent. mThe rate of ischemic stroke among patients with nonval-
lar AF averages 5% per year, 2 to 7 times that of people
ithout AF (20,21,29,32,33,47) (Fig. 6). One of every 6
rokes occurs in a patient with AF (54). Additionally, when
ansient ischemic attacks (TIAs) and clinically “silent”
rokes detected by brain imaging are considered, the rate of
ain ischemia accompanying nonvalvular AF exceeds 7%
r year (35,55–58) In patients with rheumatic heart disease
d AF in the Framingham Heart Study, stroke risk was
creased 17-fold compared with age-matched controls (59),
d attributable risk was 5 times greater than that in those
ith nonrheumatic AF (21). In the Manitoba Follow-up
tudy, AF doubled the risk of stroke independently of other
sk factors (33), and the relative risks for stroke in nonrheu-
atic AF were 6.9% and 2.3% in the Whitehall and the
egional Heart studies, respectively. Among AF patients
om general practices in France, the Etude en Activité
ibérale sur le Fibrillation Auriculaire (ALFA) study found a
4% incidence of thromboembolism over a mean of 8.6 mo
follow-up (29). The risk of stroke increases with age; in the
ramingham Study, the annual risk of stroke attributable to
F was 1.5% in participants 50 to 59 y old and 23.5% in
ose aged 80 to 89 y (21).
. Pathophysiological Mechanisms
.1. Atrial Factors
.1.1. Atrial Pathology as a Cause of Atrial Fibrillation
he most frequent pathoanatomic changes in AF are atrial
brosis and loss of atrial muscle mass. Histological exami-
tion of atrial tissue of patients with AF has shown patchy
brosis juxtaposed with normal atrial fibers, which may
count for nonhomogeneity of conduction (60–62). The
noatrial (SA) and AV nodes may also be involved, account-
g for the sick sinus syndrome and AV block. It is difficult
distinguish between changes due to AF and those due to
sociated heart disease, but fibrosis may precede the onset of
F (63).
Biopsy of the LA posterior wall during mitral valve
rgery revealed mild to moderate fibrosis in specimens
tained from patients with sinus rhythm or AF of relatively
ort duration, compared with severe fibrosis and substantial
ss of muscle mass in those from patients with long-standing
F. Patients with mild or moderate fibrosis responded more
ccessfully to cardioversion than did those with severe
brosis, which was thought to contribute to persistent AF in
ses of valvular heart disease (64). In atrial tissue specimens
om 53 explanted hearts from transplantation recipients with
lated cardiomyopathy, 19 of whom had permanent, 18
rsistent, and 16 no documented AF, extracellular matrix
modeling including selective downregulation of atrial
sulin-like growth factor II mRNA-binding protein 2
MP-2) and upregulation of matrix metalloproteinase 2
MP-2) and type 1 collagen volume fraction (CVF-1) were
sociated with sustained AF (65).
Atrial biopsies from patients undergoing cardiac surgery
vealed apoptosis (66) that may lead to replacement of atrial
yocytes by interstitial fibrosis, loss of myofibrils, accumu-
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98tion of glycogen granules, disruption of cell coupling at gap
nctions (67), and organelle aggregates (68). The concentra-
on of membrane-bound glycoproteins that regulate cell-cell
d cell-matrix interactions (disintegrin and metalloprotei-
ses) in human atrial myocardium has been reported to
uble during AF. Increased disintegrin and metalloprotei-
se activity may contribute to atrial dilation in patients with
ng-standing AF.
Atrial fibrosis may be caused by genetic defects like lamin
C gene mutations (69). Other triggers of fibrosis include
flammation (70) as seen in cardiac sarcoidosis (71) and
toimmune disorders (72). In one study, histological
anges consistent with myocarditis were reported in 66% of
rial biopsy specimens from patients with lone AF (62), but
is uncertain whether these inflammatory changes were a
use or consequence of AF. Autoimmune activity is sug-
sted by high serum levels of antibodies against myosin
avy chains in patients with paroxysmal AF who have no
entified heart disease (72). Apart from fibrosis, atrial
thological findings in patients with AF include amyloidosis
3,74), hemochromatosis (75), and endomyocardial fibrosis
5,76). Fibrosis is also triggered by atrial dilation in any type
heart disease associated with AF, including valvular
sease, hypertension, HF, or coronary atherosclerosis (77).
tretch activates several molecular pathways, including the
nin-angiotensin-aldosterone system (RAAS). Both angio-
nsin II and transforming growth factor-beta1 (TGF-beta1)
e upregulated in response to stretch, and these molecules
duce production of connective tissue growth factor (CTGF)
0). Atrial tissue from patients with persistent AF undergo-
g open-heart surgery demonstrated increased amounts of
tracellular signal-regulated kinase messenger RNA (ERK-
mRNA), and expression of angiotensin-converting enzyme
CE) was increased 3-fold during persistent AF (78). A
udy of 250 patients with AF and an equal number of
ntrols demonstrated the association of RAAS gene poly-
orphisms with this type of AF (79).
Several RAAS pathways are activated in experimental
8,80–84) as well as human AF (78,85), and ACE inhibition
d angiotensin II receptor blockade had the potential to
event AF by reducing fibrosis (84,86).
In experimental studies of HF, atrial dilation and interstitial
brosis facilitates sustained AF (86–92). The regional elec-
ical silence (suggesting scar), voltage reduction, and con-
ction slowing described in patients with HF (93) are similar
changes in the atria that occur as a consequence of aging.
AF is associated with delayed interatrial conduction and
spersion of the atrial refractory period (94). Thus, AF seems
cause a variety of alterations in the atrial architecture and
nction that contribute to remodeling and perpetuation of the
rhythmia. Despite these pathological changes in the atria,
wever, isolation of the pulmonary veins (PVs) will prevent
F in many such patients with paroxysmal AF.
.1.1.1. PATHOLOGICAL CHANGES CAUSED BY
TRIAL FIBRILLATION
st as atrial stretch may cause AF, AF can cause atrial
lation through loss of contractility and increased compli-
ce (61). Stretch-related growth mechanisms and fibrosis stcrease the extracellular matrix, especially during prolonged
riods of AF. Fibrosis is not the primary feature of AF-
duced structural remodeling (95,96), although accumula-
on of extracellular matrix and fibrosis are associated with
ore pronounced myocytic changes once dilation occurs due
AF or associated heart disease (90,97). These changes
osely resemble those in ventricular myocytes in the hiber-
ting myocardium associated with chronic ischemia (98).
mong these features are an increase in cell size, perinuclear
ycogen accumulation, loss of sarcoplasmic reticulum and
rcomeres (myolysis). Changes in gap junction distribution
d expression are inconsistent (61,99), and may be less
portant than fibrosis or shortened refractoriness in promot-
g AF. Loss of sarcomeres and contractility seems to protect
yocytes against the high metabolic stress associated with
pid rates. In fact, in the absence of other pathophysiological
ctors, the high atrial rate typical of AF may cause ischemia
at affects myocytes more than the extracellular matrix and
terstitial tissues.
Aside from changes in atrial dimensions that occur over
me, data on human atrial structural remodeling are limited
6,100) and difficult to distinguish from degenerative
anges related to aging and associated heart disease (96).
ne study that compared atrial tissue specimens from patients
ith paroxysmal and persistent lone AF found degenerative
ntraction bands in patients with either pattern of AF, while
yolysis and mitochondria hibernation were limited to those
ith persistent AF. The activity of calpain I, a proteolytic
zyme activated in response to cytosolic calcium overload,
as upregulated in both groups and correlated with ion
annel protein and structural and electrical remodeling.
ence, calpain activation may link calcium overload to
llular adaptation in patients with AF (341).
.1.2. Mechanisms of Atrial Fibrillation
he onset and maintenance of a tachyarrhythmia require both
initiating event and an anatomical substrate. With respect
AF, the situation is often complex, and available data
pport a “focal” mechanism involving automaticity or mul-
ple reentrant wavelets. These mechanisms are not mutually
clusive and may at various times coexist in the same patient
ig. 7).
.1.2.1. AUTOMATIC FOCUS THEORY
focal origin of AF is supported by experimental models of
onitine and pacing-induced AF (102,103) in which the
rhythmia persists only in isolated regions of atrial myocar-
um. This theory received minimal attention until the im-
rtant observation that a focal source for AF could be
entified in humans and ablation of this source could
tinguish AF (104). While PVs are the most frequent source
these rapidly atrial impulses, foci have also been found in
e superior vena cava, ligament of Marshall, left posterior
ee wall, crista terminalis, and coronary sinus (79,104–110).
In histological studies, cardiac muscle with preserved
ectrical properties extends into the PV (106,111–116), and
e primacy of PVs as triggers of AF has prompted substan-
al research into the anatomical and EP properties of these
ructures. Atrial tissue on the PV of patients with AF has
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinesorter refractory periods than in control patients or other
rts of the atria in patients with AF (117,118). The refractory
riod is shorter in atrial tissue in the distal PV than at the
V-LA junction. Decremental conduction in PV is more
equent in AF patients than in controls, and AF is more
adily induced during pacing in the PV than in the LA. This
terogeneity of conduction may promote reentry and form a
bstrate for sustained AF (119). Programmed electrical
imulation in PV isolated by catheter ablation initiated
stained pulmonary venous tachycardia, probably as a con-
quence of reentry (120). Rapidly firing atrial automatic foci
ay be responsible for these PV triggers, with an anatomical
bstrate for reentry vested within the PV.
Whether the source for AF is an automatic focus or a
icroreentrant circuit, rapid local activation in the LA cannot
tend to the RA in an organized way. Experiments involving
etylcholine-induced AF in Langendorf-perfused sheep
arts demonstrated a dominant fibrillation frequency in the
A with decreasing frequency as activation progressed to the
A. A similar phenomenon has been shown in patients with
roxysmal AF (121). Such variation in conduction leads to
sorganized atrial activation, which could explain the ECG
pearance of a chaotic atrial rhythm (122). The existence of
iggers for AF does not negate the role of substrate modifi-
tion. In some patients with persistent AF, disruption of the
uscular connections between the PV and the LA may
rminate the arrhythmia. In others, AF persists following
olation of the supposed trigger but does not recur after
rdioversion. Thus, in some patients with abnormal triggers,
stained AF may depend on an appropriate anatomical
bstrate.
.1.2.2. MULTIPLE-WAVELET HYPOTHESIS
he multiple-wavelet hypothesis as the mechanism of reen-
ant AF was advanced by Moe and colleagues (123), who
oposed that fractionation of wavefronts propagating
rough the atria results in self-perpetuating “daughter wave-
ts.” In this model, the number of wavelets at any time
pends on the refractory period, mass, and conduction
locity in different parts of the atria. A large atrial mass with
short refractory period and delayed conduction increases the
mber of wavelets, favoring sustained AF. Simultaneous
cordings from multiple electrodes supported the multiple-
avelet hypothesis in human subjects (127). duFor many years, the multiple-wavelet hypothesis was the
minant theory explaining the mechanism of AF, but the
ta presented above and from experimental (127a) and
inical (127b,127c) mapping studies challenge this notion.
ven so, a number of other observations support the impor-
nce of an abnormal atrial substrate in the maintenance of
F. For over 25 y, EP studies in humans have implicated
rial vulnerability in the pathogenesis of AF (128–132). In
e study of 43 patients without structural heart disease, 18 of
hom had paroxysmal AF, the coefficient of dispersion of
rial refractoriness was significantly greater in the patients
ith AF (128). Furthermore, in 16 of 18 patients with a
story of AF, the arrhythmia was induced with a single
trastimulus, while a more aggressive pacing protocol was
quired in 23 of 25 control patients without previously
cumented AF. In patients with idiopathic paroxysmal AF,
idespread distribution of abnormal electrograms in the RA
edicted development of persistent AF, suggesting an abnor-
al substrate (132). In patients with persistent AF who had
dergone conversion to sinus rhythm, there was significant
olongation of intra-atrial conduction compared with a
ntrol group, especially among those who developed recur-
nt AF after cardioversion (130).
Patients with a history of paroxysmal AF, even those with
ne AF, have abnormal atrial refractoriness and conduction
mpared with patients without AF. An abnormal signal-
eraged P-wave ECG reflects slowed intra-atrial conduction
d shorter wavelengths of reentrant impulses. The resulting
crease in wavelet density promotes the onset and mainte-
nce of AF. Among patients with HF, prolongation of the P
ave was more frequent in those prone to paroxysmal AF
33). In specimens of RA appendage tissue obtained from
tients undergoing open-heart surgery, P-wave duration was
rrelated with amyloid deposition (73). Because many of
ese observations were made prior to the onset of clinical
F, the findings cannot be ascribed to atrial remodeling that
curs as a consequence of AF. Atrial refractoriness increases
ith age in both men and women, but concurrent age-related
brosis lengthens effective intra-atrial conduction pathways.
his, coupled with the shorter wavelengths of reentrant
pulses, increases the likelihood that AF will develop
34,135). Nonuniform alterations of refractoriness and con-
Figure 7. Posterior view of principal electro-
physiological mechanisms of atrial fibrillation. A,
Focal activation. The initiating focus (indicated
by the star) often lies within the region of the
pulmonary veins. The resulting wavelets repre-
sent fibrillatory conduction, as in multiple-wavelet
reentry. B, Multiple-wavelet reentry. Wavelets
(indicated by arrows) randomly reenter tissue
previously activated by the same or another
wavelet. The routes the wavelets travel vary.
Reproduced with permission from Konings KT,
Kirchhof CJ, Smeets JR, et al. High-density
mapping of electrically induced atrial fibrillation
in humans. Circulation 1994;89:1665–80 (101).
LA indicates left atrium; PV, pulmonary vein;
ICV, inferior vena cava; SCV, superior vena
cava; and RA, right atrium.ction throughout the atria may provide a milieu for the
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98aintenance of AF. However, the degree to which changes in
e atrial architecture contribute to the initiation and mainte-
nce of AF is not known. Isolation of the PV may prevent
current AF even in patients with substantial abnormalities
atrial size and function. Finally, the duration of episodes of
F correlates with both a decrease in atrial refractoriness and
ortening of the AF cycle length, attesting to the importance
electrical remodeling in the maintenance of AF (136). The
atomical and electrophysiological substrates are detailed in
able 4.
.1.3. Atrial Electrical Remodeling
harmacological or direct-current cardioversion of AF has a
gher success rate when AF has been present for less than
h (137), whereas more prolonged AF makes restoring and
aintaining sinus rhythm less likely. These observations gave
se to the adage “atrial fibrillation begets atrial fibrillation.”
he notion that AF is self-perpetuating takes experimental
pport from a goat model using an automatic atrial fibrillator
at detected spontaneous termination of AF and reinduced
e arrhythmia by electrical stimulation (138). Initially, elec-
ically induced AF terminated spontaneously. After repeated
ductions, however, the episodes became progressively more
stained until AF persisted at a more rapid atrial rate (138).
he increasing propensity to AF was related to progressive
ortening of effective refractory periods with increasing
isode duration, a phenomenon known as EP remodeling.
hese measurements support clinical observations (139) that
e short atrial effective refractory period in patients with
roxysmal AF fails to adapt to rate, particularly during
adycardia. Confirmation came from recordings of action
tentials in isolated fibrillating atrial tissue and from patients
BLE 4. Anatomical and Electrophysiological Substrates Promo
seases Anatomical
rt A. Substrate develops during sinus rhythm (remodeling related to stretch a
Hypertension Atrial dilatation
Heart failure PV dilatation
Coronary disease Fibrosis
Valvular disease
rt B. Substrate develops due to tachycardia (tachycardia-related remodeling,
Focal AF None or†
Atrial flutter Atrial dilatation
PV dilatation
Large PV sleeves
Reduced contractility
Fibrosis
*Substrate develops either while in sinus rhythm, usually caused by ventricu
e to the rapid atrial rate during atrial fibrillation (AF), according to the princip
†The listed changes may only occur with prolonged episodes of AF at high
‡Short ERP and slow conduction may produce short wavelength, thereby pr
§ERP dispersion together with spontaneous or stretch-induced ectopic activi
The reduction of atrial contractility during AF may enhance atrial dilatation,
CTGF indicates connective tissue growth factor; ERP, effective refractory perio
nsforming growth factor-beta1.ter cardioversion (140). The duration of atrial monophasic cotion potentials was shorter after cardioversion and corre-
ted with the instability of sinus rhythm (141).
Tachycardia-induced AF may result from AV node reen-
y, an accessory pathway, atrial tachycardia, or atrial flutter
42–144). After a period of rapid atrial rate, electrical
modeling stimulates progressive intracellular calcium load-
g that leads to inactivation of the calcium current (145,146).
eduction of the calcium current in turn shortens the action
tential duration and atrial refractory period, which may
omote sustained AF. The role of potassium currents in this
tuation is less clear (145). Electrical remodeling has also
en demonstrated in PV myocytes subjected to sustained
pid atrial pacing, resulting in shorter action potential
rations and both early and delayed afterdepolarizations
47).
In addition to remodeling and changes in electrical refrac-
riness, prolonged AF disturbs atrial contractile function.
ith persistent AF, recovery of atrial contraction can be
layed for days or weeks following the restoration of sinus
ythm, which has important implications for the duration of
ticoagulation after cardioversion. (See Section 8.1.4, Pre-
nting Thromboembolism.) Both canine and preliminary
man data suggest that prolonged AF may also lengthen
nus node recovery time (148,149). The implication is that
F may be partly responsible for sinus node dysfunction in
me patients with the tachycardia-bradycardia syndrome.
Reversal of electrical remodeling in human atria may occur
different rates depending on the region of the atrium
udied (150). When tested at various times after cardiover-
on, the effective refractory period of the lateral RA in-
eased within 1 h after cardioversion, while that in the
e Initiation and/or Maintenance of Atrial Fibrillation
Substrates*
Cellular Electrophysiological
ation. The main pathways involve the RAAS, TGF-beta, and CTGF.
Myolysis Conduction abnormalities
Apoptosis, necrosis ERP dispersion
hannel expression change Ectopic activity
gulation of calcium channel and calcium handling.
None or† Ectopic activity
cium channel downregulation Microreentry
Myolysis Short ERP‡
Connexin downregulation ERP dispersion§
drenergic supersensitivity Slowed conduction
Changed sympathetic
innervation
deling, atrial pressure overload and subsequent atrial dilatation (Part A), or
“AF begets AF” (Part B.
te.
further AF.
initiate AF. Long ERPs occur in Bachmann’s bundle among other tissues.
to persistent AF.
ulmonary vein; RAAS, renin-angiotensin-aldosterone system; and TGF-beta,ting th
nd dilat
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinescovery of normal atrial refractoriness after cardioversion of
rsistent AF was complete within 3 to 4 d (151), after which
ere was no difference in refractoriness between the RA
pendage and the distal coronary sinus. The disparities
tween studies may reflect patient factors or the duration or
ttern of AF before cardioversion.
.1.4. Counteracting Atrial Electrical Remodeling
ata are accumulating on the importance of the RAAS in the
nesis of AF (145). Irbesartan plus amiodarone was associ-
ed with a lower incidence of recurrent AF after cardiover-
on than amiodarone alone (39), and use of angiotensin
hibitors and diuretics significantly reduced the incidence of
F after catheter ablation of atrial flutter (152). Amiodarone
ay reverse electrical remodeling even when AF is ongoing
53), and this explains how amiodarone can convert persis-
nt AF to sinus rhythm. Inhibition of the RAAS, alone or in
mbination with other therapies, may therefore prevent the
set or maintenance of AF (43) through several mecha-
sms. These include hemodynamic changes (lower atrial
essure and wall stress), prevention of structural remodeling
brosis, dilation, and hypertrophy) in both the LA and left
ntricle (LV), inhibition of neurohumoral activation, re-
ced blood pressure, prevention or amelioration of HF, and
oidance of hypokalemia. Treatment with trandolapril re-
ced the incidence of AF in patients with LV dysfunction
llowing acute MI (36), but it remains to be clarified whether
e antiarrhythmic effect of these agents is related to reversal
structural or electrical remodeling in the atria or to these
her mechanisms.
.1.5. Other Factors Contributing to
trial Fibrillation
ther factors potentially involved in the induction or main-
nance of AF include inflammation, autonomic nervous
stem activity, atrial ischemia (154), atrial dilation (155),
isotropic conduction (156), and structural changes associ-
ed with aging (3). It has been postulated that oxidative
ress and inflammation may be involved in the genesis of AF
57–159). In a case-control study, levels of C-reactive
otein (CRP), a marker of systemic inflammation, were
gher in patients with atrial arrhythmias than in those
ithout rhythm disturbances (159), and those with persistent
F had higher CRP levels than those with paroxysmal AF. In
population-based cohort of nearly 6000 patients, AF was
ore prevalent among patients in the highest quartile for CRP
an those in the lowest quartile. In patients without AF at
seline, CRP levels were associated with the future devel-
ment of AF (158).
The effects of HMG CoA-reductase inhibitors (“statins”),
hich have both anti-inflammatory and antioxidant proper-
es, on electrical remodeling have been evaluated in a canine
odel of atrial tachycardia (160) but have not been ade-
ately studied in human subjects. In the experimental model,
chycardia-related electrical remodeling was suppressed by
etreatment with simvastatin but not by the antioxidant
tamins C and E. The mechanism responsible for the salutary
fect of simvastatin requires further investigation, and the
ility of drugs in the statin class to prevent clinical AF has
t yet been established. inIncreased sympathetic or parasympathetic tone has been
plicated in the initiation of AF. Autonomic ganglia con-
ining parasympathetic and sympathetic fibers are present on
e epicardial surface of both the RA and LA, clustered on the
sterior wall near the ostia of the PV, superior vena cava
VC), and coronary sinus. In animal models, parasympa-
etic stimulation shortens atrial and PV refractory periods,
tentiating initiation and maintenance of AF (161,162), and
gal denervation of the atria prevents induction of AF (163).
297 patients with paroxysmal AF, vagal denervation
ncomitant with extensive endocardial catheter ablation was
sociated with significant reduction in subsequent AF in a
ird of cases (162). Pure autonomic initiation of clinical AF
uncommon and seen only in situations of high sympathetic
high vagal tone, but recordings of heart rate variability
RV) disclose autonomic perturbations in some patients that
ecede the onset of AF (164–169).
There is a strong association between obstructive sleep
nea, hypertension, and AF (170). It is likely that LV
astolic dysfunction plays a role in the genesis of AF, either
increasing pressure that affects stretch receptors in PV
iggers and other areas of the atria or by inducing direct
ructural changes in atrial myocardium (171,172). Familial
ctors are discussed in Section 6.1.5.
.2. Atrioventricular Conduction
.2.1. General Aspects
the absence of an accessory pathway or His-Purkinje
sfunction, the AV node limits conduction during AF (144).
ultiple atrial inputs to the AV node have been identified, 2
which seem dominant: one directed posteriorly via the
ista terminalis and the other aimed anteriorly via the
teratrial septum. Other factors affecting AV conduction are
e intrinsic refractoriness of the AV node, concealed con-
ction, and autonomic tone. Concealed conduction, which
curs when atrial impulses traverse part of the AV node but
e not conducted to the ventricles, plays a prominent role in
termining the ventricular response during AF (173,174).
hese impulses alter AV nodal refractoriness, slowing or
ocking subsequent atrial impulses, and may explain the
regularity of ventricular response during AF (125). When
e atrial rate is relatively slow during AF, the ventricular rate
nds to rise. Conversely, a higher atrial rate is associated
ith slower ventricular rate.
Increased parasympathetic and reduced sympathetic tone
ert negative dromotropic effects on AV nodal conduction,
hile the opposite is true in states of decreased parasympa-
etic and increased sympathetic tone (173,175,176). Vagal
ne also enhances the negative chronotropic effects of
ncealed conduction in the AV node (175,176). Fluctuations
autonomic tone can produce disparate ventricular re-
onses to AF in a given patient as exemplified by a slow
ntricular rate during sleep but accelerated ventricular re-
onse during exercise. Digitalis, which slows the ventricular
te during AF predominantly by increasing vagal tone, is
ore effective for controlling heart rate at rest in AF but less
fective during activity. Wide swings in rate due to variations
autonomic tone may create a therapeutic challenge.
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98Conducted QRS complexes are narrow during AF unless
ere is fixed or rate-related bundle-branch block or accessory
thway. Aberrant conduction is common and facilitated by
e irregularity of the ventricular response. When a long
terval is followed by a relatively short interval, the QRS
mplex that closes the short interval is often aberrantly
nducted (Ashman phenomenon) (177).
.2.2. Atrioventricular Conduction in Patients With
reexcitation Syndromes
onduction across an accessory pathway during AF can result in
dangerously rapid ventricular rate (3,178,179). Whereas a
bstantial increase in sympathetic tone may increase the pre-
cited ventricular response, alterations in vagal tone have little
fect on conduction over accessory pathways.
Transition of AV reentry into AF in patients with the
olff-Parkinson-White (WPW) syndrome can produce a
pid ventricular response that degenerates into ventricular
brillation, leading to death (178,180). Intravenous adminis-
ation of drugs such as digitalis, verapamil, or diltiazem,
hich lengthen refractoriness and slow conduction across the
V node, does not block conduction over the accessory
thway and may accelerate the ventricular rate. Hence, these
ents are contraindicated in this situation (181). Although
e potential for beta blockers to potentiate conduction across
e accessory pathway is controversial, caution should be
ercised in the use of these agents as well as in patients with
F associated with preexcitation.
.3. Myocardial and Hemodynamic
onsequences of Atrial Fibrillation
mong factors that affect the hemodynamic function during
F are loss of synchronous atrial mechanical activity, irreg-
ar ventricular response, rapid heart rate, and impaired
ronary arterial blood flow. Loss of atrial contraction may
arkedly decrease cardiac output, especially when diastolic
ntricular filling is impaired by mitral stenosis, hyperten-
on, hypertrophic cardiomyopathy (HCM), or restrictive
rdiomyopathy. Hemodynamic impairment due to variation
R-R intervals during AF has been demonstrated in a canine
odel with complete heart block, in which cardiac output fell
approximately 9% during irregular ventricular pacing at
e same mean cycle length as a regularly paced rhythm
82). In patients undergoing AV nodal ablation, irregular
ght ventricular (RV) pacing at the same rate as regular
ntricular pacing resulted in a 15% reduction in cardiac
tput (183). Myocardial contractility is not constant during
F because of force-interval relationships associated with
riations in cycle length (184). Although one might expect
storation of sinus rhythm to improve these hemodynamic
aracteristics, this is not always the case (185,186).
Myocardial blood flow is determined by the presence or
sence of coronary obstructive disease, the difference be-
een aortic diastolic pressure and LV end-diastolic pressure
yocardial perfusion pressure), coronary vascular resis-
nce, and the duration of diastole. AF may adversely impact
l of these factors. An irregular ventricular rhythm is
sociated with coronary blood flow compared with a regular
ythm at the same average rate (186). Animal studies have wnsistently shown that the decrease in coronary flow caused
experimentally induced AF relates to an increase in
ronary vascular resistance mediated by sympathetic activa-
on of alpha-adrenergic receptors that is less pronounced
an during regular atrial pacing at the same ventricular rate
87). Similarly, coronary blood flow is lower during AF than
ring regular atrial pacing in patients with angiographically
rmal coronary arteries (188). The reduced coronary flow
serve during AF may be particularly important in patients
ith coronary artery disease (CAD), in whom compensatory
ronary vasodilation is limited. These findings may explain
hy patients without previous angina sometimes develop
est discomfort with the onset of AF.
In patients with persistent AF, mean LA volume increased
er time from 45 to 64 cm3 while RA volume increased from
to 66 cm3 (189). Restoration and maintenance of sinus
ythm decreased atrial volumes (190). Moreover, transesopha-
al echocardiography (TEE) has demonstrated that contractile
nction and blood flow velocity in the LA appendage (LAA)
cover after cardioversion, consistent with a reversible atrial
rdiomyopathy in patients with AF (191,192).
Beyond its effects on atrial function, a persistently elevated
ntricular rate during AF—greater than or equal to 130
ats per minute in one study (193)—can produce dilated
ntricular cardiomyopathy (tachycardia-induced cardiomy-
athy) (3,193–196). It is critically important to recognize
is cause of cardiomyopathy, in which HF is a consequence
ther than the cause of AF. Control of the ventricular rate
ay lead to reversal of the myopathic process. In one study,
e median LV ejection fraction increased with rate control
om 25% to 52% (194). This phenomenon also has implica-
ons for timing measurements of ventricular performance in
tients with AF. A reduced ejection fraction during or in the
eeks following tachycardia may not reliably predict ventric-
ar function once the rate has been consistently controlled. A
riety of hypotheses have been proposed to explain
chycardia-mediated cardiomyopathy: myocardial energy
pletion, ischemia, abnormal calcium regulation, and re-
odeling, but the actual mechanisms are still unclear (197).
Because of the relationship between LA and LV pressure, a
pid ventricular rate during AF may adversely impact mitral
lve function, increasing mitral regurgitation. In addition,
chycardia may be associated with rate-related intraventricular
nduction delay (including left bundle-branch block), which
rther compromises the synchrony of LV wall motion and
duces cardiac output. Such conduction disturbances may
acerbate mitral regurgitation and limit ventricular filling.
ontrolling the ventricular rate may reverse these effects.
.4. Thromboembolism
lthough ischemic stroke and systemic arterial occlusion in
F are generally attributed to embolism of thrombus from the
A, the pathogenesis of thromboembolism is complex (198).
p to 25% of strokes in patients with AF may be due to
trinsic cerebrovascular diseases, other cardiac sources of
bolism, or atheromatous pathology in the proximal aorta
99,200). In patients 80 to 89 y old, 36% of strokes occur in
ose with AF. The annual risk of stroke for octogenarians
ith AF is in the range of 3% to 8% per year, depending on
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinessociated stroke risk factors (21). About half of all elderly
F patients have hypertension (a major risk factor for
rebrovascular disease) (47), and approximately 12% harbor
rotid artery stenosis (201). Carotid atherosclerosis is not
bstantially more prevalent in AF patients with stroke than
patients without AF and is probably a relatively minor
ntributing epidemiological factor (202).
.4.1. Pathophysiology of Thrombus Formation
hrombotic material associated with AF arises most fre-
ently in the LAA, which cannot be regularly examined by
ecordial (transthoracic) echocardiography (203). Doppler
EE is a more sensitive and specific method to assess LAA
nction (204) and to detect thrombus formation. Thrombi are
ore often encountered in AF patients with ischemic stroke
an in those without stroke (205). Although clinical man-
ement is based on the presumption that thrombus formation
quires continuation of AF for approximately 48 h, thrombi
ve been identified by TEE within shorter intervals
06,207). Thrombus formation begins with Virchow’s triad
stasis, endothelial dysfunction, and a hypercoagulable
ate. Serial TEE studies of the LA (208) and LAA (209)
ring conversion of AF to sinus rhythm demonstrated
duced LAA flow velocities related to loss of organized
echanical contraction during AF. Stunning of the LAA
10) seems responsible for an increased risk of thromboem-
lic events after successful cardioversion, regardless of
hether the method is electrical, pharmacological, or spon-
neous (210). Atrial stunning is at a maximum immediately
ter cardioversion, with progressive improvement of atrial
ansport function within a few days but sometimes as long as
to 4 wk, depending on the duration of AF (210,211). This
rroborates the observation that following cardioversion,
ore than 80% of thromboembolic events occur during the
rst 3 d and almost all occur within 10 d (212). Atrial
unning is more pronounced in patients with AF associated
ith ischemic heart disease than in those with hypertensive
art disease or lone AF (210). Although stunning may be
ilder with certain associated conditions or a short duration
AF, anticoagulation is recommended during cardioversion
all patients with AF lasting longer than 48 h or of unknown
ration, including lone AF except when anticoagulation is
ntraindicated.
Decreased flow within the LA/LAA during AF has been
sociated with spontaneous echo contrast (SEC), thrombus
rmation, and embolic events (213–218). Specifically, SEC,
“smoke,” a swirling haze of variable density, may be
tected by transthoracic or transesophageal echocardio-
aphic imaging of the cardiac chambers and great vessels
der low-flow conditions (219). This phenomenon relates to
brinogen-mediated erythrocyte aggregation (220) and is not
solved by anticoagulation (221). There is evidence that SEC
a marker of stasis caused by AF (222–224). Independent
edictors of SEC in patients with AF include LA enlarge-
ent, reduced LAA flow velocity (213,225). LV dysfunction,
brinogen level (218), and hematocrit (217,218). The utility
SEC for prospective thromboembolic risk stratification
yond that achieved by clinical assessment alone has,
wever, not been confirmed. tiLAA flow velocities are lower in patients with atrial flutter
an are usually seen during sinus rhythm but higher than in
F. Whether this accounts for any lower prevalence of LAA
rombus or thromboembolism associated with atrial flutter is
certain. As in AF, atrial flutter is associated with low
pendage emptying velocities following cardioversion with
e potential for thromboembolism (226,227) and anticoagu-
tion is similarly recommended. (See Section 8.1.4.1.3,
herapeutic Implications.)
Although endothelial dysfunction has been difficult to
monstrate as distinctly contributing to thrombus formation
AF, it may, along with stasis, contribute to a hypercoagu-
ble state. Systemic and/or atrial tissue levels of P-selectin
d von Willebrand factor are elevated in some patients
28–233), and AF has been associated with biochemical
arkers of coagulation and platelet activation that reflect a
stemic hypercoagulable state (228,234–236). Persistent and
roxysmal AF have been associated with increased systemic
brinogen and fibrin D-dimer levels, indicating active intravas-
lar thrombogenesis (228,236,237). Elevated thromboglobulin
d platelet factor 4 levels in selected patients with AF indicate
atelet activation (235,238,239), but these data are less robust,
line with the lower efficacy of platelet-inhibitor drugs for
evention of thromboembolism in clinical trials. Fibrin D-dimer
vels are higher in patients with AF than in patients in sinus
ythm, irrespective of underlying heart disease (240). The
vels of some markers of coagulation fall to normal during
ticoagulation therapy (234), and some increase immediately
ter conversion to sinus rhythm and then normalize (241).
hese biochemical markers do not, however, distinguish a
condary reaction to intravascular coagulation from a primary
percoagulable state.
C-reactive protein (CRP) is increased in patients with AF
mpared with controls (159,242) and correlates with clinical
d echocardiographic stroke risk factors (243). Although
ese findings do not imply a causal relationship, the associ-
ion may indicate that a thromboembolic milieu in the LA
ay involve mechanisms linked to inflammation (243).
In patients with rheumatic mitral stenosis undergoing
ans-septal catheterization for balloon valvuloplasty, levels
fibrinopeptide A, thrombin–antithrombin III complex, and
othrombin fragment F1.2 are increased in the LA compared
ith the RA and femoral vein, indicating regional activation
the coagulation system (244,245). Whether such elevations
e related to AF, for example, through atrial pressure
erload or due to another mechanism has not been deter-
ined. Regional coagulopathy is associated with SEC in the
A and hence with atrial stasis (245).
Contrary to the prevalent concept that systemic anticoag-
ation for 4 wk results in organization and endocardial
herence of LAA thrombus, TEE studies have verified
solution of thrombus in the majority of patients (246).
imilar observations have defined the dynamic nature of
A/LAA dysfunction following conversion of AF, providing
mechanistic rationale for anticoagulation for several weeks
fore and after successful cardioversion. Conversely, in-
eased flow within the LA in patients with mitral regurgita-
on has been associated with less prevalent LA SEC
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esence of LA enlargement (249).
.4.2. Clinical Implications
ecause the pathophysiology of thromboembolism in patients
ith AF is uncertain, the mechanisms linking risk factors to
chemic stroke in patients with AF are incompletely defined.
he strong association between hypertension and stroke in
F is probably mediated primarily by embolism originating
the LAA (200), but hypertension also increases the risk of
ncardioembolic strokes in patients with AF (200,250).
ypertension in patients with AF is associated with reduced
AA flow velocity, SEC, and thrombus formation
25,251,252). Ventricular diastolic dysfunction might under-
e the effect of hypertension on LA dynamics, but this
lationship is still speculative (253,254). Whether control of
pertension lowers the risk for cardioembolic stroke in
tients with AF is a vital question, because LV diastolic
normalities associated with hypertension in the elderly are
ten multifactorial and difficult to reverse (254,255).
The increasing stroke risk in patients with AF with
vancing age is also multifactorial. In patients with AF,
ing is associated with LA enlargement, reduced LAA flow
locity, and SEC, all of which predispose to LA thrombus
rmation (225,251,256). Aging is a risk factor for athero-
lerosis, and plaques in the aortic arch are associated with
roke independent of AF (257). Levels of prothrombin
tivation fragment F1.2, an index of thrombin generation,
crease with age in the general population (258–260) as well
in those with AF (12,261), suggesting an age-related
othrombotic diathesis. In the Stroke Prevention in Atrial
ibrillation (SPAF) studies, age was a more potent risk factor
hen combined with other risk factors such as hypertension
female gender (261,262), placing women over age 75 y
ith AF at particular risk for cardioembolic strokes (263).
LV systolic dysfunction, as indicated by a history of HF or
hocardiographic assessment, predicts ischemic stroke in pa-
nts with AF who receive no antithrombotic therapy (264–267)
t not in moderate-risk patients given aspirin (261,268). Mech-
istic inferences are contradictory; LV systolic dysfunction has
en associated both with LA thrombus and with noncardioem-
lic strokes in patients with AF (200,269).
In summary, complex thromboembolic mechanisms are
erative in AF and involve the interplay of risk factors
lated to atrial stasis, endothelial dysfunction, and systemic
d possibly local hypercoagulability.
. Causes, Associated Conditions,
linical Manifestations, and
uality of Life
.1. Causes and Associated Conditions
.1.1. Reversible Causes of Atrial Fibrillation
F may be related to acute, temporary causes, including
cohol intake (“holiday heart syndrome”), surgery, electro-
tion, MI, pericarditis, myocarditis, pulmonary embolism or
her pulmonary diseases, hyperthyroidism, and other meta-
lic disorders. In such cases, successful treatment of the coderlying condition often eliminates AF. AF that develops
the setting of acute MI portends an adverse prognosis
mpared with preinfarct AF or sinus rhythm (270,271). AF
ay be associated with atrial flutter, the WPW syndrome, or
V nodal reentrant tachycardias, and treatment of the pri-
ary arrhythmias reduces or eliminates the incidence of
current AF (172). AF is a common early postoperative
mplication of cardiac or thoracic surgery.
.1.2. Atrial Fibrillation Without Associated
eart Disease
F is often an electrical manifestation of underlying cardiac
sease. Nonetheless, approximately 30% to 45% of cases of
roxysmal AF and 20% to 25% of cases of persistent AF
cur in younger patients without demonstrable underlying
sease (“lone AF”) (27,29). AF can present as an isolated
04) or familial arrhythmia, although a responsible underly-
g disease may appear over time (272). Although AF may
cur without underlying heart disease in the elderly, the
anges in cardiac structure and function that accompany
ing, such as an increase in myocardial stiffness, may be
sociated with AF, just as heart disease in older patients may
coincidental and unrelated to AF.
.1.3. Medical Conditions Associated With
trial Fibrillation
besity is an important risk factor for development of AF
73–275). After adjusting for clinical risk factors, the excess
sk of AF appears mediated by LA dilation, because there is
graded increase in LA size as BMI increases from normal to
e overweight and obese categories (273). Weight reduction
s been linked to regression of LA enlargement (273,276).
hese findings suggest a physiological link between obesity,
F, and stroke and raise the intriguing possibility that weight
duction may decrease the risk of AF.
.1.4. Atrial Fibrillation With Associated Heart Disease
pecific cardiovascular conditions associated with AF include
lvular heart disease (most often, mitral valve disease), HF,
AD, and hypertension, particularly when LVH is present. In
dition, AF may be associated with HCM, dilated cardiomy-
athy, or congenital heart disease, especially atrial septal defect
adults. Potential etiologies also include restrictive cardiomy-
athies (e.g., amyloidosis, hemochromatosis, and endomyocar-
al fibrosis), cardiac tumors, and constrictive pericarditis. Other
art diseases, such as mitral valve prolapse with or without
itral regurgitation, calcification of the mitral annulus, cor
lmonale, and idiopathic dilation of the RA, have been asso-
ated with a high incidence of AF. AF is commonly encoun-
red in patients with sleep apnea syndrome, but whether the
rhythmia is provoked by hypoxia, another biochemical abnor-
ality, changes in pulmonary dynamics or RA factors, changes
autonomic tone, or systemic hypertension has not been
termined. Table 5 lists etiologies and factors predisposing
tients to AF. (For a list of associated heart diseases in the
LFA study, see Table 3.)
.1.5. Familial (Genetic) Atrial Fibrillation
amilial AF, defined as lone AF running in a family, is more
mmon than previously recognized but should be distin-
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinesished from AF secondary to other genetic diseases like
milial cardiomyopathies. The likelihood of developing AF
increased among those whose parents had AF, suggesting a
milial susceptibility to the arrhythmia, but the mechanisms
sociated with transmission are not necessarily electrical,
cause the relationship has also been seen in patients who
ve a family history of hypertension, diabetes, or HF (277).
The molecular defects responsible for familial AF are
rgely unknown. Specific chromosomal loci (278) have been
nked to AF in some families, suggesting distinct genetic
utations (279). Two mutations associated with gain of
nction leading to short atrial refractoriness have been
scovered in several Chinese families (280,281).
.1.6. Autonomic Influences in Atrial Fibrillation
utonomic influences play an important role in the initiation
AF. The noninvasive measurement of autonomic tone in
mans has been augmented by measures of HRV (282),
hich reflect changes in the relative autonomic modulation of
BLE 5. Etiologies and Factors Predisposing Patients to AF
ectrophysiological abnormalities
Enhanced automaticity (focal AF)
Conduction abnormality (reentry)
trial pressure elevation
Mitral or tricuspid valve disease
Myocardial disease (primary or secondary, leading to systolic or diastolic
dysfunction)
Semilunar valvular abnormalities (causing ventricular hypertrophy)
Systemic or pulmonary hypertension (pulmonary embolism)
Intracardiac tumors or thrombi
trial ischemia
Coronary artery disease
flammatory or infiltrative atrial disease
Pericarditis
Amyloidosis
Myocarditis
Age-induced atrial fibrotic changes
rugs
Alcohol
Caffeine
docrine disorders
Hyperthyroidism
Pheochromocytoma
hanges in autonomic tone
Increased parasympathetic activity
Increased sympathetic activity
rimary or metastatic disease in or adjacent to the atrial wall
ostoperative
Cardiac, pulmonary, or esophageal
ongenital heart disease
eurogenic
Subarachnoid hemorrhage
Nonhemorrhagic, major stroke
iopathic (lone AF)
milial AF
AF indicates atrial fibrillation.art rate rather than the absolute level of sympathetic or acrasympathetic tone. It appears that the balance between
mpathetic and vagal influences is as important as absolute
mpathetic or parasympathetic tone as a predictor of AF.
luctuations in autonomic tone as measured by HRV occur
ior to the development of AF. Vagal predominance in the
inutes preceding the onset of AF has been observed in some
tients with structurally normal hearts, while in others there
a shift toward sympathetic predominance (283,284). Al-
ough Coumel (285) recognized that certain patients could
characterized in terms of a vagal or adrenergic form of AF,
ese cases likely represent the extremes of either influence.
general, vagally mediated AF occurs at night or after
eals, while adrenergically induced AF typically occurs
ring the daytime in patients with organic heart disease
86). Vagally mediated AF is the more common form, and in
ch cases adrenergic blocking drugs or digitalis sometimes
orsens symptoms and anticholinergic agents such as diso-
ramide are sometimes helpful to prevent recurrent AF.
lassification of AF as of either the vagal or adrenergic form
s only limited impact on management. For AF of the
renergic type, beta blockers are the initial treatment of
oice.
.2. Clinical Manifestations
F has a heterogeneous clinical presentation, occurring in the
esence or absence of detectable heart disease. An episode of
F may be self-limited or require medical intervention for
rmination. Over time, the pattern of AF may be defined in
rms of the number of episodes, duration, frequency, mode
onset, triggers, and response to therapy, but these features
ay be impossible to discern when AF is first encountered in
individual patient.
AF may be immediately recognized by sensation of palpi-
tions or by its hemodynamic or thromboembolic conse-
ences or follow an asymptomatic period of unknown
ration. Ambulatory ECG recordings and device-based
onitoring have revealed that an individual may experience
riods of both symptomatic and asymptomatic AF (287–
0). Patients in whom the arrhythmia has become permanent
ten notice that palpitation decreases with time and may
come asymptomatic. This is particularly common among
e elderly. Some patients experience symptoms only during
roxysmal AF or only intermittently during sustained AF.
hen present, symptoms of AF vary with the irregularity and
te of ventricular response (291), underlying functional
atus, duration of AF, and individual patient factors.
The initial presentation of AF may be an embolic compli-
tion or exacerbation of HF, but most patients complain of
lpitations, chest pain, dyspnea, fatigue, lightheadedness, or
ncope. Polyuria may be associated with the release of atrial
triuretic peptide, particularly as episodes of AF begin or
rminate. AF associated with a sustained, rapid ventricular
sponse can lead to tachycardia-mediated cardiomyopathy,
pecially in patients unaware of the arrhythmia.
Syncope is an uncommon complication of AF that can
cur upon conversion in patients with sinus node dysfunc-
on or because of rapid ventricular rates in patients with
CM, in patients with valvular aortic stenosis, or when an
cessory pathway is present.
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lthough stroke certainly accounts for much of the functional
pairment associated with AF, available data suggest that
ality of life is considerably impaired in patients with AF
mpared with age-matched controls. Sustained sinus rhythm
associated with improved quality of life and better exercise
rformance than AF in some studies but not others (292–
6). In the SPAF study cohort, Ganiats et al (297) found the
ew York Heart Association functional classification, origi-
lly developed for HF, an insensitive index of quality of life
patients with AF. In another study (298), 47 of 69 patients
8%) with paroxysmal AF considered the arrhythmia disruptive
lifestyle, but this perception was not associated with either the
equency or duration of symptomatic episodes.
. Clinical Evaluation
.1. Basic Evaluation of the Patient With
trial Fibrillation
.1.1. Clinical History and Physical Examination
he diagnosis of AF is based on history and clinical exami-
tion and confirmed by ECG recording, sometimes in the
rm of bedside telemetry or ambulatory Holter recordings.
he initial evaluation of a patient with suspected or proved
F involves characterizing the pattern of the arrhythmia as
roxysmal or persistent, determining its cause, and defining
sociated cardiac and extracardiac factors pertinent to the
iology, tolerability, and history of prior management (Table
. A thorough history will result in a well-planned, focused
orkup that serves as an effective guide to therapy (3). The
orkup of a patient with AF can usually take place and
erapy initiated in a single outpatient encounter. Delay
curs when the rhythm has not been specifically documented
d additional monitoring is necessary.
Typically, AF occurs in patients with underlying heart
sease, such as hypertensive heart disease (33,299). (See
ection 6, Causes, Associated Conditions, Clinical Manifes-
tions, and Quality of Life.) Atherosclerotic or valvular heart
seases are also common substrates, whereas pulmonary
thology, preexcitation syndromes, and thyroid disease are
ss frequent causes (300). Because of reports of genetic
ansmission of AF, the family history is important as well
72,301). Although various environmental triggers can ini-
ate episodes of AF, this aspect may not emerge from the
story given spontaneously by the patient and often requires
ecific inquiry. Commonly mentioned triggers include alco-
l, sleep deprivation, and emotional stress, but vagally
ediated AF may occur during sleep or after a large meal and
more likely to arise during a period of rest succeeded by a
riod of stress. Stimulants such as caffeine or exercise may
so precipitate AF.
The physical examination may suggest AF on the basis of
regular pulse, irregular jugular venous pulsations, and vari-
ion in the intensity of the first heart sound or absence of a
urth sound heard previously during sinus rhythm. Exami-
tion may also disclose associated valvular heart disease,
yocardial abnormalities, or HF. The findings are similar in
tients with atrial flutter, except that the rhythm may be mgular and rapid venous oscillations may occasionally be
sible in the jugular pulse.
.1.2. Investigations
he diagnosis of AF requires ECG documentation by at least
single-lead recording during the arrhythmia, which may be
cilitated by review of emergency department records,
olter monitoring, or transtelephonic or telemetric record-
gs. A portable ECG recording tool may help establish the
agnosis in cases of paroxysmal AF and provide a permanent
CG record of the arrhythmia. In patients with implanted
cemakers or defibrillators, the diagnostic and memory
nctions may allow accurate and automatic detection of AF
02). A chest radiograph may detect enlargement of the
rdiac chambers and HF but is valuable mostly to detect
trinsic pulmonary pathology and evaluate the pulmonary
sculature. It is less important than echocardiography for
utine evaluation of patients with AF. As part of the initial
aluation, all patients with AF should have 2-dimensional,
oppler echocardiography to assess LA and LV dimensions
d LV wall thickness and function and to exclude occult
lvular or pericardial disease and HCM. LV systolic and
astolic performance helps guide decisions regarding antiar-
ythmic and antithrombotic therapy. Thrombus should be
ught in the LA but is seldom detected without TEE
03,303,304).
Blood tests are routine but can be abbreviated. It is
portant that thyroid, renal, and hepatic function, serum
ectrolytes, and the hemogram be measured at least once in
e course of evaluating a patient with AF (305).
.2. Additional Investigation of Selected
atients With Atrial Fibrillation
bnormalities in P-wave duration detected by signal-averaged
CG during sinus rhythm that reflect slow intra-atrial conduc-
n are associated with an increased risk of developing AF
33,306–308). The sensitivity and negative predictive value of
gnal-averaged P-wave ECG are high, but specificity and
sitive predictive value are low, limiting the usefulness of this
chnique (309). Measurement of HRV has failed to provide
eful information for risk stratification (309).
Both B-type natriuretic peptide (assessed by measuring
NP or N-terminal pro-BNP), which is produced mainly in
e ventricles, and atrial naturetic peptide (ANP), which is
oduced primarily in the atria, are associated with AF.
lasma levels of both peptides are elevated in patients with
roxysmal and persistent AF and decrease rapidly after
storation of sinus rhythm (310–313). Thus, the presence of
F should be considered when interpreting plasma levels of
ese peptides. In the absence of HF, there is an inverse
rrelation between LA volume and ANP/BNP levels (251);
ontaneous conversion to sinus rhythm is associated with
gher ANP levels during AF and with smaller LA volumes
11). In long-standing persistent AF, lower plasma ANP
vels may be related to degeneration of atrial myocytes
14). High levels of BNP may be predictive of thromboem-
lism (315) and recurrent AF (40,316), but further studies
e needed to evaluate the utility of BNP as a prognostic
arker.
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xercise Testing
rolonged or frequent monitoring may be necessary to reveal
BLE 6. Clinical Evaluation in Patients With AF
inimum evaluation
1. History and physical examination, to define
Presence and nature of symptoms associated with AF
Clinical type of AF (first episode, paroxysmal, persistent, or permanent)
Onset of the first symptomatic attack or date of discovery of AF
Frequency, duration, precipitating factors, and modes of termination of AF
Response to any pharmacological agents that have been administered
Presence of any underlying heart disease or other reversible conditions (e
2. Electrocardiogram, to identify
Rhythm (verify AF)
LV hypertrophy
P-wave duration and morphology or fibrillatory waves
Preexcitation
Bundle-branch block
Prior MI
Other atrial arrhythmias
To measure and follow the R-R, QRS, and QT intervals in conjunction wit
3. Transthoracic echocardiogram, to identify
Valvular heart disease
LA and RA size
LV size and function
Peak RV pressure (pulmonary hypertension)
LV hypertrophy
LA thrombus (low sensitivity)
Pericardial disease
4. Blood tests of thyroid, renal, and hepatic function
For a first episode of AF, when the ventricular rate is difficult to control
dditional testing
ne or several tests may be necessary.
1. Six-minute walk test
If the adequacy of rate control is in question
2. Exercise testing
If the adequacy of rate control is in question (permanent AF)
To reproduce exercise-induced AF
To exclude ischemia before treatment of selected patients with a type IC
3. Holter monitoring or event recording
If diagnosis of the type of arrhythmia is in question
As a means of evaluating rate control
4. Transesophageal echocardiography
To identify LA thrombus (in the LA appendage)
To guide cardioversion
5. Electrophysiological study
To clarify the mechanism of wide-QRS-complex tachycardia
To identify a predisposing arrhythmia such as atrial flutter or paroxysmal
To seek sites for curative ablation or AV conduction block/modification
6. Chest radiograph, to evaluate
Lung parenchyma, when clinical findings suggest an abnormality
Pulmonary vasculature, when clinical findings suggest an abnormality
Type IC refers to the Vaughan Williams classification of antiarrhythmic drugs
AF indicates atrial fibrillation; AV, atrioventricular; LA, left atrial; LV, left ventisodes of asymptomatic AF, which may be a cause of doyptogenic stroke. Ambulatory ECG (e.g., Holter) monitor-
g is also useful to judge the adequacy of rate control. This
chnology may provide valuable information to guide drug
erthyroidism or alcohol consumption)
rhythmic drug therapy
ythmic drug
ntricular tachycardia
ble 19).
MI, myocardial infarction; RA, right atrial; and RV, right ventricular..g., hyp
h antiar
antiarrh
suprave
(see Tasage for rate control or rhythm management (317).
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98Exercise testing should be performed if myocardial isch-
ia is suspected and prior to initiating type IC antiarrhyth-
ic drug therapy. Another reason for exercise testing is to
udy the adequacy of rate control across a full spectrum of
tivity, not only at rest, in patients with persistent or
rmanent AF.
.2.2. Transesophageal Echocardiography
EE is not part of the standard initial investigation of patients
ith AF. By placing a high-frequency ultrasound transducer
ose to the heart, however, TEE provides high-quality
ages of cardiac structure (318) and function (319). It is the
ost sensitive and specific technique to detect sources and
tential mechanisms for cardiogenic embolism (320). The
chnology has been used to stratify stroke risk in patients
ith AF and to guide cardioversion. (See Section 8.1.4,
reventing Thromboembolism.) Several TEE features have
en associated with thromboembolism in patients with
nvalvular AF, including LA/LAA thrombus, LA/LAA
EC, reduced LAA flow velocity, and aortic atheromatous
normalities (252). Although these features are associated
ith cardiogenic embolism (268,321), prospective investiga-
ons are needed to compare these TEE findings with clinical
d transthoracic echocardiographic predictors of thrombo-
bolism. Detection of LA/LAA thrombus in the setting of
roke or systemic embolism is convincing evidence of a
rdiogenic mechanism (207).
TEE of patients with AF before cardioversion has shown
A or LAA thrombus in 5% to 15% (304,321–323), but
romboembolism after conversion to sinus rhythm has been
ported even when TEE did not show thrombus (324). These
ents typically occur relatively soon after cardioversion in
tients who were not treated with anticoagulation, reinforc-
g the need to maintain continuous therapeutic anticoagula-
on in patients with AF undergoing cardioversion even when
thrombus is identified. For patients with AF of greater than
-h duration, a TEE-guided strategy or the traditional
rategy of anticoagulation for 4 wk before and 4 wk after
ective cardioversion resulted in similar rates of thrombo-
bolism (less than 1% during the 8 wk) (325). Contrast-
hanced magnetic resonance imaging is an emerging tech-
que for detection of intracardiac thrombi that appears more
nsitive than precordial echocardiography and comparable
TEE (326).
.2.3. Electrophysiological Study
n EP study can be helpful when AF is a consequence of
entrant tachycardia such as atrial flutter, intra-atrial reentry,
AV reentry involving an accessory pathway. Detection of
delta wave on the surface ECG in a patient with a history of
F or syncope is a firm indication for EP study and ablation
the bypass tract. Some patients with documented atrial
utter also have AF, and ablation of flutter can eliminate AF,
though this is not common and successful ablation of flutter
es not eliminate the possibility of developing AF in the
ture (327). AF associated with rapid ventricular rates and
ide-complex QRS morphology may sometimes be misla-
led as ventricular tachycardia, and an EP study will
fferentiate the 2 arrhythmias. In short, EP testing is indi-ted when ablative therapy of arrhythmias that trigger AF or
lation of AF is planned.
In patients with AF who are candidates for ablation, an EP
udy is critical to define the targeted site or sites of ablation
the LA and/or right-sided structures. Evolving strategies in
e ablation of AF are discussed in Section 8.0.
. Management (UPDATED)
or new or updated text, view the
011 Focused Update and the 2011
ocused Update on Dabigatran. Text
upporting unchanged recommendations
as not been updated.
anagement of patients with AF involves 3 objectives—rate
ntrol, prevention of thromboembolism, and correction of
e rhythm disturbance, and these are not mutually exclusive.
he initial management decision involves primarily a rate-
ntrol or rhythm-control strategy. Under the rate-control
rategy, the ventricular rate is controlled with no commit-
ent to restore or maintain sinus rhythm. The rhythm-control
rategy attempts restoration and/or maintenance of sinus
ythm. The latter strategy also requires attention to rate
ntrol. Depending on the patient’s course, the strategy
itially chosen may prove unsuccessful and the alternate
rategy is then adopted. Regardless of whether the rate-
ntrol or rhythm-control strategy is pursued, attention must
so be directed to antithrombotic therapy for prevention of
romboembolism.
At the initial encounter, an overall management strategy
ould be discussed with the patient, considering several
ctors: (1) type and duration of AF, (2) severity and type of
mptoms, (3) associated cardiovascular disease, (4) patient
e, (5) associated medical conditions, (6) short-term and
ng-term treatment goals, and (7) pharmacological and
npharmacological therapeutic options. A patient with a
rst-documented episode of AF in whom rate control is
hieved does not require hospitalization.
URATION AND PATTERN OF ATRIAL FIBRILLATION. As defined
in Section 3, AF may be categorized as paroxysmal
(self-terminating), persistent (requiring electrical or phar-
macological termination), or permanent (cardioversion
impossible or futile). The duration since onset may be
known or unknown in an individual patient depending
upon the presence or absence of specific symptoms or
ECG documentation of the arrhythmia.
YPE AND SEVERITY OF SYMPTOMS. As described in Section 6.2,
few arrhythmias present with such protean manifestations,
some of which are subtle. Some patients with AF become
accommodated to a poor state of health and may feel
markedly better once sinus rhythm is restored. In contrast,
other patients have no or minimal symptoms during AF and
restoration of sinus rhythm would not change their functional
status. Before deciding on whether a patient is truly asymp-
tomatic, it may be helpful to ask whether the patient has
noticed a decline in activity over time, especially when there
is no other obvious explanation.
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March 15, 2011:e101–98 ACC/AHA/ESC Practice GuidelinesSSOCIATED CARDIOVASCULAR DISEASE. The likelihood that
symptoms may progress is typically related to the presence
of cardiovascular disease. The presence of ventricular
hypertrophy could, for example, lead to symptoms as dia-
stolic compliance worsens. Such a patient may not feel
different in sinus rhythm when initially evaluated but may
face difficulties in the future if left in AF until it becomes
difficult to restore sinus rhythm because of atrial remodeling.
OTENTIAL FOR CHANGES IN CARDIAC FUNCTION RELATED TO
AGE. Before choosing rate control as a long-term strategy,
the clinician should consider how permanent AF is likely
to affect the patient in the future. In a patient with
asymptomatic persistent AF, attempts to restore sinus
rhythm may not be needed. Prospective studies like Rate
Control vs Electrical cardioversion for persistent atrial
fibrillation (RACE) and Atrial Fibrillation Follow-up In-
vestigation of Rhythm Management (AFFIRM) showed
that patients who could tolerate rate-controlled AF had
outcomes similar to those randomized to rhythm control.
However, these studies enrolled predominantly older pa-
tients (average 70 y), most of whom had persistent AF and
heart disease, and follow-up extended over just a few
years. Thus, the trial data do not necessarily apply to
younger patients without heart disease or to patients whose
dependency upon sinus rhythm is likely to change appre-
ciably over time. Among the latter may be patients in HF,
who are prone to deteriorate over time if left in AF. The
problem with allowing AF to persist for years is that it
may then be impossible to restore sinus rhythm as a
consequence of electrical and structural remodeling,
which preclude successful restoration or maintenance of
sinus rhythm and favor permanent AF. This makes it
important to ensure that a window of opportunity to
maintain sinus rhythm is not overlooked early in the
course of management of a patient with AF.
.1. Pharmacological and
onpharmacological Therapeutic Options
rugs and ablation are effective for both rate and rhythm
ntrol, and in special circumstances surgery may be the
eferred option. Regardless of the approach, the need for
ticoagulation is based on stroke risk and not on whether
nus rhythm is maintained. For rhythm control, drugs are
pically the first choice and LA ablation is a second-line
oice, especially in patients with symptomatic lone AF. In
me patients, especially young ones with very symptomatic
F who need sinus rhythm, radiofrequency ablation may be
eferred over years of drug therapy. Patients with pre-
erative AF undergoing cardiac surgery face a unique
portunity. While few patients are candidates for a stand-
one surgical procedure to cure AF using the maze or LA
lation techniques, these approaches can be an effective
junct to coronary bypass or valve repair surgery to prevent
current postoperative AF. Applied in this way, AF may be
iminated without significant additional risk. Because the
AA is the site of over 95% of detected thrombi, this
ructure should be removed from the circulation when
ssible during cardiac surgery in patients at risk of devel- toing postoperative AF, although this has not been proved to
event stroke (328).
Drugs are the primary treatment for rate control in most
tients with AF. While ablation of the AV conduction
stem and permanent pacing (the “ablate and pace” strategy)
an option that often yields remarkable symptomatic relief,
owing concern about the negative effect of long-term RV
cing makes this a fallback rather than a primary treatment
rategy. LV pacing, on the other hand, may overcome many
the adverse hemodynamic effects associated with RV
cing.
.1.1. Pharmacological Therapy
.1.1.1. DRUGS MODULATING THE
ENIN-ANGIOTENSIN- ALDOSTERONE SYSTEM
xperimental and clinical studies have demonstrated that
CE inhibitors and angiotensin receptor antagonists may
crease the incidence of AF (36) (see Section 8.5, Primary
revention). ACE inhibitors decrease atrial pressure, reduce
e frequency of atrial premature beats (329), reduce fibrosis
6), and may lower the relapse rate after cardioversion
9,330,331) in patients with AF. These drugs can reduce
gnal-averaged P-wave duration, the number of defibrillation
tempts required to restore sinus rhythm, and the number of
spital readmissions for AF (332). Withdrawal of ACE-
hibitor medication is associated with postoperative AF in
tients undergoing coronary bypass surgery (333), and
ncurrent therapy with ACE-inhibitor and antiarrhythmic
ents enhances maintenance of sinus rhythm (334).
In patients with persistent AF and normal LV function, the
mbination of enalapril or irbesartan plus amiodarone re-
lted in lower rates of recurrent AF after electrical conver-
on than amiodarone alone (39,331). The role of treatment
ith inhibitors of the RAAS in long-term maintenance of
nus rhythm in patients at risk of developing recurrent AF
quires clarification in randomized trials before this ap-
oach can be routinely recommended.
.1.1.2. HMG COA-REDUCTASE INHIBITORS (STATINS)
vailable evidence supports the efficacy of statin-type
olesterol-lowering agents in maintaining sinus rhythm in
tients with persistent lone AF. Statins decrease the risk of
currences after successful direct-current cardioversion
ithout affecting the defibrillation threshold (335). The
echanisms by which these drugs prevent AF recurrence are
orly understood but include an inhibitory effect on the
ogression of CAD, pleiotropic (anti-inflammatory and an-
oxidant) effects (336,337), and direct antiarrhythmic effects
volving alterations in transmembrane ion channels (338).
.1.2. Heart Rate Control Versus Rhythm Control
.1.2.1. DISTINGUISHING SHORT-TERM AND
NG-TERM TREATMENT GOALS
he initial and subsequent management of symptomatic AF
ay differ from one patient to another. For patients with
mptomatic AF lasting many weeks, initial therapy may be
ticoagulation and rate control, while the long-term goal is
restore sinus rhythm. When cardioversion is contemplated
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98d the duration of AF is unknown or exceeds 48 h, patients
ho do not require long-term anticoagulation may benefit
om short-term anticoagulation. If rate control offers inade-
ate symptomatic relief, restoration of sinus rhythm be-
mes a clear long-term goal. Early cardioversion may be
cessary if AF causes hypotension or worsening HF, making
e establishment of sinus rhythm a combined short- and
ng-term therapeutic goal. In contrast, amelioration of symp-
ms by rate control in older patients may steer the clinician
ay from attempts to restore sinus rhythm. In some circum-
ances, when the initiating pathophysiology of AF is revers-
le, as for instance in the setting of thyrotoxicosis or after
rdiac surgery, no long-term therapy may be necessary.
.1.2.2. CLINICAL TRIALS COMPARING RATE CONTROL
ND RHYTHM CONTROL
andomized trials comparing outcomes of rhythm- versus
te-control strategies in patients with AF are summarized in
ables 7 and 8. Among these, AFFIRM (Atrial Fibrillation
ollow-up Investigation of Rhythm Management) found no
BLE 7. Trials Comparing Rate Control and Rhythm Control Str
ial Reference
Patients
(n)
AF
Duration
Follow-Up
(y)
Age (
y 
FIRM (2002) 296 4060 †/NR 3.5 70
CE (2002) 293 522 1 to 399 d 2.3 68
F (2000) 294 252 7 to 360 d 1 61
AF (2003) 343 200 63 mo 1.6 66
T CAFÉ (2004) 344 205 7 to 730 d 1.7 61
*Comparison between rate and rhythm control groups.
†Approximately one third of patients were enrolled with first episode of atria
AFFIRM indicates Atrial Fibrillation Follow-Up Investigation of Rhythm Manag
armacological Intervention in Atrial Fibrillation; RACE, Rate Control Versus El
rategies of Treatment of Atrial Fibrillation.
BLE 8. General Characteristics of Rhythm Control and Rate Co
al Reference
Patients
(n)
Mean
Age
(y)
Mean Length
of Follow-Up
(y) Inclusion Criteria
F (2000) 294 252 61.0 1.0 Persistent AF (7 to 360 d)
CE (2002) 293 522 68.0 2.3 Persistent AF or flutter for less than 1
and 1 to 2 cardioversions over 2 y an
oral anticoagulation
AF (2002) 343 200 66.0 1.6 Persistent AF (longer than 4 wk and le
than 2 y), left atrial size greater than 4
mm, CHF NYHA II–IV, LVEF less than
FIRM
02)
296 4060 69.7 3.5 Paroxysmal AF or persistent AF, age 6
or older, or risk of stroke or death
T CAFÉ
04)
344 205 60.8 1.7 First clinically overt episode of persiste
AF (7 d or more and less than 2 y), 5
75 y old
Reprinted with permission from Pelargonio G, Prystowsky EN. Rate versus r
rdiovasc Med 2005;2:514–21 (346).
AF indicates atrial fibrillation; AFFIRM, Atrial Fibrillation Follow-up Investiga
suscitation; HOT CAFÉ, How to Treat Chronic Atrial Fibrillation; LVEF, left ven
tervention in Atrial Fibrillation; PM, pacemaker; RACE, Rate Control Versus Elect
Atrial Fibrillation.fference in mortality or stroke rate between patients as-
gned to one strategy or the other. The RACE (Rate Control
. Electrical cardioversion for persistent atrial fibrillation)
ial found rate control not inferior to rhythm control for
evention of death and morbidity. Clinically silent recur-
nces of AF in asymptomatic patients treated with antiar-
ythmic drugs may be responsible for thromboembolic
ents after withdrawal of anticoagulation. Hence, patients at
gh risk for stroke may require anticoagulation regardless of
hether the rate-control or rhythm-control strategy is chosen,
t the AFFIRM trial was not designed to address this
estion. While secondary analyses support this notion (339),
e stroke rate in patients assigned to rhythm control who
opped warfarin is uncertain, and additional research is
eded to address this important question.
Depending upon symptoms, rate control may be reasonable
itial therapy in older patients with persistent AF who have
pertension or heart disease. For younger individuals, espe-
ally those with paroxysmal lone AF, rhythm control may be
in Patients With AF
Patients in SR*
Clinical Events (n)
Stroke/Embolism Death
Rate Rhythm Rate Rhythm
35% vs. 63% (at 5 y) 88/2027 93/2033 310/2027 356/2033
10% vs. 39% (at 2.3 y) 7/256 16/266 18/256 18/266
10% vs. 56% (at 1 y) 0/125 2/127 2/125 2/127
11% vs. 26% (at 2 y) 2/100 5/100 8/100 4/100
NR vs. 64% 1/101 3/104 1/101 3/104
tion (AF).
HOT CAFÉ, How to Treat Chronic Atrial Fibrillation; NR, not reported; PIAF,
Cardioversion for Persistent Atrial Fibrillation; SR, sinus rhythm; and STAF,
rials in Patients With AF
Primary Endpoint
Patients Reaching
Primary Endpoint (n)
pRate Control Rhythm Control
mptomatic improvement 76/125(60.8%) 70/127(55.1%) 0.317
mposite: cardiovascular death, CHF,
vere bleeding, PM implantation,
omboembolic events, severe adverse
ects of antiarrhythmic drugs
44/256(17.2%) 60/266(22.6%) 0.11
mposite: overall mortality,
rebrovascular complications, CPR,
bolic events
10/100(10.0%) 9/100 (9.0%) 0.99
-cause mortality 310/2027(25.9%) 356/2033(26.7%) 0.08
mposite; death, thromboembolic
mplications; intracranial or other major
morrhage
1/101 (1.0%) 4/104 (3.9%) Greater
than 0.71
ontrol in the management of patients with atrial fibrillation. Nat Clin Pract
hythm Management, CHF, congestive heart failure; CPR, cardiopulmonary
ejection fraction; NYHA, New York Heart Association; PIAF, Pharmacological
dioversion for Persistent Atrial Fibrillation; and STAF, Strategies of Treatmentategies
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinesbetter initial approach. Often medications that exert both
tiarrhythmic and rate-controlling effects are required. Cath-
er ablation should be considered to maintain sinus rhythm
selected patients who failed to respond to antiarrhythmic
ug therapy (340).
.1.2.3. EFFECT ON SYMPTOMS AND QUALITY OF LIFE
formation about the effects of antiarrhythmic and chrono-
opic therapies on quality of life is inconsistent (292,294,
5). The AFFIRM (293,296), RACE (293,295), PIAF (Phar-
acologic Intervention in Atrial Fibrillation) (342), and
TAF (Strategies of Treatment of Atrial Fibrillation) (343)
udies found no differences in quality of life with rhythm
ntrol compared with rate control. Rhythm control in the
IAF and How to Treat Chronic Atrial Fibrillation (HOT
AFÉ) (344) studies resulted in better exercise tolerance than
te control, but this did not translate into improved quality of
fe. In the Canadian Trial of Atrial Fibrillation (CTAF) study
47), there was no difference between amiodarone and
talol or propafenone as assessed by responses to the Short
orm-36 questionnaire, while a symptom severity scale
owed benefit of amiodarone over the other drugs. In the
otalol Amiodarone Atrial Fibrillation Efficacy Trial
AFE-T) (292), restoration and maintenance of sinus rhythm
patients with AF significantly improved quality of life in
rtain domains, but amiodarone was associated with a
crease in mental health function compared with sotalol or
acebo (292). Symptomatic improvement has also been
ported after the maze procedure in patients with AF (348).
In a substudy of AFFIRM, there was no significant
sociation between achieved HR and quality-of-life mea-
rements, New York Heart Association functional class, or
min walking distance in patients with AF compared with
ss well-controlled patients (345). On the whole, rate- and
ythm-control strategies do not affect quality of life signif-
antly or differently. Even when sinus rhythm can be
aintained, symptoms of associated cardiovascular condi-
ons may obscure changes in quality of life related to AF.
linicians must exercise judgment, however, in translating
ifts in quality of life in these study populations to the sense
well-being experienced by individual patients. Patients
ith similar health status may experience entirely different
alitiy of life, and treatment must be tailored to each
dividual, depending on the nature, intensity, and frequency
symptoms, patient preferences, comorbid conditions, and
e ongoing response to treatment.
Long-term oral anticoagulant therapy with vitamin K
tagonists involves multiple drug interactions and frequent
ood testing, which influences quality of life in patients with
F. Gage et al (349) quantified this as a mean 1.3% decrease
utility, a measure of quality of life in quantitative decision
alysis. Some patients (16%) thought that their quality of
fe would be greater with aspirin than with oral anticoagu-
nts, despite its lesser efficacy. Other investigators, using
cision analysis to assess patient preferences, found that
% of 97 patients preferred anticoagulation to no treatment,
smaller proportion than that for which published guidelines
commend treatment (350). In the future, these comparisons thuld be influenced by the development of more convenient
proaches to antithrombotic therapy.
.1.2.4. EFFECTS ON HEART FAILURE
F may develop or deteriorate during either type of treatment
r AF due to progression of underlying cardiac disease,
adequate control of the ventricular rate at the time of
current AF, or antiarrhythmic drug toxicity. Patients man-
ed with rate compared with rhythm control did not,
wever, differ significantly in development or deterioration
HF. In the AFFIRM study, 2.1% of those in the rate-
ntrol group and 2.7% in the rhythm-control group devel-
ed AF after an average follow-up of 3.5 y. In the RACE
udy, the incidence of hospitalization for HF was 3.5%
ring a management strategy directed at rate control and
5% with rhythm control, during an average follow-up of
3 y. Similarly, there were no differences in the STAF or
OT CAFE studies. The Atrial Fibrillation and Congestive
eart Failure (AF-CHF) study (53) is currently investigating
is issue in a large number of patients.
.1.2.5. EFFECTS ON THROMBOEMBOLIC COMPLICATIONS
he majority of patients in the AFFIRM and RACE trials had
or more stroke risk factors in addition to AF, and the
ythm-control strategy did not lower the stroke rate more
fectively than rate control and anticoagulation (296,339,
1) (see Table 7). One methodological concern is that the
ccess of rhythm control at maintaining sinus rhythm was
sessed by intermittent ECG recordings, whereas longer-
rm monitoring might have identified patients at lower
romboembolic risk. Most strokes were diagnosed after
scontinuation of anticoagulation or at subtherapeutic inten-
ty (International Normalized Ratio [INR] below 2.0). In
dition, while recurrent AF was detected in only about
e-third of those in the rhythm-control groups who devel-
ed stroke, at the time of ischemic stroke, patients in the
te-control groups typically had AF. Long-term oral antico-
ulation therefore seems appropriate for most patients with
F who have risk factors for thromboembolism, regardless of
eatment strategy and of whether AF is documented at any
ven time.
.1.2.6. EFFECTS ON MORTALITY AND HOSPITALIZATION
the AFFIRM study, a trend toward increased overall
ortality was observed in patients treated for rhythm control
mpared with rate control after an average of 3.5 y (26.7%
. 25.9%, p  0.08) (296). The rhythm-control strategy was
sociated with excess mortality among older patients, those
ith HF, and those with CAD, but the tendency persisted
ter adjustment for these covariates. A substudy suggested
at deleterious effects of antiarrhythmic drugs (mortality
crease of 49%) may have offset the benefits of sinus rhythm
hich was associated with a 53% reduction in mortality)
52). Hospitalization was more frequent in the rhythm-
ntrol arms in all trials, mainly due to admissions for
rdioversion. A substudy of RACE compared anticoagulated
tients in the rhythm-control group who sustained sinus
ythm with patients in the rate-control group who had
rmanent AF and found no benefit of rhythm control even in
is selected subgroup (353). The implication that adverse
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ert an adverse effect on morbidity and mortality that is not
ercome by maintaining sinus rhythm must be interpreted
utiously because the comparisons of patient subgroups in
ese secondary analyses are not based on randomization
able 9).
.1.2.7. IMPLICATIONS OF THE RHYTHM-CONTROL VERSUS
ATE-CONTROL STUDIES
heoretically, rhythm control should have advantages over
te control, yet a trend toward lower mortality was observed
the rate-control arm of the AFFIRM study and did not
ffer in the other trials from the outcome with the rhythm-
ntrol strategy. This might suggest that attempts to restore
nus rhythm with presently available antiarrhythmic drugs
e obsolete. The RACE and AFFIRM trials did not address
F in younger, symptomatic patients with little underlying
art disease, in whom restoration of sinus rhythm by
rdioversion antiarrhythmic drugs or nonpharmacological
terventions still must be considered a useful therapeutic
proach. One may conclude from these studies that rate
ntrol is a reasonable strategy in elderly patients with
inimal symptoms related to AF. An effective method for
aintaining sinus rhythm with fewer side effects would
dress a presently unmet need.
.1.3. Rate Control During Atrial Fibrillation
PDATED) For new or updated text, view the 2011
ocused Update. Text supporting unchanged recom-
endations has not been updated.
RITERIA FOR RATE CONTROL. In patients with AF, the
ventricular rate may accelerate excessively during exercise
even when it is well controlled at rest. In addition to
allowing adequate time for ventricular filling and avoiding
rate-related ischemia, enhancement of intraventricular
conduction with rate reduction may result in improved
hemodynamics. It may be useful to evaluate the heart rate
response to submaximal or maximal exercise or to monitor
the rate over an extended period (e.g., by 24-h Holter
BLE 9. Comparison of Adverse Outcomes in Rhythm Control a
Trial Reference
Deaths of All
Causes
(n rate/rhythm)
Deaths From
Cardiovascula
Causes
CE (2002) 293 36 18/18
AF (2000) 294 4 1/1
AF (2003) 343 12 (8/4) 8/3
FIRM (2002) 296 666 (310/356) 167/164
T CAFÉ (2004) 344 4 (1/3) 0/2
*Total number of patients not reported.
Reprinted with permission from Pelargonio G, Prystowsky EN. Rate versus r
rdiovasc Med 2005;2:514–21 (346).
AF indicates atrial fibrillation; AFFIRM, Atrial Fibrillation Follow-up Investigation
termined; PIAF, Pharmacological Intervention in Atrial Fibrillation; RACE, Rate
rategies of Treatment of Atrial Fibrillation.recording). In addition, rate variability during AF providesinformation about the status of the autonomic nervous
system that may have independent prognostic implications
(356–359).
The definition of adequate rate control has been based
primarily on short-term hemodynamic benefits and has
not been well studied with respect to regularity or
irregularity of the ventricular response to AF, quality of
life, or symptoms or development of cardiomyopathy.
No standard method for assessment of heart rate control
has been established to guide management of patients
with AF. Criteria for rate control vary with patient age
but usually involve achieving ventricular rates between
60 and 80 beats per minute at rest and between 90 and
115 beats per minute during moderate exercise. For the
AFFIRM trial, adequate control was defined as an
average heart rate up to 80 beats per minute at rest and
either an average rate up to 100 beats per minute over
at least 18-h ambulatory Holter monitoring with no rate
above 100% of the maximum age-adjusted predicted
exercise heart rate or a maximum heart rate of 110 beats
per minute during a 6-min walk test (360). In the RACE
trial, rate control was defined as less than 100 beats per
minute at rest. Only about 5% of patients from these
large clinical trials required AV ablation to achieve
heart rate control within these limits.
EMODYNAMIC AND CLINICAL CONSEQUENCES OF RAPID RATE.
Patients who are symptomatic with rapid ventricular rates
during AF require prompt medical management, and
cardioversion should be considered if symptomatic hypo-
tension, angina, or HF is present. A sustained, uncon-
trolled tachycardia may lead to deterioration of ventricular
function (tachycardia-related cardiomyopathy) (361) and
that improves with adequate rate control. In the Ablate and
Pace Trial (APT), 25% of patients with AF who had an
ejection fraction below 45% displayed a greater than 15%
increase in ejection fraction after ablation (363).
Tachycardia-induced cardiomyopathy tends to resolve
within 6 mo of rate or rhythm control; when tachycardia
recurs, LV ejection fraction declines and HF develops
over a shorter period, and this is associated with a
e Control Trials in Patients With AF
Deaths From
Noncardiovascular
Causes Stroke
Thromboembolic
Events Bleeding
ND ND 14/21 12/9
1* ND ND ND
0/1 1/5 ND 8/11
113/165 77/80 ND 107/96
1/1 0/3 ND 5/8
ontrol in the management of patients with atrial fibrillation. Nat Clin Pract
hm Management; HOT CAFÉ, How to Treat Chronic Atrial Fibrillation; ND, not
l Versus Electrical Cardioversion for Persistent Atrial Fibrillation; and STAF,nd Rat
r
hythm c
of Rhyt
Controrelatively poor prognosis (364).
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TRIAL FIBRILLATION
ECOMMENDATIONS
ASS I
Measurement of the heart rate at rest and control of the rate
using pharmacological agents (either a beta blocker or nondi-
hydropyridine calcium channel antagonist, in most cases) are
recommended for patients with persistent or permanent AF.
(Level of Evidence: B)
In the absence of preexcitation, intravenous administration of
beta blockers (esmolol, metoprolol, or propranolol) or nondihy-
dropyridine calcium channel antagonists (verapamil, diltiazem)
is recommended to slow the ventricular response to AF in the
acute setting, exercising caution in patients with hypotension
or HF. (Level of Evidence: B)
Intravenous administration of digoxin or amiodarone is recom-
mended to control the heart rate in patients with AF and HF
who do not have an accessory pathway. (Level of Evidence: B)
In patients who experience symptoms related to AF during
activity, the adequacy of heart rate control should be assessed
during exercise, adjusting pharmacological treatment as nec-
essary to keep the rate in the physiological range. (Level of
Evidence: C)
Digoxin is effective following oral administration to control the
heart rate at rest in patients with AF and is indicated for
patients with HF, LV dysfunction, or for sedentary individuals.
(Level of Evidence: C)
ASS IIa
A combination of digoxin and either a beta blocker or nondihy-
dropyridine calcium channel antagonist is reasonable to con-
trol the heart rate both at rest and during exercise in patients
with AF. The choice of medication should be individualized and
the dose modulated to avoid bradycardia. (Level of Evidence: B)
It is reasonable to use ablation of the AV node or accessory
pathway to control heart rate when pharmacological therapy is
insufficient or associated with side effects. (Level of Evidence: B)
Intravenous amiodarone can be useful to control the heart rate
in patients with AF when other measures are unsuccessful or
contraindicated. (Level of Evidence: C)
When electrical cardioversion is not necessary in patients with
AF and an accessory pathway, intravenous procainamide or
ibutilide is a reasonable alternative. (Level of Evidence: C)
ASS IIb
When the ventricular rate cannot be adequately controlled
both at rest and during exercise in patients with AF using a
beta blocker, nondihydropyridine calcium channel antagonist,
or digoxin, alone or in combination, oral amiodarone may be
administered to control the heart rate. (Level of Evidence: C)
Intravenous procainamide, disopyramide, ibutilide, or amioda-
rone may be considered for hemodynamically stable patients
with AF involving conduction over an accessory pathway.
(Level of Evidence: B)
When the rate cannot be controlled with pharmacological
agents or tachycardia-mediated cardiomyopathy is suspected,
catheter-directed ablation of the AV node may be considered in
patients with AF to control the heart rate. (Level of Evidence: C) prASS III
Digitalis should not be used as the sole agent to control the
rate of ventricular response in patients with paroxysmal AF.
(Level of Evidence: B)
Catheter ablation of the AV node should not be attempted
without a prior trial of medication to control the ventricular
rate in patients with AF. (Level of Evidence: C)
In patients with decompensated HF and AF, intravenous ad-
ministration of a nondihydropyridine calcium channel antago-
nist may exacerbate hemodynamic compromise and is not
recommended. (Level of Evidence: C)
Intravenous administration of digitalis glycosides or nondihy-
dropyridine calcium channel antagonists to patients with AF
and a preexcitation syndrome may paradoxically accelerate
the ventricular response and is not recommended. (Level of
Evidence: C)
The main determinants of ventricular rate during AF are
e intrinsic conduction characteristics and refractoriness of
e AV node and sympathetic and parasympathetic tone. The
nctional refractory period of the AV node correlates in-
rsely with ventricular rate during AF, and drugs that
olong the refractory period are generally effective for rate
ntrol. The efficacy of pharmacological interventions de-
gned to achieve rate control in patients with AF has been
out 80% in clinical trials (365). There is no evidence that
armacological rate control has any adverse influence on LV
nction, but bradycardia and heart block may occur as an
wanted effect of beta blockers, amiodarone, digitalis gly-
sides, or nondihydropyridine calcium channel antagonists,
rticularly in patients with paroxysmal AF, especially the
derly. When rapid control of the ventricular response to AF
required or oral administration of medication is not
asible, medication may be administered intravenously. Oth-
wise, in hemodynamically stable patients with a rapid
ntricular response to AF, negative chronotropic medication
ay be administered orally (Table 10). Combinations may be
cessary to achieve rate control in both acute and chronic
tuations, but proper therapy requires careful dose titration.
ome patients develop symptomatic bradycardia that requires
rmanent pacing. Nonpharmacological therapy should be
nsidered when pharmacological measures fail.
.1.3.1.1. Beta Blockers. Intravenous beta blockade with
opranolol, atenolol, metoprolol, or esmolol is effective for
ntrol of the rate of ventricular response to AF. These agents
ay be particularly useful in states of high adrenergic tone
.g., postoperative AF). After noncardiac surgery, intrave-
us esmolol produced more rapid conversion to sinus
ythm than diltiazem, but rates after 2 and 12 h were similar
ith both treatments (366).
In 7 of 12 comparisons, beta-adrenergic blockade proved
fe and effective for control of heart rate in patients with AF
d superior to placebo. Nadolol and atenolol were the most
ficacious of the drugs tested. Patients taking beta blockers
ay experience slow rates at rest, or exercise tolerance may
compromised when the rate response is blunted exces-
vely (367). Sotalol, a nonselective beta-blocking drug with
pe III antiarrhythmic activity used for rhythm control, also
ovides excellent rate control in the event of AF recurrence
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ring exercise. Atenolol, metoprolol, and sotalol provide
tter control of exercise-induced tachycardia than digoxin
69,370). Carvedilol also lowers the ventricular rate at rest
BLE 10. Intravenous and Orally Administered Pharmacologica
Drug
Class/LOE
Recommendation Loading Dose
UTE SETTING
Heart rate control in patients without accessory pathway
Esmolol*† Class I, LOE C 500 mcg/kg IV over 1 min
Metoprolol† Class I, LOE C 2.5 to 5 mg IV bolus over 2
min; up to 3 doses
Propranolol† Class I, LOE C 0.15 mg/kg IV
Diltiazem Class I, LOE B 0.25 mg/kg IV over 2 min 2
Verapamil Class I, LOE B 0.075 to 0.15 mg/kg IV
over 2 min
3
Heart rate control in patients with accessory pathway§
Amiodarone‡ Class IIa, LOE C 150 mg over 10 min
Heart rate control in patients with heart failure and without accessory pathw
Digoxin Class I, LOE B 0.25 mg IV each 2 h, up to
1.5 mg
60 m
Amiodarone‡ Class IIa, LOE C 150 mg over 10 min
NON-ACUTE SETTING and CHRONIC MAINTENANCE THERAPY¶
Heart rate control
Metoprolol† Class I, LOE C Same as maintenance dose 4
Propranolol† Class I, LOE C Same as maintenance dose 60
Diltiazem Class I, LOE B Same as maintenance dose 2
Verapamil Class I, LOE B Same as maintenance dose 1
Heart rate control in patients with heart failure and without accessory pathw
Digoxin Class I, LOE C 0.5 mg by mouth daily
Amiodarone‡ Class IIb, LOE C 800 mg daily for 1 wk,
orally 600 mg daily for 1
wk, orally 400 mg daily for
4 to 6 wk, orally
1
*Onset is variable and some effect occurs earlier.
†Only representative members of the type of beta-adrenergic antagonist drug
appropriate doses. Beta blockers are grouped in an order preceding the alph
‡Amiodarone can be useful to control the heart rate in patients with atrial fi
§Conversion to sinus rhythm and catheter ablation of the accessory pathw
propriate in certain patients.
If rhythm cannot be converted or ablated and rate control is needed, intrav
¶Adequacy of heart rate control should be assessed during physical activity
2BP indicates hypotension; 2HR, bradycardia; HB, heart block; HF, heart fd during exercise in such patients and reduces ventricular bltopy (371). With or without digoxin in the AFFIRM study,
ta blockers were the most effective drug class for rate
ntrol, achieving the specified heart rate endpoints in 70% of
tients compared with 54% with use of calcium channel
s for Heart Rate Control in Patients With Atrial Fibrillation
Maintenance Dose Major Side Effects
60 to 200 mcg/kg/min IV 2BP, HB, 2HR, asthma, HF
NA 2BP, HB, 2HR, asthma, HF
NA 2BP, HB, 2HR, asthma, HF
5 to 15 mg/h IV 2BP, HB, HF
NA 2BP, HB, HF
0.5 to 1 mg/min IV 2BP, HB, pulmonary toxicity, skin
discoloration, hypothyroidism,
hyperthyroidism, corneal deposits,
optic neuropathy, warfarin
interaction, sinus bradycardia
re§ 0.125 to 0.375 mg daily IV or
orally
Digitalis toxicity, HB, 2HR
0.5 to 1 mg/min IV 2BP, HB, pulmonary toxicity, skin
discoloration, hypothyroidism,
hyperthyroidism, corneal deposits,
optic neuropathy, warfarin
interaction, sinus bradycardia
25 to 100 mg twice a day,
orally
2BP, HB, 2HR, asthma, HF
in 80 to 240 mg daily in divided
doses, orally
2BP, HB, 2HR, asthma, HF
120 to 360 mg daily in
divided doses; slow release
available, orally
2BP, HB, HF
120 to 360 mg daily in
divided doses; slow release
available, orally
2BP, HB, HF, digoxin interaction
0.125 to 0.375 mg daily,
orally
Digitalis toxicity, HB, 2HR
200 mg daily, orally 2BP, HB, pulmonary toxicity, skin
discoloration, hypothyroidism,
hyperthyroidism, corneal deposits,
optic neuropathy, warfarin
interaction, sinus bradycardia
luded in the table, but other, similar agents could be used for this indication
l listing of drugs.
(AF) when other measures are unsuccessful or contraindicated.
generally recommended; pharmacological therapy for rate control may be
V) amiodarone is recommended.
as at rest.
OE, level of evidence; and NA, not applicable.l Agent
Onset
5 min
5 min
5 min
to 7 min
to 5 min
Days
ay
in or mo
Days
to 6 h
to 90 m
to 4 h
to 2 h
ay
2 days
to 3 wk
s are inc
abetica
brillation
ay are
enous (I
as wellockers (360). Beta blockers should be initiated cautiously in
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72).
.1.3.1.2. Nondihydropyridine Calcium Channel
ntagonists. The nondihydropyridine calcium channel an-
gonist agents verapamil and diltiazem are commonly used
r treatment of AF and are the only agents that have been
sociated with an improvement in quality of life and exercise
lerance. Intravenous bolus injection of either drug is effec-
ve to control the ventricular rate (367,373), although their
ort duration of action usually requires continuous intrave-
us infusion to maintain rate control. These agents should be
ed cautiously or avoided in patients with HF due to systolic
sfunction because of their negative inotropic effects. Eight
ndomized studies comparing calcium channel blockers to
acebo (370) found significant decrease in heart rate with
ltiazem. Verapamil decreased heart rate both at rest (by 8 to
beats per minute) and during exercise (by 20 to 34 beats
r minute). Direct comparisons of verapamil and diltiazem
ve demonstrated similar effectiveness (374), with preserved
improved exercise tolerance in most patients (374). These
ents may be preferred for long-term use over beta blockers
patients with bronchospasm or chronic obstructive pulmo-
ry disease.
.1.3.1.3. Digoxin. Although intravenous digoxin may
ow the ventricular response to AF at rest, there is a delay of
least 60 min before onset of a therapeutic effect in most
tients, and the peak effect does not develop for up to 6 h.
igoxin is no more effective than placebo in converting AF to
nus rhythm and may perpetuate AF (375,376). Its efficacy is
duced in states of high sympathetic tone, a possible precip-
ant of paroxysmal AF. In a review of 139 episodes of
roxysmal AF detected by Holter monitoring, there was no
fference in the ventricular rates of patients taking digoxin
d those not taking this agent (376). Other investigators,
wever, have reported that digoxin reduces the frequency
d severity of AF recurrences (30), and the combination of
goxin and atenolol is effective for rate control (377). Given
e availability of more effective agents, digoxin is no longer
nsidered first-line therapy for rapid management of AF,
cept in patients with HF or LV dysfunction, or perhaps in
tients who are so sedentary as to obviate the need for rate
ntrol during activity.
Digoxin exerts only a transient rate-slowing effect in
tients with recent-onset AF (378), perhaps as a result of a
gotonic effect on the AV node. In contrast to its limited
gative chronotropic effect in patients with paroxysmal AF,
goxin is moderately effective in those with persistent AF,
rticularly when HF is present (362,370). According to a
stematic review, digoxin administered alone slows the heart
te more than placebo by an average of 4 to 21 beats per
inute at rest, but it does not slow heart rate during exercise
patients with AF (367,370). The most frequent adverse
fects of digoxin are ventricular arrhythmias, atrioventricular
ock, and sinus pauses, all of which are dose dependent.
ecause of drug interactions, the serum digoxin concentration
ay rise and toxic effects may be potentiated when verapamil
antiarrhythmic agents such as propafenone or amiodaronee administered concurrently. as.1.3.1.4. Antiarrhythmic Agents. Amiodarone has both
mpatholytic and calcium antagonistic properties, depresses
V conduction, and is effective for controlling the ventricular
te in patients with AF. Intravenous amiodarone is generally
ell tolerated in critically ill patients who develop rapid atrial
chyarrhythmias refractory to conventional treatment, but
ficacy has not been sufficiently evaluated in this indication
79). Amiodarone is considered a suitable alternative agent
r heart rate control when conventional measures are inef-
ctive (379). When conventional measures are ineffective,
iodarone may be considered as an alternative agent for
art rate control in patients with AF (379), but this repre-
nts an off-label use in the United States and in some other
untries and the potential benefit must be carefully weighed
ainst the considerable potential toxicity of this drug.
atients given amiodarone who did not convert from AF to
nus rhythm experienced substantially lower ventricular
tes than those treated with placebo (370), but important
verse effects make this agent a second-line therapy for rate
ntrol. In one study, oral amiodarone decreased the ventric-
ar rate without affecting exercise capacity, quality of life, or
F symptoms (380). High-dose oral amiodarone loading can
orsen hemodynamics in patients with recent decompensa-
on of HF or hypotension (381). Amiodarone may cause
tentially fatal toxicity, including pulmonary fibrosis, he-
tic injury, and proarrhythmia.
Dofetilide and ibutilide are effective for conversion of
rial flutter and AF but are not effective for control of the
ntricular rate. Propafenone exerts mild beta-blocking ef-
cts that may slow conduction across the AV node, but this
seldom sufficient to control the rate in patients with AF, and
V conduction may accelerate when the atrial rhythm be-
mes slower and more regular, so other agents in addition to
opafenone are generally required to maintain control of the
art rate when AF recurs.
.1.3.1.5. Combination Therapy. Combinations of drugs
ay be required to achieve adequate rate control in some
tients with AF, but care should be taken to avoid brady-
rdia (370). The addition of other drugs to digoxin is
mmonly required to control the rate during exercise. The
mbination of digoxin and atenolol produces a synergistic
fect on the AV node (377), and the combination of digoxin
d pindolol provided better control during exercise than
goxin alone or in combination with verapamil (382). In
neral, the combination of digoxin and a beta blocker
pears more effective than the combination of digoxin with
calcium channel antagonist (377).
.1.3.1.6. Special Considerations in Patients With the
olff-Parkinson-White (WPW) Syndrome. Intrave-
us beta blockers, digitalis, adenosine, lidocaine, and non-
hydropyridine calcium channel antagonists, all of which
ow conduction across the AV node, are contraindicated in
tients with the WPW syndrome and tachycardia associated
ith ventricular preexcitation, because they can facilitate
tegrade conduction along the accessory pathway during AF
), resulting in acceleration of the ventricular rate, hypoten-
on, or ventricular fibrillation (181). When the arrhythmia is
sociated with hemodynamic compromise, however, early
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able patients with preexcitation, type I antiarrhythmic
ents or amiodarone may be administered intravenously.
eta blockers and calcium channel blockers are reasonable
r oral chronic use (383).
.1.3.2. PHARMACOLOGICAL THERAPY TO CONTROL
EART RATE IN PATIENTS WITH BOTH ATRIAL FIBRILLATION
ND ATRIAL FLUTTER
patient treated with AV nodal blocking drugs whose
ntricular rate is well controlled during AF may experience
rise or fall in rate if he or she develops atrial flutter. This is
so true when antiarrhythmic agents such as propafenone or
ecainide are used to prevent recurrent AF. These compounds
ay increase the likelihood of 1:1 AV conduction during
rial flutter, leading to a very rapid ventricular response.
hus, when these agents are given for prophylaxis against
current paroxysmal AF or atrial flutter, AV nodal blocking
ugs should be routinely coadministered. An exception may
patients with paroxysmal AF who have undergone catheter
lation of the cavotricuspid isthmus to prevent atrial flutter.
.1.3.3. REGULATION OF ATRIOVENTRICULAR NODAL
ONDUCTION BY PACING
ecause ventricular pacing prolongs the AV nodal refractory
riod as a result of concealed retrograde penetration, it
iminates longer ventricular cycles and may reduce the
mber of short ventricular cycles related to rapid AV
nduction during AF. Pacing at approximately the mean
ntricular rate during spontaneous AV conduction can reg-
ate the ventricular rhythm during AF (384). This may be
eful for patients with marked variability in ventricular rates
for those who develop resting bradycardia during treatment
ith medication. In some patients, the hemodynamic benefit
revascularization may be offset by asynchronous ventric-
ar activation during RV pacing. At least 2 multicenter
udies examined a ventricular rate regularization algorithm.
one study, patients with paroxysmal AF indicated a
eference for the paced regularization strategy, while pa-
ents with permanent AF showed no preference despite a
% improvement of irregularity (385). In another study,
ntricular rate regularization did not improve quality of life
patients with paroxysmal or permanent AF (386).
.1.3.4. AV NODAL ABLATION
V nodal ablation in conjunction with permanent pacemaker
plantation provides highly effective control of the heart rate
d improves symptoms in selected patients with AF
63,387–389). In general, patients most likely to benefit
om this strategy are those with symptoms or tachycardia-
ediated cardiomyopathy related to rapid ventricular rate
ring AF that cannot be controlled adequately with antiar-
ythmic or negative chronotropic medications. Meta-
alysis of 21 studies published between 1989 and 1998 that
cluded a total of 1181 patients concluded that AV nodal
lation and permanent pacemaker implantation significantly
proved cardiac symptoms, quality of life, and healthcare
ilization for patients with symptomatic AF refractory to
edical treatment (389). In the APT, 156 patients with nofractory AF displayed improvements in quality of life,
ercise capacity, and ventricular function over 1 y (363). In
study of 56 patients with impaired LV function (ejection
action less than 40%), the mean ejection fraction improved
om 26% plus or minus 8% to 34% plus or minus 13% after
V nodal ablation and pacemaker implantation and became
rmal in 16 patients (29%) (390). Patients with persistent
V dysfunction after ablation were more likely to have
ructural heart disease associated with less than 60% survival
5 y. In small randomized trials involving patients with
roxysmal (388) and persistent (387). AF, significantly
eater proportions experienced improvement in symptoms
d quality of life after AV nodal ablation than with antiar-
ythmic medication therapy. Of 2027 patients randomized to
ake control in the AFFIRM study, AV nodal ablation was
rformed in 5% (360) after failure to achieve adequate rate
ntrol with a mean of 2.4 plus or minus 0.7 medications.
nother 147 patients required pacemaker implantation be-
use of symptomatic bradycardia. Catheter ablation of infe-
or atrial inputs to the AV node slows the ventricular rate
ring AF and improves symptoms without pacemaker im-
antation (391,392). This technique has several limitations,
wever, including inadvertent complete AV block and a
ndency of ventricular rate to rise over the 6 mo following
lation. Two small, randomized trials comparing this type of
V nodal modification with complete AV nodal ablation and
rmanent pacemaker implantation demonstrated better
mptom relief with the complete interruption procedure.
hus, AV nodal modification without pacemaker implanta-
on is only rarely used.
Ablation of the AV inputs in the atrium may improve the
liability of the junctional escape mechanism (393). This
volves selective ablation of fast and slow AV nodal
thways followed, if necessary, by ablation between these
puts to achieve complete AV block. Complications of AV
dal ablation include those associated with pacemaker
plantation, ventricular arrhythmias, thromboembolism as-
ciated with interruption of anticoagulation, the rare occur-
nce of LV dysfunction, and progression from paroxysmal to
rsistent AF. The 1-y mortality rate after AV nodal ablation
d permanent pacemaker implantation is approximately
3% (95% confidence interval [CI] 5.5% to 7.2%), including
2.0% risk of sudden death (95% CI 1.5% to 2.6%).
lthough a causal relationship between the procedure and
dden death remains controversial, it has been suggested that
ogramming the pacemaker to a relatively high nominal rate
0 beats per minute) for the first month after ablation may
duce the risk (394,395).
Although the symptomatic benefits of AV nodal ablation
e clear, limitations include the persistent need for antico-
ulation, loss of AV synchrony, and lifelong pacemaker
pendency. There is also a finite risk of sudden death due to
rsades de pointes or ventricular fibrillation (396). Patients
ith abnormalities of diastolic ventricular compliance who
pend on AV synchrony to maintain cardiac output, such as
ose with hypertrophic cardiomyopathy or hypertensive
art disease, may experience persistent symptoms after AV
dal ablation and pacemaker implantation. Hence, patients
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fore proceeding with this irreversible measure.
The adverse hemodynamic effects of RV apical pacing
llowing AV nodal ablation have been a source of concern.
ompared with RV apical pacing, LV pacing significantly
proves indices of both LV systolic function (pressure-
lume loop, stroke work, ejection fraction, and dP/dt) and
astolic filling (397). Acutely, LV pacing was associated
ith a 6% increase in ejection fraction and a 17% decrease in
itral regurgitation (398). The Post AV Node Ablation
valuation (PAVE) randomized 184 patients undergoing AV
dal ablation because of permanent AF to standard RV
ical pacing or biventricular pacing (399). After 6 mo, the
ventricular pacing group walked 25.6 meters farther in 6
in (p  0.03), had greater peak oxygen consumption, and
d higher scores in 9 of 10 quality-of-life domains than the
V pacing group. While there was no difference in LV
ection fraction between the groups at baseline, the LV
ection fraction remained stable in the biventricular pacing
oup while it declined in the RV pacing group (46% vs.
%, respectively; p  0.03). There was no significant
fference in mortality. A subgroup analysis suggested that
nctional improvements were confined to patients with LV
ection fraction below 35% before ablation.
Patients with normal LV function or reversible LV dys-
nction undergoing AV nodal ablation are most likely to
nefit from standard AV nodal ablation and pacemaker
plantation. For those with impaired LV function not due to
chycardia, a biventricular pacemaker with or without defi-
illator capability should be considered. Upgrading to a
ventricular device should be considered for patients with
F and an RV pacing system who have undergone AV node
lation (400).
.1.4. Preventing Thromboembolism
or recommendations regarding antithrombotic therapy in
tients with AF undergoing cardioversion, see Section 8.2.7.
ECOMMENDATIONS
ASS I
Antithrombotic therapy to prevent thromboembolism is recom-
mended for all patients with AF, except those with lone AF or
contraindications. (Level of Evidence: A)
The selection of the antithrombotic agent should be based
upon the absolute risks of stroke and bleeding and the relative
risk and benefit for a given patient. (Level of Evidence: A)
For patients without mechanical heart valves at high risk of
stroke, chronic oral anticoagulant therapy with a vitamin K
antagonist is recommended in a dose adjusted to achieve the
target intensity INR of 2.0 to 3.0, unless contraindicated.
Factors associated with highest risk for stroke in patients with
AF are prior thromboembolism (stroke, TIA, or systemic embo-
lism) and rheumatic mitral stenosis. (Level of Evidence: A)
Anticoagulation with a vitamin K antagonist is recommended
for patients with more than 1 moderate risk factor. Such
factors include age 75 y or greater, hypertension, HF, impaired
LV systolic function (ejection fraction 35% or less or fractional
shortening less than 25%), and diabetes mellitus. (Level of
Evidence: A)INR should be determined at least weekly during initiation of
therapy and monthly when anticoagulation is stable. (Level of
Evidence: A)
Aspirin, 81–325 mg daily, is recommended as an alternative to
vitamin K antagonists in low-risk patients or in those with
contraindications to oral anticoagulation. (Level of Evidence: A)
For patients with AF who have mechanical heart valves, the
target intensity of anticoagulation should be based on the type
of prosthesis, maintaining an INR of at least 2.5. (Level of
Evidence: B)
Antithrombotic therapy is recommended for patients with atrial
flutter as for those with AF. (Level of Evidence: C)
ASS IIa
For primary prevention of thromboembolism in patients with
nonvalvular AF who have just 1 of the following validated risk
factors, antithrombotic therapy with either aspirin or a vitamin
K antagonist is reasonable, based upon an assessment of the
risk of bleeding complications, ability to safely sustain ad-
justed chronic anticoagulation, and patient preferences: age
greater than or equal to 75 y (especially in female patients),
hypertension, HF, impaired LV function, or diabetes mellitus.
(Level of Evidence: A)
For patients with nonvalvular AF who have 1 or more of the
following less well-validated risk factors, antithrombotic ther-
apy with either aspirin or a vitamin K antagonist is reasonable
for prevention of thromboembolism: age 65 to 74 y, female
gender, or CAD. The choice of agent should be based upon the
risk of bleeding complications, ability to safely sustain ad-
justed chronic anticoagulation, and patient preferences. (Level
of Evidence: B)
It is reasonable to select antithrombotic therapy using the
same criteria irrespective of the pattern (i.e., paroxysmal,
persistent, or permanent) of AF. (Level of Evidence: B)
In patients with AF who do not have mechanical prosthetic
heart valves, it is reasonable to interrupt anticoagulation for up
to 1 wk without substituting heparin for surgical or diagnostic
procedures that carry a risk of bleeding. (Level of Evidence: C)
It is reasonable to reevaluate the need for anticoagulation at
regular intervals. (Level of Evidence: C)
ASS IIb
In patients 75 y of age and older at increased risk of bleeding
but without frank contraindications to oral anticoagulant ther-
apy, and in other patients with moderate risk factors for
thromboembolism who are unable to safely tolerate anticoag-
ulation at the standard intensity of INR 2.0 to 3.0, a lower INR
target of 2.0 (range 1.6 to 2.5) may be considered for primary
prevention of ischemic stroke and systemic embolism. (Level
of Evidence: C)
When surgical procedures require interruption of oral anticoag-
ulant therapy for longer than 1 wk in high-risk patients,
unfractionated heparin may be administered or low-molecular-
weight heparin given by subcutaneous injection, although the
efficacy of these alternatives in this situation is uncertain.
(Level of Evidence: C)
Following percutaneous coronary intervention or revasculariza-
tion surgery in patients with AF, low-dose aspirin (less than
100 mg per d) and/or clopidogrel (75 mg per d) may be given
concurrently with anticoagulation to prevent myocardial isch-
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evaluated and are associated with an increased risk of bleed-
ing. (Level of Evidence: C)
In patients undergoing percutaneous coronary intervention,
anticoagulation may be interrupted to prevent bleeding at the
site of peripheral arterial puncture, but the vitamin K antago-
nist should be resumed as soon as possible after the procedure
and the dose adjusted to achieve an INR in the therapeutic
range. Aspirin may be given temporarily during the hiatus, but
the maintenance regimen should then consist of the combina-
tion of clopidogrel, 75 mg daily, plus warfarin (INR 2.0 to 3.0).
Clopidogrel should be given for a minimum of 1 mo after
implantation of a bare metal stent, at least 3 mo for a
sirolimus-eluting stent, at least 6 mo for a paclitaxel-eluting
stent, and 12 mo or longer in selected patients, following
which warfarin may be continued as monotherapy in the
absence of a subsequent coronary event. When warfarin is
given in combination with clopidogrel or low-dose aspirin, the
dose intensity must be carefully regulated. (Level of Evidence: C)
In patients with AF younger than 60 y without heart disease or
risk factors for thromboembolism (lone AF), the risk of throm-
boembolism is low without treatment and the effectiveness of
aspirin for primary prevention of stroke relative to the risk of
bleeding has not been established. (Level of Evidence: C)
In patients with AF who sustain ischemic stroke or systemic
embolism during treatment with low-intensity anticoagulation
(INR 2.0 to 3.0), rather than add an antiplatelet agent, it may
be reasonable to raise the intensity of anticoagulation to a
maximum target INR of 3.0 to 3.5. (Level of Evidence: C)
ASS III
ng-term anticoagulation with a vitamin K antagonist is not
recommended for primary prevention of stroke in patients
below the age of 60 y without heart disease (lone AF) or any
risk factors for thromboembolism. (Level of Evidence: C)
.1.4.1. RISK STRATIFICATION
.1.4.1.1. Epidemiological Data. In a small, retrospec-
ve, population-based study in Olmsted County, Minnesota,
er 3 decades, the 15-y cumulative stroke rate in people with
ne AF (defined as those younger than 60 y with no clinical
story or echocardiographic signs of cardiopulmonary dis-
se) was 1.3% (11). Conversely, in the Framingham Study
8), the age-adjusted stroke rate over a mean follow-up
riod of 11 y was 28.2% in those with lone AF, more
berally defined to include patients with a history of hyper-
nsion or cardiomegaly on chest roentgenography, compared
ith 6.8% in normal controls (28). In the SPAF study, the
nualized rate of ischemic stroke during aspirin treatment
as similar in those with paroxysmal (3.2%) and permanent
.3%) AF (401). Those with prior stroke or TIA have a rate
subsequent stroke of 10% to 12% per year when treated
ith aspirin, and these patients benefit substantially from
justed-dose oral anticoagulation (402,403). In addition to
ior thromboembolism, HF, hypertension, increasing age,
d diabetes mellitus have consistently emerged as indepen-
nt risk factors for ischemic stroke associated with nonval-
lar AF (47,261,264,382,405). Other factors, such as female
nder, systolic blood pressure over 160 mm Hg, and LV
sfunction, have been variably linked to stroke (261,266, of6). The relative risk for ischemic stroke associated with
ecific clinical features, derived from a collaborative analy-
s of participants given no antithrombotic therapy in the
ntrol groups of 5 randomized trials, is displayed in
able 11.
In patients with nonvalvular AF, prior stroke or TIA is the
rongest independent predictor of stroke, significantly asso-
ated with stroke in all 6 studies in which it was evaluated,
ith incremental relative risk between 1.9 and 3.7 (averaging
proximately 3.0). Attempts to identify patients with prior
roke or TIA who have relatively low stroke risks by virtue
the absence of other risk factors did not identify any
liable predictors (261,407–409). The pathogenic constructs
stroke in AF are incomplete, but available data indicate
at all patients with prior stroke or TIA are at high risk of
current thromboembolism and require anticoagulation un-
ss there are firm contraindications in a given patient. Efforts
enhance risk stratification should remove such patients
om consideration and focus instead on the predictive value
pertinent risk factors and absolute stroke rates for primary
evention. Patient age is a consistent independent predictor
stroke (Fig. 8). In 7 studies in which the variable was
sessed, hazard ratios averaged 1.5 per decade. Nearly half
AF-associated strokes occur in patients over 75 y, and AF
the most frequent cause of disabling stroke in elderly
omen (21,405,406). Older people are also at increased risk
r anticoagulant-related bleeding (410) and are less likely to
treated with oral anticoagulation, even in situations for
hich it has been proved efficacious, in part because of
ncern about the risk of bleeding (411). Special consider-
ion of these older patients is therefore a critical aspect of
fective stroke prophylaxis (405).
Female gender has emerged as an independent predictor of
roke in 3 cohort studies of patients with AF but not in
veral others (47,268,404). The relative increase was 1.6 in
e largest study of the ATRIA cohort (262). In the SPAF
alyses of aspirin-treated patients, gender interacted with
e such that women over 75 y old were at particularly high
sk, but this interaction was not apparent in the AnTicoagu-
tion and Risk factors In Atrial fibrillation (ATRIA) cohort
62,412).
Similarly, hypertension is a consistent, powerful predictor
BLE 11. Risk Factors for Ischemic Stroke and Systemic
bolism in Patients With Nonvalvular Atrial Fibrillation
sk Factors Relative Risk
evious stroke or TIA 2.5
abetes mellitus 1.7
story of hypertension 1.6
art failure 1.4
vanced age (continuous, per decade) 1.4
Data derived from collaborative analysis of 5 untreated control groups in
imary prevention trials (47). As a group, patients with nonvalvular atrial
rillation (AF) carry about a 6-fold increased risk of thromboembolism
mpared with patients in sinus rhythm. Relative risk refers to comparison of
tients with AF to patients without these risk factors.
TIA indicates transient ischemic attack.stroke, with a history of hypertension independently
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0) and systolic blood pressure significant in 2 others (mean
lative risk approximately 2.0). A history of hypertension
d systolic blood pressure over 160 mm Hg were indepen-
ntly predictive of stroke in the SPAF aspirin-treated
horts.
Diabetes was a significant independent predictor in 4
udies, associated with an average relative risk of 1.8, but not
2 other studies. The strength of diabetes as a predictor may
greater in lower-risk patients with AF, prompting specu-
tion that it may be associated with noncardioembolic
rokes. Diabetes is a less powerful independent predictor
an prior stroke/TIA, hypertension, or age, but analysis of
e type, duration, or control of diabetes has not been
dertaken to refine its predictive value for thromboembo-
sm in patients with AF. The reduction in stroke among
arfarin-treated patients with diabetes was below average in
studies (413,414).
In 2 studies, CAD was a univariate predictor of stroke in
herwise low-risk patients (47,415); it has not been shown to
ve independent predictive value for stroke in patients with
F.
Clinical HF has not been conclusively shown to have
dependent predictive value for stroke in any study of AF
tients. In the SPAF I and II studies (412), recent (within 3
o) HF or impaired LV systolic function (defined as M-mode
hocardiographic fractional shortening less than 25%) was a
gnificant independent predictor, as was LV systolic dys-
nction by 2-dimensional echocardiography in placebo-
eated patients in some studies (266) but not in others
61,268). Clinical diagnosis of HF may be difficult in elderly
tients with AF, and misclassification could blunt the power
association. In short, while it seems logical based on
thophysiological concepts and echocardiographic corre-
tes that HF should be an independent predictor of stroke in
tients with nonvalvular AF, available data do not provide
rong support.
.1.4.1.2. Echocardiography and Risk Stratification.
chocardiography is valuable to define the origin of AF (e.g.,
tecting rheumatic mitral valve disease or HCM) and may
d information useful in stratifying thromboembolic risk.
gure 8. Stroke rates in relation to age among patients in un-
eated control groups of randomized trials of antithrombotic
erapy. Data are from the Atrial Fibrillation Investigators. Risk
ctors for stroke and efficacy of antithrombotic therapy in atrial
rillation. Analysis of pooled data from five randomized con-
olled trials. Arch Intern Med 1994;154:1449–57 (47).mong high-risk AF patients, impaired LV systolic functiontransthoracic echocardiography, thrombus, dense SEC or
duced velocity of blood flow in the LAA, and complex
heromatous plaque in the thoracic aorta on TEE have been
sociated with thromboembolism, and oral anticoagulation
fectively lowers the risk of stroke in AF patients with these
atures. LA diameter and fibrocalcific endocardial abnormal-
ies have been less consistently associated with thromboem-
lism. Whether the absence of these echocardiographic
normalities identifies a low-risk group of patients who
uld safely avoid anticoagulation has not been established,
miting the value of echocardiography as a prime determi-
nt of the need for chronic anticoagulation in patients with
F.
RANSTHORACIC ECHOCARDIOGRAPHY. Correlations in
placebo-assigned participants in randomized trials of an-
tithrombotic therapy provide information about the inde-
pendent predictive value of transthoracic echocardiogra-
phy for thromboembolic events in patients with
nonvalvular AF (265,416). Meta-analysis of 3 trials found
moderate to severe LV dysfunction to be the only inde-
pendent echocardiographic predictor of stroke in patients
with AF after adjustment for clinical features; the diameter
of the LA was less useful (266).
Secondary analyses of aspirin-assigned patients in mul-
ticenter trials yield variable results regarding the role of
transthoracic echocardiography for predicting thrombo-
embolic risk (54,203). In the SPAF I and II studies, LV
fractional shortening less than 25% (estimated by M-mode
echocardiography) was the only independent echocardio-
graphic predictor of stroke. Among 2012 aspirin-assigned
patients in the SPAF trials (including 290 in SPAF-III
assigned to a relatively ineffective fixed-dose combination
of aspirin plus warfarin), no transthoracic echocardio-
graphic parameter independently predicted thromboembo-
lism when clinical risk factors were considered. Similarly,
no independent predictors of thromboembolism were iden-
tified by transthoracic echocardiography and TEE at entry
in the Embolism in the Left Atrial Thrombi (ELAT) study
of 409 patients with nonvalvular AF taking aspirin, 160
mg daily (268).
RANSESOPHAGEAL ECHOCARDIOGRAPHY. TEE is a sensitive
and specific technique for detection of LA and LAA
thrombus, far surpassing transthoracic echocardiography
(203). This modality also permits superior evaluation for
other causes of cardiogenic embolism (320), as well as a
means of measuring LAA function (319). Several TEE
features have been associated with thromboembolism,
including thrombus, reduced flow velocity, and SEC in the
LA or LAA and atheromatous disease of the aorta
(252,417).
Detection of LA/LAA thrombus stands as a contraindi-
cation to elective cardioversion of AF. Unfortunately, the
absence of a detectable thrombus does not preclude stroke
after cardioversion in the absence of anticoagulation
therapy (324,418). A TEE-guided strategy for elective
cardioversion of AF yielded comparable outcomes for
thromboembolism and death compared with conventional
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sion (320).
.1.4.1.3. Therapeutic Implications. The efficacy and
fety of oral anticoagulation and platelet inhibitor therapy
ith aspirin for prevention of stroke in patients with AF have
en well characterized (420). The selection of appropriate
tithrombotic therapy is discussed below in the context of
romboembolic risk (see Section 8.1.6, Pharmacological
gents to Maintain Sinus Rhythm, and Section 8.1.7, Out-
-Hospital Initiation of Antiarrhythmic Drugs in Patients
ith Atrial Fibrillation). Patients with AF who have low rates
stroke when treated with aspirin may not gain sufficient
nefit from anticoagulation to outweigh the attendant risks
d the need for close medical monitoring (421,422). Esti-
ating the risk of stroke for individual AF patients is crucial
r the decision to provide anticoagulation therapy to indi-
dual patients with AF (54), but the threshold risk that
arrants anticoagulation is controversial. Patients with a
roke risk of 2% per year or less do not benefit substantially
om oral anticoagulation, which would require treating 100
more patients for 1 y to prevent a single stroke (420). For
gh-risk AF patients with stroke rates of 6% per year or
eater, the comparable number needed-to-treat is 25 or
wer, strongly favoring anticoagulation. Opinion remains
vided about routine anticoagulation for patients at interme-
ate stroke risk (annual rate 3% to 5%).
To stratify the risk of ischemic stroke in patients with AF,
veral clinical schemes have been proposed based on anal-
es of prospectively monitored cohorts of participants in
inical trials in which antithrombotic therapy was controlled
91,421,423). One set of criteria (Atrial Fibrillation Inves-
gators [AFI]) is based on multivariate pooled analysis of
93 participants assigned to the control or placebo groups of
randomized primary prevention trials in which 106 isch-
ic strokes occurred over a mean follow-up of 1.4 y (47).
atients were divided into 2 strata, distinguishing low-risk
tients from those at intermediate or high risk. Although
hocardiographic features were not considered initially, a
bsequent analysis of 3 of the trials identified abnormal LV
stolic function as an independent predictor of stroke (421).
he SPAF study criteria were based on multivariate analysis
854 patients assigned to aspirin and followed for a mean of
3 y, during which 68 ischemic strokes were observed. These
iteria were subsequently used to select a low-risk cohort for
eatment with aspirin in the SPAF III study. Over a mean
llow-up of 2 y, the rate of ischemic stroke was 2.0% per
ar (95% CI 1.5% to 2.8%) and the rate of disabling
chemic stroke was 0.8% per year (95% CI 0.5% to 1.3%).
atients with a history of hypertension had a higher rate of
romboembolism (3.6% per year) than those without hyper-
nsion (1.1% per year; p less than 0.001). Other criteria have
en developed by expert consensus (423,424) based on
nsideration of the foregoing schemes to classify patients
to low-, intermediate-, and high-risk groups. Still others
ve employed recursive partitioning and other techniques to
entify low-risk patients.
Nine schemes that included more than 30 stroke events have
en promulgated based on multivariate analysis of clinical idd/or echocardiographic predictors. Three were derived from
erlapping patient cohorts, while 6 were derived from entirely
dependent cohorts (47,261,266,412,415). Of the 6 studies with
stinct patient cohorts, 2 involved participants in randomized
ials, 2 were based on clinical case series, one was a population-
sed epidemiological study, and the other was a hospital-based
se-control study. The largest study (262) was limited to
alysis of female gender as an independent predictor.
A multivariate analysis from the Framingham Heart Study
amined risk factors for stroke among 705 patients with
cently detected AF, excluding those who had sustained
chemic stroke, TIA, or death within 30 d of diagnosis (425).
he only significant predictors of ischemic stroke were age
R  1.3 per decade), female gender (RR  1.9), prior
roke or TIA (RR  1.9), and diabetes mellitus (RR  1.8),
nsistent with earlier studies. Systolic blood pressure be-
me a significant predictor of stroke when warfarin was
cluded in a time-dependent Cox proportional hazards
odel. With a scoring system based on age, gender, systolic
pertension, diabetes, and prior stroke or TIA, the propor-
on of patients classified as low risk varied from 14.3% to
.6% depending upon whether stroke rate thresholds were
ss than 1.5% per year or less than 2% per year. Observed
roke rates were 1.1% to 1.5% per year based on 88 validated
ents. In the future, it may be possible to consider other
aracteristics that may contribute to stroke risk, including
netic abnormalities of hemostatic factors and endothelial
sfunction, but none have yet been identified that have
fficient predictive value for clinical use in risk stratification
30,413).
Another stroke risk classification scheme, known as
HADS2 (Cardiac Failure, Hypertension, Age, Diabetes,
troke [Doubled]) integrates elements from several of the
regoing schemes. The CHADS2 risk index is based on a
int system in which 2 points are assigned for a history of
roke or TIA and 1 point each is assigned for age over 75 y,
history of hypertension, diabetes, or recent HF (Table 12)
15,426). The predictive value of this scoring system was
aluated in 1733 Medicare beneficiaries with nonvalvular
F between the ages of 65 and 95 y who were not given
arfarin at hospital discharge. Although high scores were
sociated with an increased stroke rate in this elderly cohort,
w patients had a score of 5 or more or a score of 0. In the
me cohort, the modified AFI scheme had high-risk (prior
roke or TIA, hypertension, or diabetes) and moderate-risk
ge greater than 65 y without other high-risk features)
tegories, corresponding to stroke rates of 5.4% per year
5% CI 4.2% to 6.5% per year) for high-risk and 2.2% per
ar (95% CI 1.1% to 3.5% per year) for moderate-risk
tients. Patients with high-risk features according to the
PAF criteria (prior stroke or TIA, women older than 75 y, or
cent HF) had a stroke rate of 5.7% per year (95% CI 4.4%
7.0% per year); moderate-risk patients (history of hyper-
nsion with no other high-risk features) had a rate of 3.3%
r year (95% CI 1.7% to 5.2% per year); and low-risk
tients (without risk factors) had a stroke rate of 1.5% per
ar (95% CI 0.5% to 2.8% per year).
Although the schemes for stratification of stroke riskentify patients who benefit most and least from anticoagu-
la
si
th
S
w
se
w
en
ch
an
da
su
th
fo
pa
pe
an
si
ti
re
in
4
ov
1.
co
hy
at
co
at
pr
cr
av
8
O
B
em
li
pr
ce
to
rh
pa
w
vo
in
1.
In
M
or
or
in
TA
Tr
no
cl
fo
Ga
sc
Fi
Di
isc
TA
Ri
No
On
An
Le
Ri
Fe
Ag
Co
Th
e135JACC Vol. 57, No. 11, 2011 Fuster et al.
March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinestion, the threshold for use of anticoagulation is controver-
al. Opinion is particularly divided about anticoagulation for
ose at intermediate risk (stroke rate 3% to 5% per year).
ome advocate the routine use of anticoagulation for those
ith stroke rates in this range (427), whereas others favor
lective anticoagulation of patients at intermediate risk, with
eight given to individual bleeding risks and patient prefer-
ces (54,428). The threshold of benefit at which AF patients
oose anticoagulation varies; some at intermediate risk elect
ticoagulation, whereas others do not (429). Our recommen-
tions for antithrombotic therapy in patients with AF are
mmarized in Table 13.
BLE 12. Stroke Risk in Patients With Nonvalvular AF Not
eated With Anticoagulation According to the CHADS2 Index
CHADS2 Risk Criteria Score
Prior stroke or TIA 2
Age 75 y 1
Hypertension 1
Diabetes mellitus 1
Heart failure 1
Patients
(N1733)
Adjusted Stroke
Rate (%/y)*
(95% CI) CHADS2 Score
120 1.9 (1.2 to 3.0) 0
463 2.8 (2.0 to 3.8) 1
523 4.0 (3.1 to 5.1) 2
337 5.9 (4.6 to 7.3) 3
220 8.5 (6.3 to 11.1) 4
65 12.5 (8.2 to 17.5) 5
5 18.2 (10.5 to 27.4) 6
*The adjusted stroke rate was derived from multivariate analysis assuming
aspirin usage. Data are from van Walraven WC, Hart RG, Wells GA, et al. A
inical prediction rule to identify patients with atrial fibrillation and a low risk
r stroke while taking aspirin. Arch Intern Med 2003;163:936–43 (415); and
ge BF, Waterman AD, Shannon W, et al. Validation of clinical classification
hemes for predicting stroke: results from the National Registry of Atrial
brillation. JAMA 2001;285:2864–70 (426).
AF indicates atrial fibrillation; CHADS2, Cardiac Failure, Hypertension, Age,
abetes, and Stroke (Doubled); CI, confidence interval; and TIA, transient
hemic attack.
BLE 13. Antithrombotic Therapy for Patients With Atrial Fibrill
sk Category
risk factors
e moderate-risk factor
y high-risk factor or more than 1 moderate-risk factor
ss Validated or Weaker
sk Factors Moderate-Ris
male gender Age greater than o
e 65 to 74 y Hyperten
ronary artery disease Heart fa
yrotoxicosis LV ejection fractio
Diabetes m
*If mechanical valve, target international normalized ratio (INR) greater thanINR indicates international normalized ratio; LV, left ventricular; and TIA, transient isAtrial flutter is uncommon as a chronic arrhythmia, and
e risk of thromboembolism is not as well established as it is
r AF but is generally estimated as higher than that for
tients with sinus rhythm and less than that for those with
rsistent or permanent AF. On the basis of multivariate
alysis, Wood et al (430) reported hypertension as the only
gnificant correlate of previous thromboembolism for pa-
ents with chronic atrial flutter. From a review of 8 y of
trospective data from 749 988 hospitalized older patients,
cluding 17 413 with atrial flutter and 337 428 with AF, 3 of
patients with atrial flutter also had or developed AF. The
erall stroke risk ratio for patients with atrial flutter was
406, and for those with AF, it was 1.642 compared with the
ntrol group. Coexisting HF, rheumatic heart disease, and
pertension predicted an episode of AF in patients with
rial flutter. Risk ratios for patients with these comorbid
nditions were 1.243, 1.464, and 1.333, respectively (431).
Although the overall thromboembolic risk associated with
rial flutter may be somewhat lower than with AF, it seems
udent to estimate risk by the use of similar stratification
iteria for both arrhythmias until more robust data become
ailable (Tables 13 and 14).
.1.4.2. ANTITHROMBOTIC STRATEGIES FOR PREVENTION
F ISCHEMIC STROKE AND SYSTEMIC EMBOLISM
efore 1990, antithrombotic therapy for prevention of isch-
ic stroke and systemic embolism in patients with AF was
mited mainly to those with rheumatic heart disease or
osthetic heart valves (21). Anticoagulation was also ac-
pted therapy for patients who had sustained ischemic stroke
prevent recurrence but was often delayed to avoid hemor-
agic transformation. Some advocated anticoagulation of
tients with thyrotoxicosis or other conditions associated
ith cardiomyopathy. Since then, 24 randomized trials in-
lving patients with nonvalvular AF have been published,
cluding 20 012 participants with an average follow-up of
6 y, a total exposure of about 32 800 patient-y (Table 15).
these studies, patient age averaged 71 y; 36% were women.
ost trials originated in Europe (14 trials, 7273 participants)
North America (7 trials, 8349 participants). Most studied
al vitamin K inhibitors or aspirin in varying dosages/
tensities, but other anticoagulants (low-molecular-weight
Recommended Therapy
Aspirin, 81 to 325 mg daily
Aspirin, 81 to 325 mg daily, or warfarin (INR 2.0 to 3.0, target 2.5)
Warfarin (INR 2.0 to 3.0, target 2.5)*
s High-Risk Factors
to 75 y Previous stroke, TIA or embolism
Mitral stenosis
Prosthetic heart valve*
r lessation
k Factor
r equal
sion
ilure
n 35% o
ellitus
2.5.chemic attack.
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98parin, ximelagatran) and other antiplatelet agents (dipyrid-
ole, indobufen, trifulsal) have also been tested. Nine trials
d double-blind designs for antiplatelet (57,403,432–435) or
ticoagulation (436–438) comparisons.
.1.4.2.1. Anticoagulation With Vitamin K Antagonist
gents. Five large randomized trials published between
89 and 1992 evaluated oral anticoagulation mainly for
imary prevention of thromboembolism in patients with
nvalvular AF (57,428,432,436,437) (Fig. 9, Table 15). A
xth trial focused on secondary prevention among patients
ho had survived nondisabling stroke or TIA (403). Meta-
alysis according to the principle of intention to treat
owed that adjusted-dose oral anticoagulation is highly
ficacious for prevention of all stroke (both ischemic and
morrhagic), with a risk reduction of 62% (95% CI 48% to
%) versus placebo (420) (Fig. 9). This reduction was
milar for both primary and secondary prevention and for
th disabling and nondisabling strokes. By on-treatment
alysis (excluding patients not undergoing oral anticoagula-
on at the time of stroke), the preventive efficacy of oral
ticoagulation exceeded 80%. Four of these trials were
acebo controlled; of the 2 that were double blinded with
gard to anticoagulation (437), one was stopped early
cause of external evidence that oral anticoagulation was
perior to placebo, and the other included no female sub-
cts. In 3 of the trials, oral anticoagulant dosing was
gulated according to the prothrombin time ratio; 2 used INR
rget ranges of 2.5 to 4.0 and 2.0 to 3.0. These trials are
mmarized in Table 15. The duration of follow-up was
nerally between 1 and 2 y; the longest was 2.2 y, whereas
clinical practice, the need for antithrombotic therapy in
tients with AF typically extends over much longer periods.
All reported trials excluded patients considered at high risk
bleeding. Patient age and the intensity of anticoagulation
e the most powerful predictors of major bleeding (449–
BLE 14. Risk-Based Approach to Antithrombotic Therapy in P
tient Features
e less than 60 y, no heart disease (lone AF) As
e less than 60 y, heart disease but no risk factors*
e 60 to 74 y, no risk factors*
e 65 to 74 y with diabetes mellitus or CAD
e 75 y or older, women
e 75 y or older, men, no other risk factors Ora
e 65 or older, heart failure
ejection fraction less than 35% or fractional
ortening less than 25%, and hypertension
eumatic heart disease (mitral stenosis)
osthetic heart valves Or
ior thromboembolism Or
rsistent atrial thrombus on TEE Or
*Risk factors for thromboembolism include heart failure (HF), left ventricular
AF indicates atrial fibrillation; CAD, coronary artery disease; INR, internationa4). Trial participants, at an average age of 69 y, were inrefully selected and managed, however, and it is unclear
hether the relatively low observed rates of major hemor-
age also apply to patients with AF in clinical practice, who
ve a mean age of about 75 y and less closely regulated
ticoagulation therapy (19,431,455).
The target intensity of anticoagulation involves a balance
tween prevention of ischemic stroke and avoidance of
morrhagic complications (Fig. 10). Targeting the lowest
equate intensity of anticoagulation to minimize the risk of
eeding is particularly important for elderly AF patients.
aximum protection against ischemic stroke in AF is prob-
ly achieved at an INR range of 2.0 to 3.0 (456), whereas an
R range of 1.6 to 2.5 is associated with incomplete efficacy,
timated at approximately 80% of that achieved with higher-
tensity anticoagulation (432,449). Two randomized trials
ith a target INR of 1.4 to 2.8 (estimated mean achieved INR
0 to 2.1) found the largest relative risk reductions for
chemic stroke. A trial in which AF patients with prior stroke
TIA were randomly assigned to target INR ranges of 2.2 to
5 versus 1.5 to 2.1 found a greater rate of major hemorrhage
ith the higher intensity (450). For patients with nonvalvular
F, an INR of 1.6 to 3.0 is efficacious and relatively safe. For
imary prevention in most AF patients under age 75 y and
r secondary prevention, an INR of 2.5 (target range 2.0 to
0) is recommended. A target INR of 2.0 (target range 1.6 to
5) seems reasonable for primary prevention in patients older
an 75 y who are considered at high risk of bleeding. In
inical trials, INRs achieved during follow-up were more
ten below than above the target range. Low-intensity
ticoagulation requires special efforts to minimize time
ent below the target range, during which stroke protection
sharply reduced. The major bleeding rate for 5 randomized
inical trials was 1.2% per year (202) (Fig. 11).
Despite anticoagulation of more elderly patients with AF,
tes of intracerebral hemorrhage are considerably lower than
With Atrial Fibrillation
Antithrombotic Therapy
Class of
Recommendation
to 325 mg per day) or no therapy I
irin (81 to 325 mg per day) I
irin (81 to 325 mg per day) I
nticoagulation (INR 2.0 to 3.0) I
nticoagulation (INR 2.0 to 3.0) I
agulation (INR 2.0 to 3.0) or aspirin
(81 to 325 mg per day)
I
nticoagulation (INR 2.0 to 3.0) I
nticoagulation (INR 2.0 to 3.0) I
nticoagulation (INR 2.0 to 3.0) I
agulation (INR 2.0 to 3.0 or higher) I
agulation (INR 2.0 to 3.0 or higher) I
agulation (INR 2.0 to 3.0 or higher) IIa
ction fraction less than 35%, and history of hypertension.
lized ratio; and TEE, transesophageal echocardiography.atients
pirin (81
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinesports. This may reflect lower anticoagulation intensity,
ore careful dose regulation, or better control of hyperten-
on (438,457). In 2 time-dependent INR analyses of antico-
ulation in elderly AF cohorts, intracranial bleeding in-
eased with INR values over 3.5 to 4.0, and there was no
crement with values between 2.0 and 3.0 compared with
wer INR levels (454,456). Pooled results of randomized
ials and a large cohort comparison, however, suggest a
ubling of intracranial hemorrhages with mean INR values
tween 2.0 and 2.5 (458). Other than dose intensity, ad-
nced age, and hypertension, factors associated with higher
tes of intracerebral hemorrhage during anticoagulant ther-
y include associated cerebrovascular disease and possibly
ncomitant antiplatelet therapy, tobacco or alcohol con-
mption, ethnicity, genotype, and certain vascular abnormal-
ies detected by brain imaging, such as amyloid angiopathy,
ukoaraiosis, or microbleeds (457). No stratification scheme
r prediction of intracerebral hemorrhage during anticoagu-
BLE 15. Randomized Trials of Antithrombotic Therapy in Patie
ials Reference
rge published trials
Copenhagen Atrial Fibrillation, Aspirin,
Anticoagulation I (AFASAK I)
432
Copenhagen Atrial Fibrillation, Aspirin,
Anticoagulation II (AFASAK II)
439
Stroke Prevention in Atrial Fibrillation I (SPAF I) 57
Stroke Prevention in Atrial Fibrillation II (SPAF II) 440
Stroke Prevention in Atrial Fibrillation III (SPAF III) 402
Boston Area Anticoagulation Trial for Atrial
Fibrillation (BAATAF)
428
Canadian Atrial Fibrillation Anticoagulation (CAFA) 436
Stroke Prevention in Nonrheumatic Atrial
Fibrillation (SPINAF)
437
European Atrial Fibrillation Trial (EAFT) 403
Studio Italiano Fibrillazione Atriale (SIFA) 441
Minidose Warfarin in Nonrheumatic Atrial
Fibrillation
442
Prevention of Arterial Thromboembolism in Atrial
Fibrillation (PATAF)
443
Stroke Prevention using an Oral Direct Thrombin
Inhibitor In Patients with Atrial Fibrillation
(SPORTIF-III)
477
Stroke Prevention using an Oral Direct Thrombin
Inhibitor In Patients With Atrial Fibrillation
(SPORTIF-V)
438
National Study for Prevention of Embolism in
Atrial Fibrillation (NASPEAF)
445
all or pilot trials
Harenberg et al. 446
Low-dose Aspirin, Stroke, Atrial Fibrillation
(LASAF)
447
bgroups with AF in other trials
European Stroke Prevention Study II (ESPS II) 404
Adapted with permission from Hart RG, Benavente O, McBride R, et al. Antithr
n Intern Med 1999;131:492–501 (420).
AF, atrial fibrillation; ASA, aspirin; DTI, direct thrombin inhibitor; LDA, low-dont therapy has been prospectively evaluated. di.1.4.2.2. Aspirin for Antithrombotic Therapy in
atients With Atrial Fibrillation. Aspirin offers only
odest protection against stroke for patients with AF
6,57,403,432,439,440,443,447,448) (Fig. 12). Meta-
alysis of 5 randomized trials showed a stroke reduction of
% (95% CI 2% to 34%) (420). The effect of aspirin on
roke in these trials was less consistent than that of oral
ticoagulation (420,459), but differences in patient features
ay have influenced aspirin efficacy. For example, aspirin
duced stroke occurrence by 33% in primary prevention
udies (in which the stroke rate with placebo averaged 5%
r year) versus 11% for secondary prevention trials (in
hich the stroke rate with placebo averaged 14% per year)
20). Aspirin may be more efficacious for AF patients with
pertension or diabetes (459) and for reduction of noncar-
oembolic versus cardioembolic ischemic strokes in AF
tients (200). Cardioembolic strokes are, on average, more
th Nonvalvular AF
r Published No. of Patients Interventions
1989 1007 VKA, ASA, placebo
1998 677 VKA, ASA, LDA  ASA, LDA
1991 1330 VKA, ASA, placebo
1994 1100 VKA, ASA
1996 1044 VKA, LDA  ASA
1990 420 VKA, control
1991 378 VKA, placebo
1992 571 VKA, placebo
1993 1007 VKA, ASA, placebo
1997 916 VKA, indobufen
1998 303 VKA, LDA*
1999 729 VKA, LDA,* ASA
2003 3407 DTI, VKA
2005 3922 DTI, VKA
2004 1209 VKA, triflusal, VKA 
triflusal
1993 75 LMW heparin, control
1996 285 ASA, placebo
1997 429 ASA, dipyridamole, placebo
therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.
in; LMW, low-molecular-weight; and VKA, vitamin K antagonist.nts Wi
Yea
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98ars to prevent nondisabling strokes more than disabling
rokes (420). Thus, the greater the risk of disabling cardio-
bolic stroke in a population of patients with AF, the less
otection is afforded by aspirin (250).
Additional information about event rates on aspirin or no
tithrombotic therapy can be extracted from contemporary
tabases such as the ATRIA cohort of 13 428 ambulatory
tients with AF enrolled in the Kaiser Permanente Medical
are Program in North Carolina during the period 1996
rough 1999 (262,456,458,461). In the 11 526 patients
ithout apparent contraindications to anticoagulation (458),
20 patients were treated with warfarin. Among the 5089
tients not treated with warfarin, the absolute rate of
romboembolism was 2.0% per year (461). There was a
story of stroke or TIA in only 4% of the patients not treated
ith anticoagulation, making this mainly a primary preven-
on cohort (458). During a mean follow-up of 2.2 y (median
35 y), 249 thromboembolic events (231 ischemic strokes
d 18 systemic embolic events outside the central nervous
stem) occurred among the patients who were not anticoag-
ated (2.0% per year [95% CI 1.8% to 2.3%]). From a nested
se-control study of 294 patients, it was estimated that about
% were using aspirin. When those from the larger cohort
ith contraindications to warfarin (who were older and more
ten had prior stroke or TIA) were included, the rate of
romboembolism was 2.5% per year.
While the use of administrative and claims-based data
om a managed care organization may have been prone to
derdetection of stroke events, these rates were not very
fferent from those in other reported populations. By com-
gure 9. Effects on all stroke (ischemic and hemorrhagic) of
erapies for patients with atrial fibrillation. Adjusted-dose warfa-
compared with placebo (six random trials. Adapted with per-
ission from Hart RG, Benavente O, McBride R, et al. Anti-
rombotic therapy to prevent stroke in patients with atrial
rillation: a meta-analysis. Ann Intern Med 1999;131:492–501
20). AFASAK indicates Copenhagen Atrial Fibrillation, Aspirin,
nticoagulation; BAATAF, Boston Area Anticoagulation Trial for
trial Fibrillation; CAFA, Canadian Atrial Fibrillation Anticoagula-
n; CI, confidence interval; EAFT, European Atrial Fibrillation
ial; SPAF, Stroke Prevention in Atrial Fibrillation; and SPINAF,
troke Prevention in Nonrheumatic Atrial Fibrillation.rison, among 1853 patients without prior thromboembolic (4ents assigned to aspirin in the SPAF I, II, and III trials, the
te of ischemic stroke was 2.7% per year (261). In the AFI
hort of 2732 patients from 6 randomized trials (about half
om the SPAF trials), without prior stroke or TIA, the rate of
chemic stroke was 2.1% per year with aspirin therapy.
mong 210 patients in the population-based Cardiovascular
ealth Study (mean age 74 y) followed without anticoagula-
on, the stroke rate was 2.6% per year (462). When stratified
cording to the CHADS2 stroke risk scheme (426), patients
the ATRIA cohort with a single stroke risk factor (32% of
e cohort) who were not anticoagulated had a rate of stroke
d systemic embolism of 1.5% per year (95% CI 1.2% to
9%) (458). Of 670 patients treated with aspirin in 6 clinical
ials, the stroke rate was 2.2% per year for those with a
HADS2 score of 1 (95% CI 1.6% to 3.1% per year) (463).
In summary, adjusted-dose oral anticoagulation is more
ficacious than aspirin for prevention of stroke in patients
ith AF, as suggested by indirect comparisons and by a 33%
sk reduction (95% CI 13% to 49%) in a meta-analysis of 5
ials (420). Randomized trials involving high-risk AF pa-
ents (stroke rates greater than 6% per year) show larger
lative risk reductions by adjusted-dose oral anticoagulation
lative to aspirin (Fig. 12), whereas the relative risk reduc-
ons are consistently smaller in trials of AF patients with
wer stroke rates. Accordingly, oral anticoagulation may be
ost beneficial for AF patients at higher intrinsic thrombo-
bolic risk, offering only modest reductions over aspirin in
th the relative risk and absolute rates of stroke for patients
low risk. Individual risk varies over time, so the need for
ticoagulation must be reevaluated periodically in all pa-
ents with AF.
.1.4.2.3. Other Antiplatelet Agents for Antithrom-
otic Therapy in Patients With Atrial Fibrillation. An-
coagulation with oral vitamin K antagonists has been
mpared with platelet cyclooxygenase inhibitors other than
pirin in 2 trials involving 1395 participants. In the Italian
gure 10. Adjusted odds ratios for ischemic stroke and intra-
anial bleeding in relation to intensity of anticoagulation. Modi-
d with permission from Hylek EM, Singer DE. Risk factors for
tracranial hemorrhage in outpatients taking warfarin. Ann In-
rn Med 1994;120:897–902 (451). Data from Odén A, Fahlén M
d Hart RG. Optimal INR for prevention of stroke and death in
rial fibrillation: a critical appraisal. Thromb Res 2006;117:493–9
52).
S
in
w
is
no
te
ca
st
w
S
F
of
w
ic
em
th
an
w
of
fo
st
M
pl
ag
da
pa
to
im
ta
Fi
at
se
ab
at
A
S reven
Fi
rin
th
C
S
as
S
e139JACC Vol. 57, No. 11, 2011 Fuster et al.
March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinestudio Italiano Fibrillazione Atriale (SIFA) study (441),
dobufen, 100 to 200 mg twice daily, was compared with
arfarin (INR 2.0 to 3.5) in 916 patients with recent cerebral
chemic events. Incidences of the combined endpoint of
nfatal stroke, intracerebral bleeding, pulmonary or sys-
mic embolism, MI, and vascular death were not signifi-
ntly different between treatment groups, but more ischemic
rokes occurred in the indobufen group (18) than in the
arfarin group (10). In the primary prevention cohort of the
panish National Study for Prevention of Embolism in Atrial
ibrillation (NASPEAF) trial (445), the rate of the composite
thromboembolism plus cardiovascular death was lower
ith acenocoumarol than with triflusal. There was no signif-
ant difference in rates of ischemic stroke and systemic
bolism. Neither indobufen nor trifusal is widely available;
gure 11. Annual rates of major hemorrhage during anticoagulatio
rial fibrillation. The mean age of participants was 69 years. Major
vere enough to require hospitalization, transfusion or surgical int
ling or fatal. Data adapted from Hart RG, Benavente O, McBride
rial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492–50
nticoagulation; BAATAF, Boston Area Anticoagulation Trial for Atr
PAF, Stroke Prevention in Atrial Fibrillation; and SPINAF, Stroke P
gure 12. Effects on all stroke (ischemic and hemorrhagic) of ther
and aspirin compared with placebo. Modified with permission f
erapy to prevent stroke in patients with atrial fibrillation: a meta-a
openhagen Atrial Fibrillation, Aspirin, Anticoagulation; CI, confide
troke Prevention Study; LASAF, Low-dose Aspirin, Stroke, Atrial
pirin trial; PATAF, Prevention of Arterial Thromboembolism in Atrial
troke Prevention in Nonrheumatic Atrial Fibrillation.ese agents have not been compared with aspirin for efficacy
d safety, nor do they offer advantages over anticoagulation
ith a vitamin K antagonist in patients with AF at high risk
thromboembolism.
In the Atrial Fibrillation Clopidogrel Trial with Irbesartan
r Prevention of Vascular Events (ACTIVE-W), which was
opped on the recommendation of the Data Safety and
onitoring Board before planned follow-up was com-
eted, the combination of the thienopyridine antiplatelet
ent clopidogrel (75 mg daily) plus aspirin (75 to 100 mg
ily) proved inferior to warfarin (target INR 2.0 to 3.0) in
tients with an average of 2 stroke risk factors in addition
AF (464). Additional studies are ongoing to assess the
pact of this therapy for patients unable or unwilling to
ke warfarin.
rimary prevention trials involving patients with nonvalvular
rrhage was variously defined but typically involved bleeding
on, involved a critical anatomical site, or was permanently dis-
al. Antithrombotic therapy to prevent stroke in patients with
). AFASAK indicates Copenhagen Atrial Fibrillation, Aspirin,
rillation; CAFA, Canadian Atrial Fibrillation Anticoagulation;
tion in Nonrheumatic Atrial Fibrillation.
for patients with atrial fibrillation: warfarin compared with aspi-
rt RG, Benavente O, McBride R, Pearce LA. Antithrombotic
s. Ann Intern Med 1999;131:492–501 (420). AFASAK indicates
erval; EAFT, European Atrial Fibrillation Trial; ESPS, European
ion; UK-TIA, The United Kingdom transient ischaemic attack
tion; SPAF, Stroke Prevention in Atrial Fibrillation; and SPINAF,n in p
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latelet-Inhibitor Therapy (UPDATED)
or new or updated text, view the 2011 Focused Update.
ext supporting unchanged recommendations has not
een updated. Combinations of oral anticoagulants plus
tiplatelet agents to reduce the risk of hemorrhage by
lowing lower intensities of anticoagulation or to augment
ficacy for selected patients at particularly high risk of
romboembolism, such as those with prior stroke, have been
aluated in several trials. Such a strategy has been successful
reducing the risk of thromboembolism in patients with
echanical heart valves (465). Still another objective of
mbination therapy is to enhance protection against isch-
ic cardiac events in patients with AF who have established
ronary atherosclerosis or diabetes. In 2 trials, SPAF III and
openhagen Atrial FIbrillation, Aspirin, and Anticoagulation
FASAK) 2, the combination of low-dose oral anticoagula-
on (INR less than 1.5) with aspirin added little protection
ainst stroke compared with aspirin alone in patients with
F (402,439).
In 2 other trials, substantially higher intensities of antico-
ulation combined with platelet inhibitor agents were eval-
ted in patients with AF. The French Fluindione-Aspirin
ombination in High Risk Patients With AF (FFAACS)
udy compared the oral anticoagulant fluindione (target INR
0 to 2.6) plus placebo or in combination with aspirin, 100
g daily, versus fluindione alone in patients at high risk of
roke. The trial was stopped with only 157 patients enrolled
ean follow-up 0.84 y) because of excessive hemorrhage in
e group receiving the combination therapy (433).
In the larger Spanish National Study for Primary Preven-
on of Embolism in Nonrheumatic Atrial Fibrillation (NA-
PEAF) study, patients were stratified into a high-risk group
 495) with AF and rheumatic mitral stenosis or AF and
history of stroke, TIA, or systemic embolism, and a
wer-risk group (n  714) with AF and age greater than
y, hypertension, or HF (445). The higher-risk patients
ere randomized to anticoagulation with acenocoumrarol
arget INR 2.0 to 3.0) or to acenocoumarol (INR 1.4 to 2.4)
mbined with the platelet cyclooxygenase inhibitor triflusal
00 mg daily). The lower-risk patients were randomized to
iflusal alone, acenocoumarol alone (INR 2.0 to 3.0), or the
mbination of triflusal plus acenocoumarol (INR 1.25 to
0). The achieved anticoagulation intensities in the antico-
ulation and combination therapy arms were closer to one
other than intended, however (mean INR 2.5 with aceno-
umarol alone in both risk strata versus 1.96 and 2.18 for the
mbination arms in the lower- and higher-risk groups during
edian follow-up of 2.6 and 2.9 y, respectively). The primary
tcome was a composite of thromboembolism plus cardio-
scular death (sudden death or death due to thromboembo-
sm, stroke, bleeding, or HF but not MI). Patients in both risk
tegories had a lower risk of primary events with the
mbination therapy than with acenocoumarol alone. These
servations suggest that a combination of platelet inhibitor
d anticoagulant therapy might be effective and relatively
otective if targeted INR levels are closer to the standard wnge, but the superiority of combination therapy over mono-
erapy with a vitamin K antagonist for prevention of
chemic stroke and MI has not been convincingly
tablished.
Combining aspirin with an oral anticoagulant at higher
tensities may accentuate intracranial hemorrhage, particu-
rly in elderly AF patients (466). In a retrospective analysis
10 093 patients with AF after hospital discharge (mean age
y), platelet inhibitor medication was associated with a
gher rate of intracerebral hemorrhage (relative risk 3.0,
% CI 1.6% to 5.5%) (467), but 2 case-control studies
elded conflicting results (454,468).
The superior efficacy of anticoagulation over aspirin for
evention of recurrent stroke in patients with AF was
monstrated in the European Atrial Fibrillation Trial (403).
herefore, unless a clear contraindication exists, AF patients
ith a recent stroke or TIA should be treated with long-term
ticoagulation rather than antiplatelet therapy. There is no
idence that combining anticoagulation with an antiplatelet
ent reduces the risk of stroke compared with anticoagulant
erapy alone. Hence, pending further data for AF patients
ho sustain cardioembolic events while receiving low-
tensity anticoagulation, anticoagulation intensity should be
creased to a maximum target INR of 3.0 to 3.5 rather than
utinely adding antiplatelet agents.
Several studies have evaluated anticoagulation in combi-
tion with aspirin for prevention of ischemic cardiac events
patients with CAD. From these it may be possible to draw
ferences regarding management of antithrombotic therapy
patients who have both CAD and AF. A meta-analysis of
randomized trials of oral anticoagulant therapy published
tween 1960 and 1999 involving patients with CAD treated
r at least 3 mo and stratified by the intensities of anticoag-
ation and aspirin therapy came to the following conclusions
69). High-intensity (INR 2.8 to 4.8) and moderate-intensity
NR 2.0 to 3.0) oral anticoagulation regimens reduced rates
MI and stroke but increased the risk of bleeding 6.0- to
7-fold. Combining aspirin with low-intensity anticoagula-
on (INR less than 2.0) was not superior to aspirin alone.
hile the combination of moderate- to high-intensity oral
ticoagulation plus aspirin appeared promising compared
ith aspirin alone, the combination was associated with
creased bleeding.
From the results of more contemporary trials involving
ng-term treatment of patients with acute myocardial isch-
ia (470–473) and the Combined Hemotherapy and Mor-
lity Prevention Study (CHAMP) (474), it appears that
gh-intensity oral anticoagulation (INR 3.0 to 4.0) is more
fective than aspirin but increases the risk of bleeding. The
mbination of aspirin and moderate-intensity warfarin (INR
0 to 3.0) is more effective than aspirin alone but is
sociated with a greater risk of bleeding. The combination of
pirin and moderate-intensity warfarin (INR 2.0 to 3.0) is as
fective as high-intensity warfarin and associated with a
milar risk of bleeding. The contemporary trials, however,
ve not addressed the effectiveness of moderate-intensity
arfarin (INR 2.0 to 3.0) alone. In the absence of direct
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rin is superior to aspirin in preventing death or reinfarction.
he choice for long-term management of patients with CAD
d AF therefore involves aspirin alone, aspirin plus
oderate-intensity warfarin (INR 2.0 to 3.0), or warfarin
one (INR 2.0 to 3.0). For those with risk factors for stroke,
e latter 2 regimens are more effective than aspirin alone but
e associated with more bleeding and inconvenience. Fur-
er, without close INR control, the combination regimen
ay be associated with a greater risk of bleeding. For most
tients with AF who have stable CAD, warfarin anticoagu-
tion alone (target INR 2.0 to 3.0) should provide satisfac-
ry antithrombotic prophylaxis against both cerebral and
yocardial ischemic events.
The importance of platelet-inhibitor drugs for prevention
recurrent myocardial ischemia is enhanced in patients
dergoing percutaneous coronary intervention, but no ade-
ate studies have been published that specifically address
is issue in patients who also require chronic anticoagulation
cause of AF. It is the consensus of the authors of these
idelines that the most important agent for the maintenance
coronary and stent patency is the thienopyridine derivative
opidogrel and that the addition of aspirin to the chronic
ticoagulant regimen contributes more risk than benefit.
lthough it is usually necessary to interrupt or reduce
ticoagulation to prevent bleeding at the site of peripheral
terial puncture, the vitamin K antagonist should be resumed
soon as possible after the procedure and the dose adjusted
achieve an INR in the therapeutic range. Aspirin may be
ven temporarily during the hiatus, but the maintenance
gimen should then consist of the combination of clopi-
grel, 75 mg daily, plus warfarin (INR 2.0 to 3.0) for 9 to 12
o, following which warfarin may be continued as mono-
erapy in the absence of a subsequent coronary event.
.1.4.2.5. Emerging and Investigational Antithrombotic
gents (UPDATED) For new or updated text, view the
011 Focused Update and 2011 Update on Dabigatran.
ext supporting unchanged recommendations has not
een updated. While clearly efficacious against stroke in
tients with AF, warfarin carries a substantial risk of
morrhage, a narrow therapeutic margin necessitating fre-
ent monitoring of the INR level, and interactions with
merous drugs and foods that may cause a need for dose
justments. These limitations result in undertreatment of a
nsiderable proportion of the AF population at risk, partic-
arly the elderly, for whom numerous concomitant medica-
ons are typically prescribed (455,475), engendering a quest
r safer, more convenient alternatives.
Because of its central role in thrombogenesis, thrombin
actor IIa) represents an attractive target for specific inhibi-
on. Direct thrombin inhibitors bind to the active site of
rombin and prevent it from cleaving fibrinogen to form
brin. These compounds also suppress thrombin-mediated
tivation of platelets and coagulation factors V, VIII, XI, and
III. Ximelagatran is administered orally and converted after
sorption to the active direct thrombin inhibitor melagatran. frhe compound appears to have stable pharmacokinetics
dependent of the hepatic P450 enzyme system and a low
tential for food or drug interactions (476). Two long-term
ase III studies compared ximelagatran with warfarin in
tients with AF, SPORTIF (Stroke Prevention using an
ral Thrombin Inhibitor in patients with atrial Fibrillation)
II and -V, with a combined population of more than 7000
44). In these trials, ximelagatran was administered with-
t dose titration or coagulation monitoring and was
mpared with warfarin (INR 2.0 to 3.0) for the primary
dpoint of all stroke (ischemic and hemorrhagic) and sys-
mic embolism.
SPORTIF-III involved an open-label design (444) and
reful regulation of dosing among patients assigned to
arfarin, with INR values within the therapeutic range for
% of the duration of exposure. The relative risk reduction
29% and absolute risk reduction of 0.7% per year accord-
g to intention-to-treat confirmed the noninferiority of xi-
elagatran to warfarin. By on-treatment analysis, the relative
sk reduction with ximelagatran was 41% (p  0.018. There
as no significant difference between treatments in rates of
morrhagic stroke, fatal bleeding, or other major bleeding,
t when minor hemorrhages are considered as well, ximela-
tran caused significantly less bleeding (25.5% vs. 29.5%
r year, p  0.007).
The results of the SPORTIF-V trial, in which treatment
as administered in a double-blind manner, were similar to
ose of SPORTIF-III (438). The primary event rates were
6% per year with ximelagatran and 1.2% per year with
arfarin (absolute difference 0.45% per year, 95% CI 0.13%
1.03% per year, p less than 0.001 for the noninferiority
pothesis), and there was no difference between treatment
oups in rates of major bleeding, but as in the SPORTIF-III
udy, total bleeding (major plus minor) was lower with
melagatran.
In both the SPORTIF-III and V trials, serum alanine
inotransferase levels rose to greater than 3 times the upper
mit of normal in about 6% of patients treated with ximela-
tran. Hence, despite evidence of efficacy comparable to
refully adjusted warfarin and some advantage in terms of
eeding risk, ximelagatran will not be marketed for clinical
e as an anticoagulant, mainly because of concerns about
patic toxicity (478). Trials of a variety of investigational
al anticoagulant compounds that directly inhibit thrombin,
tagonize factor Xa, or inactivate prothrombin are ongoing
planned, but there are no currently available alternatives to
tamin K antagonists.
.1.4.2.6. Interruption of Anticoagulation for Diagnostic
r Therapeutic Procedures. From time to time, it may be
cessary to interrupt oral anticoagulant therapy in prepara-
on for elective surgical procedures. In patients with mechan-
al prosthetic heart valves, it is generally appropriate to
bstitute unfractionated or low-molecular-weight heparin to
event thrombosis (479,480). In patients with AF who do not
ve mechanical valves, however, based on extrapolationom the annual rate of thromboembolism in patients with
no
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at anticoagulation may be interrupted for a period of up to
wk for surgical or diagnostic procedures that carry a risk of
eeding without substituting heparin. In high-risk patients
articularly those with prior stroke, TIA, or systemic embo-
sm) or when a series of procedures requires interruption of
al anticoagulant therapy for longer periods, unfractionated
low-molecular-weight heparin may be administered intra-
nously or subcutaneously.
The use of low-molecular-weight heparin instead of un-
actionated heparin in patients with AF is based largely on
trapolation from venous thromboembolic disease states and
om limited observational studies (481). In general, low-
olecular-weight heparins have several pharmacological ad-
ntages over unfractionated heparin. These include a longer
lf-life, more predictable bioavailability (greater than 90%
ter subcutaneous injection), predictable clearance (enabling
ce- or twice-daily subcutaneous administration), and a
edictable antithrombotic response based on body weight,
hich permits fixed-dose treatment without laboratory mon-
oring except under special circumstances such as obesity,
nal insufficiency, or pregnancy (482). Treatment with low-
olecular-weight heparin is associated with a lower risk of
parin-induced thrombocytopenia than unfractionated hepa-
n (483). The favorable properties of low-molecular-weight
parins may simplify the treatment of AF in acute situations
d shorten or eliminate the need for hospitalization to
itiate anticoagulation. Self-administration of low-
olecular-weight heparins out of hospital by patients with
F undergoing elective cardioversion is a promising ap-
oach that may result in cost savings (484).
1.4.3. NONPHARMACOLOGICALAPPROACHESTOPREVENTION
F THROMBOEMBOLISM (UPDATED)
R NEW OR UPDATED TEXT, VIEW THE 2011 FOCUSED
PDATE. TEXT SUPPORTING UNCHANGED RECOMMENDA-
IONS HAS NOT BEEN UPDATED.
n emerging option for patients with AF who cannot safely
dergo anticoagulation, which is not yet sufficiently inves-
gated to allow general clinical application, is obliteration of
e LAA to remove a principal nidus of thrombus formation
85,486). In addition to direct surgical amputation or
uncation of appendage, several methods are under devel-
ment to achieve this with intravascular catheters or
anspericardial approaches (487). The efficacy of these
chniques is presumably related to the completeness and
rmanence of elimination of blood flow into and out of
e LAA. This has been demonstrated by TEE at the time
intervention, but the durability of the effect has not been
nfirmed by subsequent examinations over several years.
hether mechanical measures intended to prevent embo-
sm from thrombotic material in the LAA will prove to
comparably effective and safer than anticoagulation
r some patients remains to be established (488). These
ust presently be considered investigational, and indica-
ons for this type of intervention have not been convinc-
gly established. th.1.5. Cardioversion of Atrial Fibrillation
ECOMMENDATIONS
ecommendations for Pharmacological Cardioversion of
trial Fibrillation
ASS I
Administration of flecainide, dofetilide, propafenone, or ibutil-
ide is recommended for pharmacological cardioversion of AF.
(Level of Evidence: A)
ASS IIa
Administration of amiodarone is a reasonable option for phar-
macological cardioversion of AF. (Level of Evidence: A)
A single oral bolus dose of propafenone or flecainide (“pill-in-
the-pocket”) can be administered to terminate persistent AF
outside the hospital once treatment has proved safe in hospital
for selected patients without sinus or AV node dysfunction,
bundle-branch block, QT-interval prolongation, the Brugada
syndrome, or structural heart disease. Before antiarrhythmic
medication is initiated, a beta blocker or nondihydropyridine
calcium channel antagonist should be given to prevent rapid
AV conduction in the event atrial flutter occurs. (Level of Evi-
dence: C)
Administration of amiodarone can be beneficial on an outpa-
tient basis in patients with paroxysmal or persistent AF when
rapid restoration of sinus rhythm is not deemed necessary.
(Level of Evidence: C)
ASS IIb
dministration of quinidine or procainamide might be considered
for pharmacological cardioversion of AF, but the usefulness of
these agents is not well established. (Level of Evidence: C)
ASS III
Digoxin and sotalol may be harmful when used for pharmaco-
logical cardioversion of AF and are not recommended. (Level of
Evidence: A)
Quinidine, procainamide, disopyramide, and dofetilide should
not be started out of hospital for conversion of AF to sinus
rhythm. (Level of Evidence: B)
.1.5.1. BASIS FOR CARDIOVERSION OF
TRIAL FIBRILLATION
ardioversion may be performed electively to restore sinus
ythm in patients with persistent AF. The need for cardio-
rsion may be immediate when the arrhythmia is the main
ctor responsible for acute HF, hypotension, or worsening of
gina pectoris in a patient with CAD. Nevertheless, cardio-
rsion carries a risk of thromboembolism unless anticoagu-
tion prophylaxis is initiated before the procedure, and this
sk is greatest when the arrhythmia has been present for
nger than 48 h.
.1.5.2. METHODS OF CARDIOVERSION
ardioversion may be achieved by means of drugs or elec-
ical shocks. Drugs were commonly used before direct-
rrent cardioversion became a standard procedure. The
velopment of new drugs has increased the popularity of
armacological cardioversion, but the disadvantages include
e risk of drug-induced torsades de pointes or other serious
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinesrhythmias. Moreover, pharmacological cardioversion is less
fective than direct-current cardioversion when biphasic
ocks are used. The disadvantage of electrical cardioversion
that it requires conscious sedation or anesthesia, which
armacological cardioversion does not.
There is no evidence that the risk of thromboembolism or
roke differs between pharmacological and electrical meth-
s of cardioversion. The recommendations for anticoagula-
on are therefore the same for both methods, as outlined in
ection 8.1.4 (Preventing Thromboembolism. Cardioversion
patients with AF following recent heart surgery or MI is
dressed later (see Section 8.4, Special Considerations).
.1.5.3. PHARMACOLOGICAL CARDIOVERSION
he quality of evidence available to gauge the effectiveness
pharmacological cardioversion is limited by small samples,
ck of standard inclusion criteria (many studies include both
tients with AF and those with atrial flutter), variable
tervals from drug administration to assessment of outcome,
d arbitrary dose selection. Although pharmacological and
rect-current cardioversion have not been compared directly,
armacological approaches appear simpler but are less
ficacious. The major risk is related to the toxicity of
tiarrhythmic drugs. In developing these guidelines,
acebo-controlled trials of pharmacological cardioversion in
hich drugs were administered over short periods of time
ecifically to restore sinus rhythm have been emphasized.
rials in which the control group was given another antiar-
ythmic drug have, however, been considered as well.
Pharmacological cardioversion seems most effective when
itiated within 7 d after the onset of an episode of AF
89 – 492). A majority of these patients have a first-
cumented episode of AF or an unknown pattern of AF at
e time of treatment. (See Section 3, Classification.) A large
oportion of patients with recent-onset AF experience spon-
neous cardioversion within 24 to 48 h (493–495). Sponta-
ous conversion is less frequent in patients with AF of
BLE 16. Recommendations for Pharmacological Cardioversion
ug* Route of Administration
ents with proven efficacy
Dofetilide Oral
Flecainide Oral or intravenous
Ibutilide Intravenous
Propafenone Oral or intravenous
Amiodarone Oral or intravenous
ss effective or incompletely studied agents
Disopyramide Intravenous
Procainamide Intravenous
Quinidine Oral
ould not be administered
Digoxin Oral or intravenous
Sotalol Oral or intravenous
*The doses of medications used in these studies may not be the same as tho
tegory of recommendation and level of evidence.nger than 7-d duration, and the efficacy of pharmacological anrdioversion is markedly reduced in these patients as well.
harmacological cardioversion may accelerate restoration of
nus rhythm in patients with recent-onset AF, but the
vantage over placebo is modest after 24 to 48 h, and drug
erapy is much less effective in patients with persistent AF.
ome drugs have a delayed onset of action, and conversion
ay not occur for several days after initiation of treatment
96). Drug treatment abbreviated the interval to cardiover-
on compared with placebo in some studies without affecting
e proportion of patients who remained in sinus rhythm after
h (494). A potential interaction of antiarrhythmic drugs
ith vitamin K antagonist oral anticoagulants, increasing or
creasing the anticoagulant effect, is an issue whenever these
ugs are added or withdrawn from the treatment regimen.
he problem is amplified when anticoagulation is initiated in
eparation for elective cardioversion. Addition of an antiar-
ythmic drug to enhance the likelihood that sinus rhythm
ill be restored and maintained may perturb the intensity of
ticoagulation beyond the intended therapeutic range, rais-
g the risk of bleeding or thromboembolic complications.
A summary of recommendations concerning the use of
armacological agents and recommended doses is presented
Tables 16, 17, and 18. Algorithms for pharmacological
anagement of AF are given in Figures 13, 14, 15, and 16.
hroughout this document, reference is made to the Vaughan
illiams classification of antiarrhythmic drugs (497), modi-
ed to include drugs that became available after the original
assification was developed (Table 19). Considerations spe-
fic to individual agents are summarized below. Within each
tegory, drugs are listed alphabetically. The antiarrhythmic
ugs listed have been approved by federal regulatory agen-
es in the United States and/or Europe for clinical use, but their
e for the treatment of AF has not been approved in all cases.
urthermore, not all agents are approved for use in all countries.
he recommendations given in this document are based on
blished data and do not necessarily adhere to the regulations
ial Fibrillation of Up to 7-d Duration
Class of
ommendation
Level of
Evidence References
I A 498–503
I A 489–491, 493, 504–509
I A 510–515
I A 491, 494, 495, 505, 509, 516–526, 557
IIa A 496, 504, 516, 527–534
IIb B 544
IIb B 510, 512, 536
IIb B 489, 494, 524, 529, 537–539, 698
III A 375, 494, 505, 526, 530, 542
III A 513, 538–540, 543
mmended by the manufacturers. Drugs are listed alphabetically within eachof Atr
Rec
se recod labeling requirements of government agencies.
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ARDIOVERSION OF ATRIAL FIBRILLATION
.1.5.4.1. Amiodarone. Data on amiodarone are confus-
g because the drug may be given intravenously or orally
d the effects vary with the route of administration. Five
eta-analyses of trials compared amiodarone to placebo or
her drugs for conversion of recent-onset AF (546–549).
ne concluded that intravenous amiodarone was no more
fective than placebo (550), while another found amiodarone
fective but associated with adverse reactions (546). Another
eta-analysis found amiodarone more effective than placebo
ter 6 to 8 h and at 24 h but not at 1 to 2 h (547). Amiodarone
as inferior to type IC drugs for up to 8 h, but there was no
fference at 24 h, indicating delayed conversion with amio-
rone. In another meta-analysis of 21 trials involving heter-
eneous populations, the relative likelihood of achieving
nus rhythm over a 4-wk period with oral/intravenous
iodarone was 4.33 in patients with AF of longer than 48-h
ration and 1.40 in those with AF of less than 48-h duration
48). In a meta-analysis of 18 trials, the efficacy of amioda-
ne ranged from 34% to 69% with bolus (3 to 7 mg/kg body
eight) regimens and 55% to 95% when the bolus was
llowed by a continuous infusion (900 to 3000 mg daily)
50). Predictors of successful conversion were shorter dura-
on of AF, smaller LA size, and higher amiodarone dose.
miodarone was not superior to other antiarrhythmic drugs
r conversion of recent-onset AF but was relatively safe in
tients with structural heart disease, including those with LV
sfunction for whom administration of class IC drugs is
ntraindicated. In addition, limited information suggests that
iodarone is equally effective for conversion of AF or atrial
utter. Because safety data are limited, randomized trials are
eded to determine the benefit of amiodarone for conversion
recent-onset AF in specific patient populations.
In the SAFE-T trial involving 665 patients with persistent
F, conversion occurred in 27% of patients after 28 d of
eatment with amiodarone, compared with 24% with sotalol
BLE 17. Recommendations for Pharmacological Cardioversion
ug* Route of Administration
ents with proven efficacy
Dofetilide Oral
Amiodarone Oral or intravenous
Ibutilide Intravenous
ss effective or incompletely studied agents
Disopyramide Intravenous
Flecainide Oral
Procainamide Intravenous
Propafenone Oral or intravenous
Quinidine Oral
ould not be administered
Digoxin Oral or intravenous
Sotalol Oral or intravenous
*The doses of medications used in these studies may not be the same as tho
tegory by class and level of evidence.d 0.8% with placebo (292). Although the speed of response loay differ during sustained oral therapy, amiodarone,
opafenone, and sotalol seemed equally effective in convert-
g persistent AF to sinus rhythm. Apart from intravenous
ug therapy for conversion early after onset of AF (within
h), antiarrhythmic drug agents may also be given over a
nger period of time in an effort to achieve cardioversion
ter a longer period of AF. Under these circumstances,
ministration of oral amiodarone is associated with a con-
rsion rate between 15% and 40% over 28 d (292,529,533,
1). In a comparative study, amiodarone and propafenone
ere associated with similar rates (40%) of converting
rsistent AF averaging 5 mo in duration (551). Remarkably,
l cases in which conversion followed administration of
iodarone occurred after 7 d, with responses continuing to
d, whereas conversion occurred more rapidly with
opafenone (between 1 and 14 d).
Adverse effects of amiodarone include bradycardia, hypoten-
on, visual disturbances, thyroid abnormalities, nausea, and
nstipation after oral administration and phlebitis after periph-
al intravenous administration. Serious toxicity has been re-
rted, including death due to bradycardia ending in cardiac
rest (496,504,516,527–534,537,551).
.1.5.4.2. Dofetilide. Oral dofetilide is more effective than
acebo for cardioversion of AF that has persisted longer than
wk, but available studies have not further stratified patients
the basis of the duration of the arrhythmia. Dofetilide
pears more effective for cardioversion of atrial flutter than
AF. A response may take days or weeks when the drug is
ven orally. The intravenous form is investigational (498–
2).
.1.5.4.3. Flecainide. Flecainide administered orally or in-
avenously was effective for cardioversion of recent-onset
F in placebo-controlled trials. In 7 studies, the success of a
ngle oral loading dose (300 mg) for cardioversion of
cent-onset AF ranged from 57% to 68% at 2 to 4 h and 75%
91% at 8 h after drug administration (552). Single oral
ial Fibrillation Present for More Than 7 d
ecommendation
Class
Level of
Evidence References
I A 498–503
IIa A 496, 504, 516, 527–534
IIa A 510–515
IIb B 544
IIb B 489–491, 493, 504–509
IIb C 510, 512, 536, 557
IIb B 494, 495, 505, 509, 516–526
IIb B 489, 494, 524, 529, 537–539, 698
III B 375, 494, 505, 526, 530, 542
III B 513, 538–540, 543
mmended by the manufacturers. Drugs are listed alphabetically within eachof Atr
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ter oral administration and 1 h after intravenous adminis-
ation. Arrhythmias, including atrial flutter with rapid ven-
icular rates and bradycardia after conversion, are relatively
equent adverse effects. Transient hypotension and mild
urological side effects may also occur. Overall, adverse
actions are slightly more frequent with flecainide than with
opafenone, and these drugs should be avoided in patients
ith underlying organic heart disease involving abnormal
ntricular function (489–491,493,504,505,507–509).
.1.5.4.4. Ibutilide. In placebo-controlled trials, intrave-
us ibutilide has proved effective for cardioversion within a
w weeks after onset of AF. Available data are insufficient to
tablish its efficacy for conversion of persistent AF of longer
ration. Ibutilide may be used in patients who fail to convert
BLE 18. Recommended Doses of Drugs Proven Effective for P
Drug*
Route of
Administration Dosage†
iodarone Oral Inpatient: 1.2 to 1.8 g per day in
divided dose until 10 g total,
then 200 to 400 mg per day
maintenance or 30 mg/kg as
single dose Outpatient: 600 to
800 mg per day divided dose
until 10 g total, then 200 to 400
mg per day maintenance
Hy
Intravenous/oral 5 to 7 mg/kg over 30 to 60 min,
then 1.2 to 1.8 g per day
continuous IV or in divided oral
doses until 10 g total, then 200
to 400 mg per day maintenance
fetilide Oral Creatinine
Clearance Dose
(mL/min) (mcg BID)
More than 60 500 QT
do40 to 60 250
20 to 40 125
Less than 20 Contraindicated
ecainide Oral 200 to 300 mg‡ Hyp
Intravenous 1.5 to 3.0 mg/kg over 10 to 20
min‡
utilide Intravenous 1 mg over 10 min; repeat 1 mg
when necessary
opafenone Oral 600 mg Hyp
Intravenous 1.5 to 2.0 mg/kg over 10 to 20
min‡
inidine§ Oral 0.75 to 1.5 g in divided doses
over 6 to 12 h, usually with a
rate-slowing drug
QT p
*Drugs are listed alphabetically.
†Dosages given in the table may differ from those recommended by the ma
‡Insufficient data are available on which to base specific recommendations for
impaired left ventricular function, and these drugs should be used cautiously
§The use of quinidine loading to achieve pharmacological conversion of atrial
ted in the table. Quinidine should be used with caution.
AF indicates atrial fibrillation; BID, twice a day; GI, gastrointestinal; and IV, inllowing treatment with propafenone (553) or in those in cehom the arrhythmia recurs during treatment with
opafenone or flecainide (554). The risk of torsades de
intes was about 1% in these studies, lower than the
proximate 4% incidence observed during ibutilide mono-
erapy (555). Presumably, this is related to the protective
fect of sodium channel blockade with type IC drugs (554).
utilide is more effective for conversion of atrial flutter than
AF. An effect may be expected within 1 h after adminis-
ation. In clinical practice, there is a 4% risk of torsades de
intes ventricular tachycardia and appropriate resuscitation
uipment must therefore be immediately available. Women
e more susceptible than men to this complication (5.6% vs.
in a meta-analysis) (555). Ibutilide should be avoided in
tients with very low ejection fractions or HF because of the
gher risk of ventricular proarrhythmia (556). Serum con-
ological Cardioversion of Atrial Fibrillation
otential Adverse Effects References
on, bradycardia, QT prolongation,
s de pointes (rare), GI upset,
onstipation, phlebitis (IV)
496, 504, 516, 527–534, 537, 545
ation, torsades de pointes; adjust
enal function, body size and age
498–503
, atrial flutter with high ventricular
rate
489–491, 493, 504, 505, 507–509
longation, torsades de pointes 510–515
, atrial flutter with high ventricular
rate
491, 494, 495, 505, 506, 509,
516–526, 557
tion, torsades de pointes, GI upset,
hypotension
489, 494, 524, 529, 537–539
rers.
of one loading regimen over another for patients with ischemic heart disease
at all in such patients.
n is controversial and safer methods are available with the alternative agents
us.harmac
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98fore administration of ibutilide, and patients should be
onitored for at least 4 h afterward. Hypotension is an
frequent adverse response (510–515).
.1.5.4.5. Propafenone. Placebo-controlled trials have
rified that propafenone, given orally or intravenously, is
fective for pharmacological cardioversion of recent-onset
F. The effect occurs between 2 and 6 h after oral adminis-
ation and earlier after intravenous injection, so that when
mpared with the intravenous regimen, oral propafenone
sulted in fewer conversions in the first 2 h. In 12 placebo-
ntrolled trials, the success rate of oral propafenone (600
g) for cardioversion of recent-onset AF ranged from 56% to
% (557). Oral propafenone was as efficacious as flecainide
t superior to oral amiodarone and quinidine plus digoxin
94,558). Limited data suggest reduced efficacy in patients
ith persistent AF, in conversion of atrial flutter, and intients with structural heart disease. Adverse effects are
common but include rapid atrial flutter, ventricular tachy-
rdia, intraventricular conduction disturbances, hypotension,
d bradycardia at conversion. Available data on the use of
rious regimens of propafenone loading in patients with
ganic heart disease are scant. This agent should be used
utiously or not at all for conversion of AF in such cases and
ould be avoided in patients with HF or severe obstructive
ng disease (491,495,505,506,509,516–526,557).
.1.5.5. LESS EFFECTIVE OR INCOMPLETELY STUDIED
GENTS FOR CARDIOVERSION OF ATRIAL FIBRILLATION
.1.5.5.1. Quinidine. Quinidine is used less frequently
an other pharmacological agents, due to the perception that it
less efficacious and has more frequent side effects, although
rect comparative studies are lacking. Quinidine is usually
Figure 13. Pharmacological management of
patients with newly discovered atrial fibrilla-
tion (AF). *See Figure 15. HF indicates heart
failure.
Figure 14. Pharmacological management of
patients with recurrent paroxysmal atrial fibril-
lation (AF). *See Figure 15. AAD indicates an-
tiarrhythmic drug.
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinesministered after digoxin or verapamil has been given to
ntrol the ventricular response rate. Potential adverse effects
clude QT-interval prolongation that may precede torsades de
intes, nausea, diarrhea, fever, hepatic dysfunction, thrombo-
topenia, and hemolytic anemia. During the initiation of quin-
ine therapy, hypotension and acceleration of the ventricular
sponse to AF may occur on a vagolytic basis. A clinical
sponse may be expected 2 to 6 h after administration
89,491,494,524,529,537–539,545).
.1.5.5.2. Procainamide. Intravenous procainamide has
en used extensively for conversion within 24 h of onset of
gure 15. (UPDATED) For new or updated text, view the 2011 Fo
t been updated. Antiarrhythmic drug therapy to maintain sinus r
tion. Within each box, drugs are listed alphabetically and not in o
ce under each condition. The seriousness of heart disease proc
e conditions depends on the most serious condition present. Se
pertrophy.
gure 16. Pharmacological management of patients with recurren
fore cardioversion to reduce the likelihood of early recurrence of AF. *SF, and several studies suggest that it may be superior to
acebo (510,512,536). Procainamide appears less useful than
me other drugs and has not been tested adequately in
tients with persistent AF. Hypotension is the major adverse
fect after intravenous administration.
.1.5.5.3. Beta Blockers. When given intravenously, the
ort-acting beta blocker esmolol may have modest efficacy
r pharmacological cardioversion of recent-onset AF, but
is has not been established by comparison with placebo.
onversion is probably mediated through slowing of the
ntricular rate. It is not useful in patients with persistent AF,
Update. Text supporting unchanged recommendations has
in patients with recurrent paroxysmal or persistent atrial fibril-
f suggested use. The vertical flow indicates order of prefer-
om left to right, and selection of therapy in patients with multi-
on 8.3.3.3 for details. LVH indicates left ventricular
stent or permanent atrial fibrillation (AF). Initiate drug therapycused
hythm
rder o
eeds fr
e Sectit persi
ee Figure 15. AAD indicates antiarrhythmic drug.
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98d there are no data comparing its relative efficacy for atrial
utter and AF. A response may be expected within 1 h after
itiation of intravenous infusion. Hypotension and broncho-
asm are the major adverse effects of esmolol and other beta
ockers (492,559).
.1.5.5.4. Nondihydropyridine Calcium Channel
ntagonists (Verapamil and Diltiazem). The nondihy-
opyridine calcium channel antagonists verapamil and dilti-
em have not been found effective for pharmacological cardio-
rsion of recent-onset or persistent AF, but they act rapidly to
ntrol the rate of ventricular response (373,491,492,532). The
gative inotropic effects of nondihydropine calcium channel
ockers might result in hypotension; caution should be used in
tients with HF.
BLE 19. Vaughan Williams Classification of
ntiarrhythmic Drugs
ype IA
Disopyramide
Procainamide
Quinidine
ype IB
Lidocaine
Mexiletine
ype IC
Flecainide
Propafenone
ype II
Beta blockers (e.g., propranolol)
ype III
Amiodarone
Bretylium
Dofetilide
Ibutilide
Sotalol
ype IV
Nondihydropyridine calcium channel antagonists (verapamil and diltiazem)
Table includes compounds introduced after publication of the original
assification.
Modified with permission from Vaughan Williams EM. A classification of
tiarrhythmic actions reassessed after a decade of new drugs. J Clin
armacol 1984;24:129-47 (497). © 1984 by Sage Publications Inc.
BLE 20. Typical Doses of Drugs Used to Maintain Sinus Rhyth
ug† Daily Dosage
iodarone‡ 100 to 400 mg Photosensitivity, pulmonary
toxicity, thyroid dysfunction
sopyramide 400 to 750 mg Torsades de pointes, HF, g
fetilide§ 500 to 1000 mcg Torsades de pointes
ecainide 200 to 300 mg Ventricular tachycardia, HF
opafenone 450 to 900 mg Ventricular tachycardia, HF
talol§ 160 to 320 mg Torsades de pointes, HF, b
*Drugs and doses given here have been determined by consensus on the ba
†Drugs are listed alphabetically.
‡A loading dose of 600 mg per day is usually given for one month or 1000
§Dose should be adjusted for renal function and QT-interval response duringAF indicates atrial fibrillation; AV, atrioventricular; GI, gastrointestinal; and HF, heart.1.5.5.5. Digoxin. Digitalis glycosides are generally not
ore effective than placebo for conversion of recent-onset AF
sinus rhythm. Digoxin may prolong the duration of
isodes of paroxysmal AF in some patients (375), and it has
t been evaluated adequately in patients with persistent AF
cept to achieve rate control. Digoxin has few adverse
fects after acute administration in therapeutic doses, aside
om AV block and increased ventricular ectopy, but all
anifestations of digitalis toxicity are dose related (375,378,
4,505,526,530,540,542).
.1.5.5.6. Disopyramide. Disopyramide has not been
sted adequately for conversion of AF but may be effective
hen administered intravenously. Adverse effects include
yness of mucous membranes, especially in the mouth,
nstipation, urinary retention, and depression of LV contrac-
lity. The last reaction makes it a relatively unattractive
tion for pharmacological conversion of AF.
.1.5.5.7. Sotalol. In contrast to its relative efficacy for
aintenance of sinus rhythm, sotalol has no proved efficacy
r pharmacological cardioversion of recent-onset or persis-
nt AF when given either orally or intravenously. It does,
wever, control the heart rate (513,538–540,543). In pa-
ents who tolerate AF relatively well, a wait-and-see ap-
oach using oral sotalol is an appropriate option. Side effects
nsist mainly of QT prolongation associated with torsades
pointes.
.1.6. Pharmacological Agents to Maintain
inus Rhythm
.1.6.1. AGENTS WITH PROVEN EFFICACY TO MAINTAIN
NUS RHYTHM
hirty-six controlled trials evaluating 7 antiarrhythmic drugs
r the maintenance of sinus rhythm in patients with paroxysmal
persistent AF, 14 controlled trials of drug prophylaxis involv-
g patients with paroxysmal AF, and 22 trials of drug prophy-
xis for maintenance of sinus rhythm in patients with persistent
F were identified. Comparative data are not sufficient to permit
bclassification by drug or etiology. Individual drugs, listed
phabetically, are described below, and doses for maintenance
sinus rhythm are given in Table 20. It should be noted that any
embrane-active agent may cause proarrhythmia.
atients With Atrial Fibrillation*
Potential Adverse Effects
, polyneuropathy, GI upset, bradycardia, torsades de pointes (rare), hepatic
mplications
, urinary retention, dry mouth
sion to atrial flutter with rapid conduction through the AV node
sion to atrial flutter with rapid conduction through the AV node
ia, exacerbation of chronic obstructive or bronchospastic lung disease
ublished studies.
day for 1 week.
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelines.1.6.1.1. Amiodarone. Available evidence suggests that
iodarone is more effective than either class I drugs, sotalol,
placebo in the long-term maintenance of sinus rhythm in
tients with paroxysmal or persistent AF refractory to other
ugs (560–574). However, amiodarone is associated with a
latively high incidence of potentially severe extracardiac
xic effects, making it a second-line or last-resort agent in
any cases. The use of low-dose amiodarone (200 mg daily
less) may be effective and associated with fewer side
fects (537,561,565,566) than higher-dose regimens. In pa-
ents with LVH, HF, CAD, and/or previous MI, amiodarone
associated with a low risk of proarrhythmia, making it an
propriate initial choice to prevent recurrent AF in these
tuations. Use of amiodarone for AF is associated with the
ded benefit of effective rate control, frequently eliminating
e need for other drugs to control the ventricular rate.
A majority of the 403 patients in the CTAF study (561) had
rst-time paroxysmal (46%) or persistent (54%) AF of less
an 6-mo duration. AF was considered persistent when more
an half the previous episodes had required cardioversion,
plying that many of the cases designated as persistent AF
tually had spontaneously terminating paroxysmal AF. Ami-
arone maintained sinus rhythm more successfully than
opafenone or sotalol (69% vs. 39%) over a 16-mo
llow-up period. The reduced recurrence of AF was associ-
ed with improved quality of life, fewer AF-related proce-
res, and lower cost (347). Nevertheless, 18% of patients
opped amiodarone because of side effects after a mean of
8 d, compared with 11% of patients assigned to sotalol or
opafenone.
Of 222 patients randomized to either amiodarone or class
agents in the AFFIRM study, 62% treated with amiodarone
mained in sinus rhythm at 1 y compared with 23% on class
agents. In 256 patients randomized between amiodarone and
talol, 60% versus 38% sustained sinus rhythm (570). In
tients with paroxysmal AF, amiodarone was more effective
an propafenone (575) and sotalol (562), but this advantage
as offset by a higher incidence of side effects (562). In
tients who develop recurrent AF during long-term therapy
ith oral amiodarone, intravenous amiodarone exerted an
ditional therapeutic effect to terminate recurrences (576).
Amiodarone increases the success rate of electric cardio-
rsion and prevents relapses by suppressing atrial ectopy in
tients with persistent AF (577–579).
Experimentally, amiodarone, but not dofetilide or flecain-
e, reverses pacing-induced atrial remodeling and inhibits
e inducibility and stability of AF (580). To date, only a few
ndomized studies have been performed with amiodarone
ter cardioversion in patients with persistent AF. Amioda-
ne was tested as a first-line agent in a study of patients
stcardioversion (537) stratified according to age, duration
AF, mitral valve disease, and cardiac surgery. After 6 mo,
iodarone was more effective (83% of patients remaining in
nus rhythm) than quinidine (43%). Amiodarone was asso-
ated with fewer side effects than quinidine over 6 mo, but
de effects often occur after more prolonged treatment with
iodarone. In a crossover study of 32 patients who had
rsistent AF for more than 3 wk randomized to amiodarone
quinidine (537) when pharmacological conversion did not ofcur with quinidine (direct-current cardioversion was not
ed), amiodarone was better tolerated and far more effective
achieving restoration and long-term maintenance of sinus
ythm. After 9 mo, 18 of 27 (67%) amiodarone-treated
tients were in sinus rhythm versus 2 of 17 (12%) taking
inidine.
The double-blind, placebo-controlled SAFE-T trial (292)
volved 665 patients with persistent AF, of whom 267
ceived amiodarone, 261 received sotalol, and 137 received
acebo. After a run-in period of 28 d allowing for a full
tiarrhythmic effect, spontaneous conversion occurred in
% of those given amiodarone, 24% on sotalol, and 0.8% on
acebo. Among patients who did not experience conversion
armacologically, direct-current shocks subsequently failed
28%, 26.5%, and 32% of patients in the 3 treatment groups,
spectively. This indicates that sotalol and amiodarone,
hen given on a chronic basis, are equally effective in
nverting persistent AF to sinus rhythm (see Section 8.1.5.4,
gents With Proven Efficacy for Cardioversion of Atrial
ibrillation). The median times to recurrence of AF were
gnificantly longer with amiodarone (487 d) than with sotalol
4 d) or placebo (6 d). In patients with ischemic heart
sease, the median time to AF recurrence did not differ
tween amiodarone (569 d) and sotalol (428 d). There were
significant differences in major adverse events, but the
ration of amiodarone therapy may have been insufficient to
pose toxicity. Although amiodarone is more effective than
talol, sotalol was equally effective in patients with CAD,
r whom it is preferred because of lower toxicity.
One uncontrolled study involved 89 patients with persis-
nt AF in whom previous treatments had failed; actuarially,
% were in sinus rhythm after 3 y of amiodarone therapy
66). In another study (563) of 110 patients with refractory
F (57 with paroxysmal AF) or atrial flutter in whom a
edian of 2 class I agents had failed, amiodarone (268 plus or
inus 100 mg daily) was associated with recurrence in 9% of
tients with persistent AF and 40% of those with paroxys-
al AF over 5 y. Several other uncontrolled studies also
pport the use of amiodarone as an agent of last resort
64,568,581,582). In one, a dose of 200 mg daily appeared
fective in patients for whom cardioversion had failed; 52%
derwent repeated cardioversion with success for 12 mo
31).
.1.6.1.2. Beta Blockers. Beta blockers are generally not
nsidered primary therapy for maintenance of sinus rhythm
patients with AF and structural heart disease. Various beta
ockers have shown moderate but consistent efficacy to
event AF recurrence or reduce the frequency of paroxysmal
F, comparable to conventional antiarrhythmic drugs (583–
6). One placebo-controlled study (583) of 394 patients with
rsistent AF found a lower risk of early recurrence after
rdioversion and slower ventricular response with sustained-
lease metoprolol than placebo (583). Two studies found
enolol (587) and bisoprolol (584) as effective as sotalol and
tter than placebo in reducing the frequency and duration of
roxysmal AF and in reducing the probability of relapse
ter cardioversion, but proarrhythmic events occurred more
ten during treatment with sotalol. In patients with persistent
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98F, carvedilol and bisoprolol initiated after cardioversion
oduced similar reductions in relapse over the course of 1 y
85). These results confirm a previous observational study in
hich beta blockers reduced the risk of developing AF during
average follow-up of 3.2 y (25). Beta blockers have the
vantage of controlling the ventricular rate when AF recurs
d reduce or abolish associated symptoms, but unawareness
recurrent AF may have disadvantages. These agents may
effective in postoperative patients but potentially aggravate
gally mediated AF.
.1.6.1.3. Dofetilide. Two large-scale, double-blind, ran-
mized studies support the efficacy of dofetilide for preven-
on of AF or atrial flutter (503). Results from the Symptom-
ic Atrial Fibrillation Investigative Research on Dofetilide
AFIRE-D) study found dofetilide associated with conver-
on to sinus rhythm (503), most (87%) within 30 h after
eatment was initiated. In SAFIRE-D (503), dofetilide (500
cg daily) exhibited 58% efficacy in maintaining sinus
ythm 1 y after cardioversion compared with only 25% in
e placebo group. In the Distensibility Improvement And
emodeling in Diastolic Heart Failure (DIAMOND) (588)
udy of patients with compromised LV function, sinus
ythm was maintained in 79% of the dofetilide group
mpared with 42% of the placebo group. The incidence of
rsades de pointes was 0.8%. Four of 5 such events occurred
the first 3 d. To reduce the risk of early proarrhythmia,
fetilide must be initiated in the hospital at a dose titrated to
nal function and the QT interval.
.1.6.1.4. Disopyramide. Several small, randomized stud-
s support the efficacy of disopyramide to prevent recurrent
F after direct-current cardioversion. One study comparing
opafenone and disopyramide showed equal efficacy, but
opafenone was better tolerated (589). Treatment with diso-
ramide for more than 3 mo after cardioversion was asso-
ated with an excellent long-term outcome in an uncon-
olled study: 98 of 106 patients were free of recurrent AF,
d 67% remained in sinus rhythm after a mean of 6.7 y.
lthough the duration of AF was more than 12 mo in most
tients, few had significant underlying cardiac disease other
an previously treated thyrotoxicosis. It is not clear, there-
re, whether disopyramide was the critical factor in sup-
essing AF (544). Disopyramide has negative inotropic and
gative dromotropic effects that may cause HF or AV block
44,589–592). Disopyramide may be considered first-line
erapy in vagally induced AF, and its negative inotropic
fects may be desirable in patients with HCM associated
ith dynamic outflow tract obstruction (593).
.1.6.1.5. Flecainide. Two placebo-controlled studies
94,595) found flecainide effective in postponing the first
currence of AF and the overall time spent in AF; and in
her randomized studies (596,597) efficacy was comparable
quinidine with fewer side effects. Several uncontrolled
udies (598–600) found that flecainide delayed recurrence.
evere ventricular proarrhythmia or sudden death was not
served at a mean dose of 199 mg daily among patients with
ttle or no structural heart disease. Side effects in 5 patients
%) were predominantly related to negative dromotropism, reith or without syncope. Flecainide (200 mg daily) was
perior to long-acting quinidine (1100 mg daily) in prevent-
g recurrent AF after cardioversion and associated with
wer side effects, but one patient died a month after entry,
esumably due to proarrhythmia (600).
.1.6.1.6. Propafenone. The United Kingdom Paroxysmal
upraventricular Tachycardia (UK PSVT) study was a large,
ndomized, placebo-controlled trial of propafenone in which
anstelephonic monitoring was used to detect relapses to AF
01). The primary endpoint was time to first recurrence or
verse event. A dose of 300 mg twice daily was effective and
0 mg 3 times daily even more effective, but the higher dose
as associated with more frequent side effects. In a small,
acebo-controlled study (602), propafenone, compared with
acebo, reduced days in AF from 51% to 27%. Propafenone
as more effective than quinidine in another randomized
mparison (603). In an open-label randomized study involv-
g 100 patients with AF (with balanced proportions of
roxysmal and persistent AF), propafenone and sotalol were
ually effective in maintaining sinus rhythm (30% vs. 37%
patients in sinus rhythm at 12 mo, respectively) (604). The
ttern of AF (paroxysmal or persistent), LA size, and
evious response to drug therapy did not predict efficacy, but
atistical power for this secondary analysis was limited.
ther uncontrolled studies, usually involving selected pa-
ents refractory to other antiarrhythmic drugs, also support
e efficacy of propafenone (605–609).
In a randomized study, propafenone and disopyramide
peared equally effective in preventing postcardioversion
F, but propafenone was better tolerated (589). A few
servational studies involving mixed cohorts of patients
ith paroxysmal and persistent AF found propafenone effec-
ve in terms of maintenance of sinus rhythm and reduction of
rhythmia-related complaints (608).
In 2 placebo-controlled studies on patients with symptom-
ic AF (610,611), a sustained-release formulation of
opafenone (225, 325, and 425 mg twice daily) delayed the
rst symptomatic recurrence and reduced the ventricular rate
the time of relapse.
Like other highly effective class IC drugs, propafenone
ould not be used in patients with ischemic heart disease or
V dysfunction due to the high risk for proarrhythmic effects.
lose follow-up is necessary to avoid adverse effects due to
e development of ischemia or HF.
.1.6.1.7. Sotalol. Sotalol is not effective for conversion of
F to sinus rhythm, but it may be used to prevent AF. Two
acebo-controlled studies (612,613) involving patients in
nus rhythm and at least one documented prior episode of AF
und sotalol safe and effective at doses ranging from 80 to
0 mg twice daily. Patients considered at risk of proarrhyth-
ia, HF, or AV conduction disturbances were excluded;
hether any of the participants had undergone previous
rect-current cardioversion was not reported (561,612). The
fects of the reverse use dependence of sotalol and proar-
ythmic risk may be greater after conversion to slower rates
sinus rhythm than during AF with a rapid ventricularsponse.
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March 15, 2011:e101–98 ACC/AHA/ESC Practice GuidelinesIn another study (604), sotalol and propafenone seemed
ually effective for maintenance of sinus rhythm in patients
ith AF. In the CTAF study, sotalol and propafenone (given
parately) were less effective than amiodarone as assessed
the number of patients without documented recurrence of
F. The difference between outcomes with these drugs was
ss marked when the number of patients continuing treat-
ent without side effects was considered. In an uncontrolled
udy of a stepped-care approach beginning with propafenone
d, after failure, then sotalol, paroxysmal AF occurred in
arly 50% of patients, but only 27% of those with persistent
F converted to sinus rhythm at 6 mo (609).
Sotalol was as effective as and better tolerated than
ow-release quinidine sulfate for preventing recurrent AF in
multicenter study (614). Moreover, sotalol was more
fective in suppressing symptoms in patients who relapsed
to AF, probably because it induced a slower ventricular
te. In patients with recurrent AF, propafenone was as
fective as sotalol in maintaining sinus rhythm 1 y after
rdioversion. Recurrences occurred later and were less
mptomatic with either drug than with placebo (615).
everal studies found sotalol and the combination of quini-
ne and verapamil equally effective after cardioversion of
F, although ventricular arrhythmias (including torsades de
intes) were more frequent with quinidine (538,615). Sota-
l should be avoided in patients with asthma, HF, renal
sufficiency, or QT interval prolongation.
.1.6.2. DRUGS WITH UNPROVEN EFFICACY OR NO
NGER RECOMMENDED
.1.6.2.1. Digoxin. Available evidence does not support a
le for digitalis in suppressing recurrent AF in most patients.
he lack of an AV blocking effect during sympathetic
imulation results in poor rate control with digoxin, and
nce it does not usually reduce symptoms associated with
current paroxysmal AF (30).
.1.6.2.2. Procainamide. No adequate studies of procain-
ide are available. Long-term treatment is frequently asso-
ated with development of antinuclear antibodies and is
casionally associated with arthralgia or agranulocytosis.
.1.6.2.3. Quinidine. Quinidine has not been evaluated
tensively in patients with paroxysmal AF but appears
proximately as effective as class IC drugs (596,597,616). In
ne study (603), quinidine was less effective than
opafenone (22% of patients free from AF with quinidine vs.
% with propafenone). Side effects are more prominent than
ith other antiarrhythmic drugs, and proarrhythmia is a
rticular concern. A meta-analysis of 6 trials found quini-
ne superior to no treatment to maintain sinus rhythm after
rdioversion of AF (50% vs. 25% of patients, respectively,
er 1 y). However, total mortality was significantly higher
ong patients given quinidine (12 of 413 patients; 2.9%)
an among those not given quinidine (3 of 387 patients;
8%) (609). In a registry analysis (616), 6 of 570 patients
ss than 65 y old died shortly after restoration of sinus
ythm while taking quinidine. Up to 30% of patients taking
inidine experience intolerable side effects, most commonly poarrhea. Other investigators (614) found sotalol and quini-
ne equally effective for maintaining sinus rhythm after
rect-current cardioversion of AF. Sotalol, but not quinidine,
duced heart rate in patients with recurrent AF, and there
ere fewer symptoms with sotalol (535,592,614,617–624).
In 2 European multicenter studies, the combination of
inidine plus verapamil was as effective as or superior to
talol in preventing recurrences of paroxysmal and persis-
nt AF. In the Suppression Of Paroxysmal Atrial Tachyar-
ythmias (SOPAT) trial (625), 1033 patients (mean age 60 y,
% male) with frequent episodes of symptomatic paroxys-
al AF either received high-dose quinidine (480 mg per day)
us verapamil (240 mg per day; 263 patients), low-dose
inidine (320 mg per day) plus verapamil (160 mg per day;
5 patients), sotalol (320 mg per day; 264 patients), or
acebo (251 patients). Each of the active treatments was
atistically superior to placebo and not different from one
other with respect to time to first recurrence or drug
scontinuation. The symptomatic AF burden also improved
.4%, 4.5%, 2.9%, and 6.1% of days for each treatment
oup, respectively). Four deaths, 13 episodes of syncope,
d 1 episode of ventricular tachycardia were documented,
ith 1 death and occurrence of VT related to quinidine plus
rapamil. Sotalol and the quinidine-verapamil combination
ere associated with more severe side effects.
The Prevention of Atrial Fibrillation After Cardioversion
AFAC) trial (287) compared the efficacy and safety of the
mbination of quinidine plus verapamil (377 patients),
talol (383 patients), and placebo (88 patients) in patients
ith persistent AF or following direct-current cardioversion,
ith daily transtelephonic monitoring for detection of recur-
nt AF. AF recurrence or death occurred in 572 patients
7%), and AF recurrence became persistent in 348 (41%).
ver 1 y, recurrence rates were 83% with placebo, 67% with
talol, and 65% with the combination of quinidine plus
rapamil, the last mentioned statistically superior to placebo
t not different from sotalol. Persistent AF occurred in 77%,
%, and 38%, respectively, with the quinidine-verapamil
mbination superior to placebo and to sotalol. About 70% of
F recurrences were asymptomatic. Adverse events were
mparable on sotalol and quinidine/verapamil, except that
rsades de pointes was confined to the sotalol group. There-
re, the combination of quinidine plus verapamil appeared
eful to prevent recurrent AF after cardioversion of persis-
nt AF.
.1.6.2.4. Verapamil and Diltiazem. There is no evi-
nce to support the antiarrhythmic efficacy of calcium
annel antagonist drugs in patients with paroxysmal AF, but
ey reduce heart rate during an attack such that symptoms
ay disappear despite recurrent AF. In one study, diltiazem
duced the number of AF episodes occurring in a 3-mo
riod by approximately 50% (626).
.1.7. Out-of-Hospital Initiation of Antiarrhythmic
rugs in Patients With Atrial Fibrillation
frequent issue related to pharmacological cardioversion of
F is whether to initiate antiarrhythmic drug therapy in
spital or on an outpatient basis. The major concern is the
tential for serious adverse effects, including torsades de
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98intes (Table 21). With the exception of those involving
w-dose oral amiodarone (533), virtually all studies of
armacological cardioversion have involved hospitalized
tients. However, one study (627) provided a clinically
eful approach with out-of-hospital patient-controlled con-
rsion using class IC drugs (see Tables 6, 7, and 8).
The “pill-in-the-pocket” strategy consists of the self-
ministration of a single oral dose of drug shortly after the
set of symptomatic AF to improve quality of life, decrease
spital admission, and reduce cost (628). Recommendations
r out-of-hospital initiation or intermittent use of antiar-
ythmic drugs differ for patients with paroxysmal and
rsistent AF. In patients with paroxysmal AF, the aims are to
rminate an episode or to prevent recurrence. In patients with
rsistent AF, the aims are to achieve pharmacological
rdioversion of AF, obviating the need for direct-current
rdioversion, or to enhance the success of direct-current
rdioversion by lowering the defibrillation threshold and
event early recurrence of AF.
In patients with lone AF without structural heart disease,
ass IC drugs may be initiated on an outpatient basis. For
her selected patients without sinus or AV node dysfunction,
ndle-branch block, QT-interval prolongation, the Brugada
ndrome, or structural heart disease, “pill-in-the-pocket”
ministration of propafenone and flecainide outside the
spital becomes an option once treatment has proved safe in
spital given the relative safety (lack of organ toxicity and
w estimated incidence of proarrhythmia) (181,557,629–
1). Before these agents are initiated, however, a beta
ocker or nondihydropyridine calcium channel antagonist is
nerally recommended to prevent rapid AV conduction in
BLE 21. Types of Proarrhythmia During Treatment With
rious Antiarrhythmic Drugs for AF or Atrial Flutter According
the Vaughan Williams Classification
ntricular proarrhythmia
Torsades de pointes (VW types IA and III drugs*)
Sustained monomorphic ventricular tachycardia (usually VW type IC drugs)
Sustained polymorphic ventricular tachycardia/VF without long QT (VW
types IA, IC, and III drugs)
rial proarrhythmia
Provocation of recurrence (probably VW types IA, IC, and III drugs)
Conversion of AF to flutter (usually VW type IC drugs)
Increase of defibrillation threshold (a potential problem with VW type IC
drugs)
normalities of conduction or impulse formation
Acceleration of ventricular rate during AF (VW types IA and IC drugs)
Accelerated conduction over accessory pathway (digoxin, intravenous
verapamil, or diltiazem†)
Sinus node dysfunction, atrioventricular block (almost all drugs)
Vaughan Williams (VW) classification of antiarrhythmic drugs from Vaughan
illiams EM. A classification of antiarrhythmic actions reassessed after a
cade of new drugs. J Clin Pharmacol 1984;24:129–47.
*This complication is rare with amiodarone.
†Although the potential for beta blockers to potentiate conduction across the
cessory pathway is controversial, caution should also be exercised for the
e of these agents in patients with AF associated with preexcitation.
AF indicates atrial fibrillation; VF, ventricular fibrillation.e event of atrial flutter (632–636). Unless AV node con- nection is impaired, a short-acting beta blocker or nondihy-
opyridine calcium channel antagonist should be given at
ast 30 min before administration of a type IC antiarrhythmic
ent to terminate an acute episode of AF, or the AV nodal
ocking agents should be prescribed as continuous back-
ound therapy. Sudden death related to idiopathic ventricular
brillation may occur in patients with the Brugada syndrome
llowing administration of class I antiarrhythmic drugs even
patients with structurally normal hearts (637,638). Because
rmination of paroxysmal AF may be associated with bra-
cardia due to sinus node or AV node dysfunction, an initial
nversion trial should be undertaken in hospital before a
tient is declared fit for outpatient “pill-in-the-pocket” use of
ecainide or propafenone for conversion of subsequent re-
rrences of AF. Table 22 lists other factors associated with
oarrhythmic toxicity, including proarrhythmic effects,
hich vary according to the electrophysiological properties
the various drugs. For class IC agents, risk factors for
oarrhythmia include female gender.
Few prospective data are available on the relative safety of
itiating antiarrhythmic drug therapy in the outpatient versus
patient setting, and the decision to initiate therapy out of
spital should be carefully individualized. The efficacy and
fety of self-administered oral loading of flecainide and
opafenone in terminating recent-onset AF outside of hos-
tal were analyzed in 268 patients with minimal heart
sease with hemodynamically well-tolerated recent-onset
F (627). Fifty-eight patients (22%) were excluded because
treatment failure or side effects. Using resolution of
lpitations within 6 h after drug ingestion as the criterion of
ficacy, treatment was successful in 534 episodes (94%),
ring 15-mo follow-up, with conversion occurring over a
ean of 2 h. Compared with conventional care, the numbers
emergency department visits and hospitalizations were
gnificantly reduced. Among patients with recurrences, treat-
ent was effective in 84%, and adverse effects were reported
7% of patients. Despite efficacy, 5% of patients dropped
t of the study because of multiple recurrences, side effects
ostly nausea), or anxiety. Thus, the “pill-in-the-pocket”
proach appears feasible and safe for selected patients with
F, but the safety of this approach without previous inpatient
aluation remains uncertain.
As long as the baseline uncorrected QT interval is less than
0 ms, serum electrolytes are normal, and risk factors
sociated with class III drug–related proarrhythmia are
nsidered (Table 23), sotalol may be initiated in outpatients
ith little or no heart disease. It is safest to start sotalol when
e patient is in sinus rhythm. Amiodarone can also usually be
ven safely on an outpatient basis, even in patients with
rsistent AF, because it causes minimal depression of
yocardial function and has low proarrhythmic potential
66), but in-hospital loading may be necessary for earlier
storation of sinus rhythm in patients with HF or other forms
hemodynamic compromise related to AF. Loading regi-
ens typically call for administration of 600 mg daily for 4
k (566) or 1 g daily for 1 wk (531), followed by lower
aintenance doses. Amiodarone, class IA or IC agents, or
talol can be associated with bradycardia requiring perma-
nt pacemaker implantation (639); this is more frequent with
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinesiodarone, and amiodarone-associated bradycardia is more
mmon in women than in men. Quinidine, procainamide,
d disopyramide should not be started out of hospital.
urrently, out-of-hospital initiation of dofetilide is not per-
itted. Transtelephonic monitoring or other methods of ECG
rveillance may be used to monitor cardiac rhythm and
nduction as pharmacological antiarrhythmic therapy is
BLE 22. Factors Predisposing to Drug-Induced Ventricular Pro
Types IA and III Agents
ng QT interval (QTc greater than or equal to 460 ms)
ng QT interval syndrome
ructural heart disease, substantial LVH
pressed LV function*
pokalemia/hypomagnesemia*
male gender
nal dysfunction*
adycardia*
1. (Drug-induced) sinus node disease or AV block
2. (Drug-induced) conversion of AF to sinus rhythm
3. Ectopy producing short-long R-R sequences
pid dose increase
gh dose (sotalol, dofetilide), drug accumulation*
dition of drugs*
1. Diuretics
2. Other QT-prolonging antiarrhythmic drugs
3. Nonantiarrhythmic drugs listed in http://www.torsades.org/
evious proarrhythmia
ter initiation of drug
Excessive QT lengthening
*Some of these factors may develop later after initiation of drug treatment.
assification of antiarrhythmic drugs from Vaughan Williams EM. A classification
84;24:129–47 (497).
AF indicates atrial fibrillation; AV, atrioventricular; LV, left ventricular; LVH, le
chycardia.
BLE 23. Pharmacological Treatment Before Cardioversion in P
Immediate Recurrence, Outcome of Transthoracic Direct-Curre
ficacy
Enhance Conversion
by DC Shock
and Prevent IRAF*
Recomm
Cla
own Amiodarone I
Flecainide
Ibutilide
Propafenone
Quinidine
Sotalol
certain/unknown Beta blockers I
Diltiazem
Disopyramide
Dofetilide
Procainamide
Verapamil
All drugs (except beta blockers and amiodarone) should be initiated in the h
*Drugs are listed alphabetically within each class of recommendation.AF indicates atrial fibrillation; DC, direct-current; IRAF, immediate recurrence of atriaitiated in patients with AF. Specifically, the PR interval
hen flecainide, propafenone, sotalol, or amiodarone are
ed), QRS duration (with flecainide or propafenone), and
T interval (with dofetilide, sotalol, or amiodarone) should
measured. As a general rule, antiarrhythmic drugs should
started at a relatively low dose and titrated based on
sponse, and the ECG should be reassessed after each dose
mia
VW Type IC Agents
Wide QRS duration (more than 120 ms)
Concomitant VT
Structural heart disease
Depressed LV function*
Rapid ventricular response rate*
1. During exercise
2. During rapid AV conduction
Rapid dose increase
High dose, drug accumulation*
Addition of drugs*
1. Negative inotropic drugs
Excessive (more than 150%) QRS widening
ction 8.3.3.3 in the full-text guidelines for details. Vaughan Williams (VW)
rrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol
icular hypertrophy; QTc, indicates corrected QT interval; and VT, ventricular
With Persistent AF: Effects of Various Antiarrhythmic Drugs
ck, or Both
n Level of
Evidence
Suppress SRAF and
Maintenance Therapy Class
B All drugs in recommendation class I
(except ibutilide) plus beta blockers
C Diltiazem
Dofetilide
Verapamilarrhyth
See Se
of antia
ft ventratients
nt Sho
endatio
ss
Ia
Ib
ospital.l fibrillation; and SRAF, subacute recurrence of atrial fibrillation.
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98ange. The heart rate should be monitored at approximately
eekly intervals by checking the pulse rate, using an event
corder, or reading ECG tracings obtained at the office. The
se of other medication for rate control should be reduced
hen the rate slows after initiation of amiodarone and
opped if the rate slows excessively. Concomitant drug
erapies (see Table 19) should be monitored closely, and
th the patient and the physician should be alert to possible
leterious interactions. The doses of digoxin and warfarin, in
rticular, should usually be reduced upon initiation of
iodarone in anticipation of the rises in serum digoxin
vels and INR that typically occur.
.1.8. Drugs Under Development
o overcome the limited efficacy and considerable toxicity of
ailable drugs for maintaining sinus rhythm, selective block-
s of atrial ion channels and nonselective ion channel
ockers are under development. Use of nonantiarrhythmic
ugs, such as inhibitors of the renin-angiotensin system, n-3
lyunsaturated fatty acids, and statins, which might modify
e underlying atrial remodeling, have not been extensively
vestigated for this purpose (640–645).
.1.8.1. ATRIOSELECTIVE AGENTS
he finding that the ultra-rapid delayed rectifier (IKur) exists
atrial but not ventricular tissue opened the possibility that
rioselective drugs without ventricular proarrhythmic toxic-
y could be developed for treatment of patients with AF
43,646). IKur blockers (NIP-142, RSD1235, AVE0118)
olong atrial refractoriness (left more than right) with no
fect on ventricular repolarization and show strong atrial
tiarrhythmic efficacy (642,644,645,647). AVE0118 is an
ur and Ito blocker that, unlike dofetilide, increases refracto-
ness in electrically remodeled atria, prolongs atrial wave-
ngth, and converts persistent AF to sinus rhythm without
sturbing intra-atrial conduction velocity or prolonging the
T interval (648).
.1.8.2. NONSELECTIVE ION CHANNEL–BLOCKING DRUGS
zimilide and dronedarone block multiple potassium, so-
um, and calcium currents and prolong the cardiac action
tential without reverse use-dependence (641–643,645).
Azimilide has a long elimination half-life (114 h), allowing
r once-daily administration. In patients with paroxysmal
VT enrolled in 4 clinical trials, azimilide at doses of 100 and
5 mg daily prolonged time to recurrence of AF and atrial
utter (647,649) and reduced symptoms associated with
currence (650). Patients with ischemic heart disease and HF
splayed greater efficacy than those without structural heart
sease. In a placebo-controlled trial involving 3717 survivors
MI with LV systolic dysfunction (651), azimilide, 100 mg
ily, was associated with a 1-y mortality rate similar to
acebo. Fewer patients in the azimilide group developed AF
new or worsening HF than those given placebo (651), and
ore patients in the azimilide group converted from AF to
nus rhythm (652). The major adverse effects of azimilide
ere severe neutropenia (less than 500 cells per microliter) in
9% and torsades de pointes in 0.5% of treated patients
51).Dronedarone is a noniodinated amiodarone derivative
53,654). In a randomized, placebo-controlled study involv-
g 204 patients undergoing cardioversion of persistent AF
55), dronedarone (800 mg daily) delayed first recurrence
om 5.3 to 60 d. Higher doses (1200 and 1600 mg daily)
ere no more effective and associated with gastrointestinal
de effects (diarrhea, nausea, and vomiting. To date, neither
gan toxicity nor proarrhythmia has been reported. In 2
acebo-controlled trials, European Trial in Atrial Fibrillation
Flutter Patients Receiving Dronedarone for Maintenance
Sinus Rhythm (EURIDIS) (656) and American-Australian
rial with Dronedarone in Atrial Fibrillation or Flutter
atients for Maintenance of Sinus Rhythm (ADONIS) (657),
onedarone prolonged the time to first documented AF/atrial
utter recurrence and helped control the ventricular rate.
Tedisamil, an antianginal agent, blocks several potassium
annels and causes a reverse rate-dependent QT-interval
olongation. Tedisamil (0.4 and 0.6 mg/kg) was superior to
acebo for rapid conversion (within 35 min) of recent-onset
F or atrial flutter (658). The main side effects were pain at
e injection site and ventricular tachycardia.
.1.8.3. RECOMMENDATIONS FOR DRONEDARONE FOR THE
EVENTION OF RECURRENT ATRIAL FIBRILLATION
EW SECTION)
or new or updated text, view the 2011 Focused Update. Text
pporting unchanged recommendations has not been updated.
.2. Direct-Current Cardioversion of Atrial
ibrillation and Flutter
ECOMMENDATIONS
ASS I
When a rapid ventricular response does not respond promptly
to pharmacological measures for patients with AF with ongo-
ing myocardial ischemia, symptomatic hypotension, angina, or
HF, immediate R-wave synchronized direct-current cardiover-
sion is recommended. (Level of Evidence: C)
Immediate direct-current cardioversion is recommended for
patients with AF involving preexcitation when very rapid tachy-
cardia or hemodynamic instability occurs. (Level of Evidence: B)
Cardioversion is recommended in patients without hemody-
namic instability when symptoms of AF are unacceptable to
the patient. In case of early relapse of AF after cardioversion,
repeated direct-current cardioversion attempts may be made
following administration of antiarrhythmic medication. (Level
of Evidence: C)
ASS IIa
Direct-current cardioversion can be useful to restore sinus
rhythm as part of a long-term management strategy for pa-
tients with AF. (Level of Evidence: B)
Patient preference is a reasonable consideration in the selec-
tion of infrequently repeated cardioversions for the manage-
ment of symptomatic or recurrent AF. (Level of Evidence: C)
ASS III
Frequent repetition of direct-current cardioversion is not rec-
ommended for patients who have relatively short periods of
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinessinus rhythm between relapses of AF after multiple cardiover-
sion procedures despite prophylactic antiarrhythmic drug ther-
apy. (Level of Evidence: C)
Electrical cardioversion is contraindicated in patients with
digitalis toxicity or hypokalemia. (Level of Evidence: C)
.2.1. Terminology
irect-current cardioversion involves delivery of an electrical
ock synchronized with the intrinsic activity of the heart by
nsing the R wave of the ECG to ensure that electrical
imulation does not occur during the vulnerable phase of the
rdiac cycle (659). Direct-current cardioversion is used to
rmalize all abnormal cardiac rhythms except ventricular
brillation. The term defibrillation implies an asynchronous
scharge, which is appropriate for correction of ventricular
brillation because R-wave synchronization is not feasible,
t not for AF.
.2.2. Technical Aspects
uccessful cardioversion of AF depends on the underlying
art disease and the current density delivered to the atrial
yocardium. Current may be delivered through external
est wall electrodes or through an internal cardiac electrode.
lthough the latter technique has been considered superior to
ternal countershocks in obese patients and in patients with
structive lung disease, it has not been widely applied. The
equency of recurrent AF does not differ between the 2
ethods (355,660–664).
The current density delivered to the heart by transthoracic
ectrodes depends on the defibrillator capacitor voltage,
tput waveform, size and position of the electrode paddles,
d thoracic impedance. For a given paddle surface area,
rrent density decreases with increasing impedance, related
the thickness and composition of the paddles, contact
edium between electrodes and skin, distance between pad-
es, body size, respiratory phase, number of shocks, and
terval between shocks (665).
Use of electrolyte-impregnated pads can minimize the
ectrical resistance between electrode and skin. Pulmonary
ssue between paddles and the heart inhibits conduction, so
ocks delivered during expiration or chest compression
liver higher energy to the heart. Large paddles lower
pedance but may make current density in cardiac tissue
sufficient; conversely, undersized paddles may cause injury
e to excess current density. Animal experiments have
own that the optimum diameter approximates the cross-
ctional area of the heart. There are no firm data regarding
e best paddle size for cardioversion of AF, but a diameter of
to 12 cm (665) is generally recommended.
Because the combination of high impedance and low
ergy reduces the success of cardioversion, measurement of
pedance has been proposed to shorten the procedure and
prove outcomes (666,667). Kerber et al (668) reported
tter efficacy by automatically increasing energy delivery
hen the impedance exceeded 70 ohms.
The output waveform also influences energy delivery
ring direct-current cardioversion. In a randomized trial, 77
tients treated with sinusoidal monophasic shocks had a
mulative success rate of 79% compared with 94% in 88
bjects cardioverted with rectilinear biphasic shocks, and the detter required less energy. In addition to rectilinear biphasic
ocks, independent correlates of successful conversion were
oracic impedance and the duration of AF (669). For
rdioversion of AF, a biphasic shock waveform has greater
ficacy, requires fewer shocks and lower delivered energy,
d results in less dermal injury than a monophasic shock
aveform, and represents the present standard for cardiover-
on of AF (670).
In their original description of cardioversion, Lown et al
59,671) recommended an anterior-posterior electrode con-
guration over anterior-anterior positioning, but others dis-
ree (665,672,673). Anterior-posterior positioning allows
rrent to reach a sufficient mass of atrial myocardium to
hieve cardioversion of AF when the pathology involves
th atria (as in patients with atrial septal defects or cardio-
yopathy). A drawback of this configuration is the amount of
lmonary tissue separating the anterior paddle and the heart,
rticularly in patients with emphysema. Placing the anterior
ectrode to the left of the sternum reduces electrode separa-
on. The paddles should be placed directly against the chest
all, under rather than over the breast tissue. Other paddle
sitions result in less current flow through crucial parts of
e heart (665). In a randomized study involving 301 subjects
dergoing elective external cardioversion, the energy re-
ired was lower and the overall success (adding the outcome
low-energy shocks to that of high-energy shocks) was
eater with the anterior-posterior configuration (87%) than
ith the anterior-lateral alignment (76%) (674). Animal
periments show a wide margin of safety between the
ergy required for cardioversion of AF and that associated
ith myocardial depression (675,676). Even without apparent
yocardial damage, transient ST-segment elevation may
pear on the ECG after cardioversion (677,678) and blood
vels of creatine kinase may rise. Serum troponin-T and
oponin-I levels did not rise significantly in a study of 72
rdioversion attempts with average energy over 400 J (range
to 1280 J) (679). In 10% of the patients, creatine
nase-MB levels rose beyond levels attributable to skeletal
uscle trauma, and this was related to energy delivered.
icroscopic myocardial damage related to direct-current
rdioversion has not been confirmed and is probably clini-
lly insignificant.
.2.3. Procedural Aspects
ardioversion should be performed with the patient under
equate general anesthesia in a fasting state. Short-acting
esthetic drugs or agents that produce conscious sedation are
eferred to enable rapid recovery after the procedure; over-
ght hospitalization is seldom required (680). The electric
ock should be synchronized with the QRS complex, trig-
red by monitoring the R wave with an appropriately
lected ECG lead that also clearly displays atrial activation
facilitate assessment of outcome. The initial energy may be
w for cardioversion of atrial flutter, but higher energy is
quired for AF. The energy output has traditionally been
creased successively in increments of 100 J to a maximum
400 J, but some physicians begin with higher energies to
duce the number of shocks and thus the total energy
livered. To avoid myocardial damage, some have sug-
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98sted that the interval between consecutive shocks should be
least 1 min (681). In 64 patients randomly assigned to
itial monophasic waveform energies of 100, 200, or 360 J,
gh initial energy was significantly more effective than low
vels (immediate success rates 14% with 100 J, 39% with
0 J, and 95% with 360 J, respectively), resulting in fewer
ocks and less cumulative energy when 360 J was delivered
itially (682). These data indicate that an initial shock of 100
with monophasic waveform is often too low for direct-
rrent cardioversion of AF; hence, an initial energy of 200 J
greater is recommended. A similar recommendation to
art with 200 J applies to biphasic waveforms, particularly
hen cardioverting patients with AF of long duration (683).
xternal cardioversion of AF with a rectilinear biphasic
aveform (99.1% of 1877 procedures in 1361 patients) was
ore effective than a monophasic sinusoidal waveform
2.4% of 2818 procedures in 2025 patients; p less than
001), but comparable for patients with atrial flutter (99.2%
d 99.8%, respectively). The median successful energy level
as 100 J with the biphasic waveform compared with 200 J
ith the monophasic waveform (684).
.2.4. Direct-Current Cardioversion in Patients With
planted Pacemakers and Defibrillators
hen appropriate precautions are taken, cardioversion of AF
safe in patients with implanted pacemaker or defibrillator
vices. Pacemaker generators and defibrillators are designed
ith circuits protected against sudden external electrical
scharges, but programmed data may be altered by current
rges. Electricity conducted along an implanted electrode
ay cause endocardial injury and lead to a temporary or
rmanent increase in stimulation threshold, resulting in loss
ventricular capture. To ensure appropriate function, the
planted device should be interrogated and, if necessary,
programmed before and after cardioversion. Devices are
pically implanted anteriorly, so the paddles used for exter-
l cardioversion should be positioned as distantly as possi-
e, preferably in the anterior-posterior configuration. The
sk of exit block is greatest when one paddle is positioned
ar the impulse generator and the other over the cardiac
ex, and lower with the anterior-posterior electrode config-
ation and with bipolar electrode systems (685,686). Low-
ergy internal cardioversion does not interfere with pace-
aker function in patients with electrodes positioned in the
A, coronary sinus, or left pulmonary artery (687).
.2.5. Risks and Complications of Direct-Current
ardioversion of Atrial Fibrillation
he risks of direct-current cardioversion are mainly related to
romboembolism and arrhythmias. Thromboembolic events
ve been reported in 1% to 7% of patients not given
ophylactic anticoagulation before cardioversion of AF
88,689). Prophylactic antithrombotic therapy is discussed
low. (See Section 8.2.7, Prevention of Thromboembolism
Patients With Atrial Fibrillation Undergoing Cardioversion.)
Various benign arrhythmias, especially ventricular and
praventricular premature beats, bradycardia, and short pe-
ods of sinus arrest, may arise after cardioversion and
mmonly subside spontaneously (690). More dangerous
rhythmias, such as ventricular tachycardia and fibrillation, thay arise in the face of hypokalemia, digitalis intoxication, or
proper synchronization (691,692). Serum potassium levels
ould be in the normal range for safe, effective cardiover-
on. Magnesium supplementation does not enhance cardio-
rsion (693). Cardioversion is contraindicated in cases of
gitalis toxicity because resulting ventricular tachyarrhyth-
ia may be difficult to terminate. A serum digitalis level in
e therapeutic range does not exclude clinical toxicity but is
t generally associated with malignant ventricular arrhyth-
ias during cardioversion (694), so it is not routinely neces-
ry to interrupt digoxin before elective cardioversion of AF.
is important, however, to exclude clinical and ECG signs of
gitalis excess and delay cardioversion until a toxic state has
en corrected, which usually requires withdrawal of digoxin
r longer than 24 h.
In patients with long-standing AF, cardioversion com-
only unmasks underlying sinus node dysfunction. A slow
ntricular response to AF in the absence of drugs that slow
nduction across the AV node may indicate an intrinsic
nduction defect. The patient should be evaluated before
rdioversion with this in mind so a transvenous or transcu-
neous pacemaker can be used prophylactically (695).
.2.6. Pharmacological Enhancement of
irect-Current Cardioversion
ECOMMENDATIONS
ASS IIa
Pretreatment with amiodarone, flecainide, ibutilide,
propafenone, or sotalol can be useful to enhance the success
of direct-current cardioversion and prevent recurrent atrial
fibrillation. (Level of Evidence: B)
In patients who relapse to AF after successful cardioversion, it
can be useful to repeat the procedure following prophylactic
administration of antiarrhythmic medication. (Level of Evi-
dence: C)
ASS IIb
For patients with persistent AF, administration of beta block-
ers, disopyramide, diltiazem, dofetilide, procainamide, or vera-
pamil may be considered, although the efficacy of these agents
to enhance the success of direct-current cardioversion or to
prevent early recurrence of AF is uncertain. (Level of Evidence: C)
Out-of-hospital initiation of antiarrhythmic medications may be
considered in patients without heart disease to enhance the
success of cardioversion of AF. (Level of Evidence: C)
Out-of-hospital administration of antiarrhythmic medications
may be considered to enhance the success of cardioversion of
AF in patients with certain forms of heart disease once the
safety of the drug has been verified for the patient. (Level of
Evidence: C)
Although most recurrences of AF occur within the first
onth after direct-current cardioversion, research with inter-
l atrial cardioversion (696) and postconversion studies
ing transthoracic shocks (697) have established several
tterns of AF recurrence (Fig. 17). In some cases, direct-
rrent countershock fails to elicit even a single isolated sinus
ectopic atrial beat, tantamount to a high atrial defibrillationreshold. In others, AF recurs within a few minutes after a
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinesriod of sinus rhythm (698,699), and recurrence after car-
oversion is sometimes delayed for days or weeks (697).
omplete shock failure and immediate recurrence occur in
proximately 25% of patients undergoing direct-current
rdioversion of AF, and subacute recurrences occur within 2
k in almost an equal proportion (698).
Restoration and maintenance of sinus rhythm are less
kely when AF has been present for longer than 1 y than in
tients with AF of shorter duration. The variation in imme-
ate success rates for direct-current cardioversion from 70%
99% in the literature (617,682,684,700,701) is partly
plained by differences in patient characteristics and the
aveform used but also depends upon the definition of
ccess, because the interval at which the result is evaluated
nges from moments to several days. Over time, the propor-
on of AF caused by rheumatic heart disease has declined,
e average age of the AF population has increased
00–702), and the incidences of lone AF have remained
nstant, making it difficult to compare the outcome of
rdioversion across various studies.
In a large consecutive series of patients undergoing car-
oversion of AF published in 1991, 24% were classified as
ving ischemic heart disease, 24% with rheumatic valvular
sease, 15% with lone AF, 11% with hypertension, 10% with
rdiomyopathy, 8% with nonrheumatic valvular disease, 6%
ith congenital heart disease, and 2% with hyperthyroidism
00). Seventy percent were in sinus rhythm 24 h after
rdioversion. Multivariate analysis found a short duration of
F, atrial flutter, and younger age to be independent predic-
rs of success, whereas LA enlargement, underlying organic
art disease, and cardiomegaly were associated with HF. A
cade later, a study of 166 consecutive patients followed
ter first direct-current cardioversion found that short dura-
gure 17. Hypothetical illustration of cardioversion failure.
ree types of recurrences after electrical cardioversion of per-
stent atrial fibrillation (AF) are shown. The efficacy of drugs
ries in enhancement of shock conversion and suppression of
currences. Modified with permission from van Gelder IC,
inenburg AE, Schoonderwoerd BS, et al. Pharmacologic ver-
s direct-current electrical cardioversion of atrial flutter and
rillation. Am J Cardiol 1999;84:147R–51R, with permission
om Excerpta Medica Inc (704). ECV indicates external cardio-
rsion; IRAF, immediate recurrence of AF defined as the first
currence of AF after cardioversion; and SR, sinus rhythm.on of AF, smaller LA size, and treatment with beta blockers, 6rapamil, or diltiazem were clinical predictors of both initial
ccess and maintenance of sinus rhythm (703). In another
ries of 100 patients, the primary success rate assessed 3 d
ter cardioversion was 86% (701), increasing to 94% when
e procedure was repeated during treatment with quinidine
disopyramide. Only 23% of patients remained in sinus
ythm after 1 y, however, and 16% remained after 2 y. In
ose who relapsed to AF, repeated cardioversion after admin-
tration of antiarrhythmic medication resulted in sinus rhythm
40% and 33% after 1 and 2 y, respectively. For patients who
lapsed again, a third cardioversion resulted in sinus rhythm in
% after 1 y and 41% after 2 y. Thus, sinus rhythm can be
stored in a substantial proportion of patients by direct-current
rdioversion, but the rate of relapse is high without concomitant
tiarrhythmic drug therapy (704) (Fig. 17).
When given in conjunction with direct-current cardiover-
on, the primary aims of antiarrhythmic medication therapy
e to increase the likelihood of success (e.g., by lowering the
rdioversion threshold) and to prevent recurrent AF. En-
nced efficacy may involve multiple mechanisms, such as
creasing the energy required to achieve cardioversion,
olonging atrial refractory periods, and suppressing atrial
topy that may cause early recurrence of AF (580,705).
ntiarrhythmic medications may be initiated out of hospital
in hospital immediately prior to direct-current cardiover-
on. (See Section 8.1.7, Out-of-Hospital Initiation of Anti-
rhythmic Drugs in Patients With Atrial Fibrillation.) The
sks of pharmacological treatment include the possibility of
radoxically increasing the defibrillation threshold, as de-
ribed with flecainide (600), accelerating the ventricular rate
hen class IA or IC drugs are given without an AV nodal
ocking agent (632–636,706), and inducing ventricular ar-
ythmias (see Table 21).
Prophylactic drug therapy to prevent early recurrence of
F should be considered individually for each patient.
atients with lone AF of relatively short duration are less
one to early recurrence of AF than are those with heart
sease and longer AF duration, who therefore stand to gain
ore from prophylactic administration of antiarrhythmic
edication. Pretreatment with pharmacological agents is
ost appropriate in patients who fail to respond to direct-
rrent cardioversion and in those who develop immediate or
bacute recurrence of AF. In patients with late recurrence
d those undergoing initial cardioversion of persistent AF,
etreatment is optional. Antiarrhythmic drug therapy is
commended in conjunction with a second cardioversion
tempt, particularly when early relapse has occurred. Addi-
onal cardioversion, beyond a second attempt, is of limited
lue and should be reserved for carefully selected patients.
frequently repeated cardioversions may be acceptable in
tients who are highly symptomatic upon relapse to AF.
pecific Pharmacological Agents for Prevention
Recurrent AF in Patients Undergoing
lectrical Cardioversion
.2.6.1. AMIODARONE
patients with persistent AF, treatment with amiodarone forwk before and after cardioversion increased the conversion
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98te and the likelihood of maintaining sinus rhythm and
duced supraventricular ectopic activity that may trigger
current AF (579). Prophylactic treatment with amiodarone
as also effective when an initial attempt at direct-current
rdioversion had failed (531,569). In patients with persistent
F randomly assigned to treatment with carvedilol, amioda-
ne, or placebo for 4 wk before direct-current cardioversion,
e 2 drugs yielded similar cardioversion rates, but amioda-
ne proved superior at maintaining sinus rhythm after
nversion (707).
.2.6.2. BETA-ADRENERGIC ANTAGONISTS
lthough beta blockers are unlikely to enhance the success of
rdioversion or to suppress immediate or late recurrence of
F, they may reduce subacute recurrences (583).
.2.6.3. NONDIHYDROPYRIDINE CALCIUM
HANNEL ANTAGONISTS
herapy with calcium-channel antagonists prior to electrical
rdioversion of AF has yielded contradictory results. Several
udies found that verapamil (708,709) reduced immediate or
rly recurrences of AF. On the other hand, verapamil and
ltiazem may increase AF duration, shorten refractoriness,
d increase the spatial dispersion of refractoriness leading to
ore sustained AF (710,711). In patients with persistent AF,
e addition of verapamil to class I or class II drugs can
event immediate recurrence after cardioversion (712), and
ophylaxis against subacute recurrence was enhanced when
is combination was given for 3 d before and after cardio-
rsion (713,714). Verapamil also reduced AF recurrence
hen a second cardioversion was performed after early
currence of AF (714). In a comparative study (715),
iodarone and diltiazem were more effective than digoxin
r prevention of early recurrence, whereas at 1 mo the
currence rate was lower with amiodarone (28%) than with
ltiazem (56%) or digoxin (78%). In patients with persistent
F, treatment with verapamil 1 mo before and after direct-
rrent cardioversion did not improve the outcome of cardio-
rsion (716).
.2.6.4. QUINIDINE
loading dose of quinidine (1200 mg orally 24 h before
rect-current cardioversion) significantly reduced the num-
r of shocks and the energy required in patients with
rsistent AF. Quinidine prevented immediate recurrence in
cases, whereas recurrence developed in 7 of 25 controls
98). When quinidine (600 to 800 mg 3 times daily for 2 d)
iled to convert the rhythm, there was no difference in
fibrillation threshold between patients randomized to con-
nue or withdraw the drug (617).
.2.6.5. TYPE IC ANTIARRHYTHMIC AGENTS
-hospital treatment with oral propafenone started 2 d before
rect-current cardioversion decreases early recurrence of AF
ter shock, thus allowing more patients to be discharged
om the hospital with sinus rhythm. Compared with placebo,
opafenone did not influence either the mean defibrillation
reshold or the rate of conversion (shock efficacy 84% vs.
%, respectively) but suppressed immediate recurrences
ithin 10 min), and 74% versus 53% of patients were innus rhythm after 2 d (522). In patients with persistent AF,
etreatment with intravenous flecainide had no significant
fect on the success of direct-current cardioversion (717).
.2.6.6. TYPE III ANTIARRHYTHMIC AGENTS
ontrolled studies are needed to determine the most effective
eatment of immediate and subacute recurrences of AF. Type
I antiarrhythmic drugs may suppress subacute recurrences
ss effectively than late recurrences of AF (Table 23).
vailable data suggest that starting pharmacological therapy
d establishing therapeutic plasma drug concentrations be-
re direct-current cardioversion enhance immediate success
d suppress early recurrences. After cardioversion to sinus
ythm, patients receiving drugs that prolong the QT interval
ould be monitored in the hospital for 24 to 48 h to evaluate
e effects of heart rate slowing and allow for prompt
tervention in the event torsades de pointes develops.
In randomized studies of direct-current cardioversion,
tients pretreated with ibutilide were more often converted
sinus rhythm than untreated controls, and those in whom
rdioversion initially failed could more often be converted
hen the procedure was repeated after treatment with ibuti-
de (556,718). Ibutilide was more effective than verapamil in
eventing immediate recurrence of AF (705).
.2.7. Prevention of Thromboembolism in Patients
ith Atrial Fibrillation Undergoing Cardioversion
ECOMMENDATIONS
ASS I
For patients with AF of 48-h duration or longer, or when the
duration of AF is unknown, anticoagulation (INR 2.0 to 3.0) is
recommended for at least 3 wk prior to and 4 wk after
cardioversion, regardless of the method (electrical or pharma-
cological) used to restore sinus rhythm. (Level of Evidence: B)
For patients with AF of more than 48-h duration requiring
immediate cardioversion because of hemodynamic instability,
heparin should be administered concurrently (unless contrain-
dicated) by an initial intravenous bolus injection followed by a
continuous infusion in a dose adjusted to prolong the activated
partial thromboplastin time to 1.5 to 2 times the reference
control value. Thereafter, oral anticoagulation (INR 2.0 to 3.0)
should be provided for at least 4 wk, as for patients undergoing
elective cardioversion. Limited data support subcutaneous
administration of low-molecular-weight heparin in this indica-
tion. (Level of Evidence: C)
For patients with AF of less than 48-h duration associated with
hemodynamic instability (angina pectoris, MI, shock, or pul-
monary edema), cardioversion should be performed immedi-
ately without delay for prior initiation of anticoagulation. (Level
of Evidence: C)
ASS IIa
During the first 48 h after onset of AF, the need for anticoag-
ulation before and after cardioversion may be based on the
patient’s risk of thromboembolism. (Level of Evidence: C)
As an alternative to anticoagulation prior to cardioversion of
AF, it is reasonable to perform TEE in search of thrombus in the
LA or LAA. (Level of Evidence: B)
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is reasonable immediately after anticoagulation with un-
fractionated heparin (e.g., initiate by intravenous bolus
injection and an infusion continued at a dose adjusted to
prolong the activated partial thromboplastin time to 1.5
to 2 times the control value until oral anticoagulation has
been established with a vitamin K antagonist (e.g., war-
farin), as evidenced by an INR equal to or greater than
2.0.). (Level of Evidence: B)
Thereafter, oral anticoagulation (INR 2.0 to 3.0) is
reasonable for a total anticoagulation period of at least 4
wk, as for patients undergoing elective cardioversion.
(Level of Evidence: B)
Limited data are available to support the subcutaneous
administration of a low-molecular-weight heparin in this
indication. (Level of Evidence: C)
2b. For patients in whom thrombus is identified by TEE, oral
anticoagulation (INR 2.0 to 3.0) is reasonable for at least
3 wk prior to and 4 wk after restoration of sinus rhythm,
and a longer period of anticoagulation may be appropriate
even after apparently successful cardioversion, because
the risk of thromboembolism often remains elevated in
such cases. (Level of Evidence: C)
For patients with atrial flutter undergoing cardioversion, anti-
coagulation can be beneficial according to the recommenda-
tions as for patients with AF. (Level of Evidence: C)
Randomized studies of antithrombotic therapy are lacking
r patients undergoing cardioversion of AF or atrial flutter,
t in case-control series, the risk of thromboembolism was
tween 1% and 5% (689,719). The risk was near the low end
this spectrum when anticoagulation (INR 2.0 to 3.0) was
ven for 3 to 4 wk before and after conversion (54,181,695).
is now common practice to administer anticoagulant drugs
hen preparing patients with AF of more than 2-d duration
r cardioversion. Manning et al (304) suggested that TEE
ight be used to identify patients without LAA thrombus
ho do not require anticoagulation, but a subsequent inves-
gation (324) and meta-analysis found this approach to be
reliable (720).
If most AF-associated strokes result from embolism of
asis-induced thrombus from the LAA, then restoration and
aintenance of atrial contraction should logically reduce
romboembolic risk. LV function can also improve after
rdioversion (721), potentially lowering embolic risk and
proving cerebral hemodynamics (722). There is no evi-
nce, however, that cardioversion followed by prolonged
aintenance of sinus rhythm effectively reduces thromboem-
lism in AF patients. Conversion of AF to sinus rhythm
sults in transient mechanical dysfunction of the LA and
AA (417) known as “stunning,” which can occur after
ontaneous, pharmacological (723,724), or electrical (724–
6) conversion of AF or after radiofrequency catheter
lation of atrial flutter (226) and which may be associated
ith SEC (417). Recovery of mechanical function may be
layed for several weeks, depending in part on the duration
AF before conversion (191,727,728). This could explain
hy some patients without demonstrable LA thrombus on
EE before cardioversion subsequently experience thrombo-bolic events (324). Presumably, thrombus forms during ate period of stunning and is expelled after the return of
echanical function, explaining the clustering of thrombo-
bolic events during the first 10 d after cardioversion (212).
Patients with AF or atrial flutter in whom LAA thrombus
identified by TEE are at high risk of thromboembolism and
ould be anticoagulated for at least 3 wk prior to and 4 wk
ter pharmacological or direct-current cardioversion. In a
ulticenter study, 1222 patients with either AF persisting
nger than 2 d or atrial flutter and previous AF (729) were
ndomized to a TEE-guided or conventional strategy. In the
oup undergoing TEE, cardioversion was postponed when
rombus was identified, and warfarin was administered for 3
k before TEE was repeated to confirm resolution of throm-
s. Anticoagulation with heparin was used briefly before
rdioversion and with warfarin for 4 wk after cardioversion.
he other group received anticoagulation for 3 wk before and
wk after cardioversion without intercurrent TEE. Both
proaches were associated with comparably low risks of
roke (0.81% with the TEE approach and 0.50% with the
nventional approach) after 8 wk, there were no differences
the proportion of patients achieving successful cardiover-
on, and the risk of major bleeding did not differ signifi-
ntly. The clinical benefit of the TEE-guided approach was
mited to saving time before cardioversion.
Anticoagulation is recommended for 3 wk prior to and 4
k after cardioversion for patients with AF of unknown
ration or with AF for more than 48 h. Although LA
rombus and systemic embolism have been documented in
tients with AF of shorter duration, the need for anticoagu-
tion is less clear. When acute AF produces hemodynamic
stability in the form of angina pectoris, MI, shock, or
lmonary edema, immediate cardioversion should not be
layed to deliver therapeutic anticoagulation, but intrave-
us unfractionated heparin or subcutaneous injection of a
w-molecular-weight heparin should be initiated before car-
oversion by direct-current countershock or intravenous
tiarrhythmic medication.
Protection against late embolism may require continuation
anticoagulation for a more extended period after the
ocedure, and the duration of anticoagulation after cardio-
rsion depends both on the likelihood that AF will recur in
individual patient with or without symptoms and on the
trinsic risk of thromboembolism. Late events are probably
e to both the development of thrombus as a consequence of
rial stunning and the delayed recovery of atrial contraction
ter cardioversion. Pooled data from 32 studies of cardio-
rsion of AF or atrial flutter suggest that 98% of clinical
romboembolic events occur within 10 d (212). These data,
t yet verified by prospective studies, support administration
an anticoagulant for at least 4 wk after cardioversion, and
ntinuation of anticoagulation for a considerably longer
riod may be warranted even after apparently successful
rdioversion.
Stroke or systemic embolism has been reported in patients
ith atrial flutter undergoing cardioversion (730–732), and
ticoagulation should be considered with either the conven-
nal or TEE-guided strategy. TEE-guided cardioversion ofrial flutter has been performed with a low rate of systemic
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ctors on the basis of clinical and/or TEE features (600,733).
.3. Maintenance of Sinus Rhythm (UPDATED)
or new or updated text, view the 2011
ocused Update. Text supporting unchanged
commendations has not been updated.
ECOMMENDATIONS
ASS I
Before initiating antiarrhythmic drug therapy, treatment of
precipitating or reversible causes of AF is recommended.
(Level of Evidence: C)
ASS IIa
Pharmacological therapy can be useful in patients with AF to
maintain sinus rhythm and prevent tachycardia-induced cardio-
myopathy. (Level of Evidence: C)
Infrequent, well-tolerated recurrence of AF is reasonable as a
successful outcome of antiarrhythmic drug therapy. (Level of
Evidence: C)
Outpatient initiation of antiarrhythmic drug therapy is reason-
able in patients with AF who have no associated heart disease
when the agent is well tolerated. (Level of Evidence: C)
In patients with lone AF without structural heart disease,
initiation of propafenone or flecainide can be beneficial on an
outpatient basis in patients with paroxysmal AF who are in
sinus rhythm at the time of drug initiation. (Level of Evidence: B)
Sotalol can be beneficial in outpatients in sinus rhythm with
little or no heart disease, prone to paroxysmal AF, if the
baseline uncorrected QT interval is less than 460 ms, serum
electrolytes are normal, and risk factors associated with class
III drug–related proarrhythmia are not present. (Level of Evi-
dence: C)
Catheter ablation is a reasonable alternative to pharmacolog-
ical therapy to prevent recurrent AF in symptomatic patients
with little or no LA enlargement. (Level of Evidence: C)
ASS III
Antiarrhythmic therapy with a particular drug is not recom-
mended for maintenance of sinus rhythm in patients with AF
who have well-defined risk factors for proarrhythmia with that
agent. (Level of Evidence: A)
Pharmacological therapy is not recommended for maintenance
of sinus rhythm in patients with advanced sinus node disease
or AV node dysfunction unless they have a functioning elec-
tronic cardiac pacemaker. (Level of Evidence: C)
.3.1. Pharmacological Therapy (UPDATED)
or new or updated text, view the 2011 Focused
pdate. Text supporting unchanged recommendations
as not been updated.
.3.1.1. GOALS OF TREATMENT
hether paroxysmal or persistent, AF is a chronic disorder,
d recurrence at some point is likely in most patients
04,734,735) (see Fig. 13). Many patients eventually need
ophylactic antiarrhythmic drug therapy to maintain sinus
ythm, suppress symptoms, improve exercise capacity and
modynamic function, and prevent tachycardia-induced car- isomyopathy due to AF. Because factors that predispose to
current AF (advanced age, HF, hypertension, LA enlarge-
ent, and LV dysfunction) are risk factors for thromboem-
lism, the risk of stroke may not be reduced by correction of
e rhythm disturbance. It is not known whether maintenance
sinus rhythm prevents thromboembolism, HF, or death in
tients with a history of AF (736,737). Trials in which rate-
rsus rhythm-control strategies were compared in patients
ith persistent and paroxysmal AF (293,294,296,343,344)
und no reduction in death, disabling stroke, hospitaliza-
ons, new arrhythmias, or thromboembolic complications in
e rhythm-control group (296). Pharmacological mainte-
nce of sinus rhythm may reduce morbidity in patients with
F (501,738), but one observational study demonstrated that
rial cardioversion in those with persistent AF did not avoid
mplications (739). Pharmacological therapy to maintain
nus rhythm is indicated in patients who have troublesome
mptoms related to paroxysmal AF or recurrent AF after
rdioversion who can tolerate antiarrhythmic drugs and have
good chance of remaining in sinus rhythm over an extended
riod (e.g., young patients without organic heart disease or
pertension, a short duration of AF, and normal LA size)
93,740). When antiarrhythmic medication does not result in
mptomatic improvement or causes adverse effects, how-
er, it should be abandoned.
.3.1.2. ENDPOINTS IN ANTIARRHYTHMIC DRUG STUDIES
arious antiarrhythmic drugs have been investigated for
aintenance of sinus rhythm in patients with AF. The number
d quality of studies with each drug are limited; endpoints
ry, and few studies meet current standards of good clinical
actice. The arrhythmia burden and quality of life have not
en assessed consistently. In studies of patients with parox-
mal AF, the time to first recurrence, number of recurrences
er a specified interval, proportion of patients without
currence during follow-up, and combinations of these data
ve been reported. The proportion of patients in sinus
ythm during follow-up is a less useful endpoint in studies of
roxysmal rather than persistent AF. Most studies of persis-
nt AF involved antiarrhythmic drug therapy administered
fore or after direct-current cardioversion. Because of clus-
ring of recurrences in the first few weeks after cardioversion
97,713), the median time to first recurrence detected by
anstelephonic monitoring may not differ between 2 treat-
ent strategies. Furthermore, because recurrent AF tends to
rsist, neither the interval between recurrences nor the
mber of episodes in a given period represents a suitable
dpoint unless a serial cardioversion strategy is employed.
iven these factors, the appropriate endpoints for evaluation
treatment efficacy in patients with paroxysmal and persis-
nt AF have little in common. This hampers comparative
aluation of treatments aimed at maintenance of sinus
ythm in cohorts containing patients with both patterns of
F, and studies of mixed cohorts therefore do not contribute
avily to these guidelines. The duration of follow-up varied
nsiderably among studies and was generally insufficient to
rmit meaningful extrapolation to years of treatment in what
often a lifelong cardiac rhythm disorder.
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March 15, 2011:e101–98 ACC/AHA/ESC Practice GuidelinesRecurrence of AF is not equivalent to treatment failure. In
veral studies (594,598), patients with recurrent AF often
ose to continue antiarrhythmic treatment, perhaps because
isodes of AF became less frequent, briefer, or less symp-
matic. A reduction in arrhythmia burden may therefore
nstitute therapeutic success for some patients, while to
hers any recurrence of AF may seem intolerable. Assess-
ent based upon time to recurrence in patients with parox-
mal AF or upon the number of patients with persistent AF
ho sustain sinus rhythm after cardioversion may overlook
tentially valuable treatment strategies. Available studies
e heterogeneous in other respects as well. The efficacy of
eatment for atrial flutter and AF is usually not reported
parately. Underlying heart disease or extracardiac disease is
esent in 80% of patients with persistent AF, but this is not
ways described in detail. It is often not clear when patients
rst experienced AF or whether AF was persistent, and the
equencies of previous AF episodes and cardioversions are
t uniformly described. Most controlled trials of antiarrhyth-
ic drugs included few patients at risk of drug-induced HF,
oarrhythmia, or conduction disturbances, and this should be
pt in mind in applying the recommendations below.
The AFFIRM substudy investigators found that with AF
currence, if one is willing to cardiovert the rhythm and keep
e patient on the same antiarrhythmic drug, or cardiovert the
ythm and treat the patient with a different antiarrhythmic
ug, about 80% of all patients will be in sinus rhythm by the
d of 1 y (570).
.3.1.3. PREDICTORS OF RECURRENT AF
ost patients with AF, except those with postoperative or
lf-limited AF secondary to transient or acute illness, even-
ally experience recurrence. Risk factors for frequent recur-
nce of paroxysmal AF (more than 1 episode per month)
clude female gender and underlying heart disease (741). In
e study of patients with persistent AF, the 4-y arrhythmia-
ee survival rate was less than 10% after single-shock
rect-current cardioversion without prophylactic drug ther-
y (735). Predictors of recurrences within that interval
cluded hypertension, age over 55 y, and AF duration longer
an 3 mo. Serial cardioversions and prophylactic drug
erapy resulted in freedom from recurrent AF in approxi-
ately 30% of patients (735), and with this approach predic-
rs of recurrence included age over 70 y, AF duration
yond 3 mo, and HF (735). Other risk factors for recurrent
F include LA enlargement and rheumatic heart disease.
.3.1.4. FUTURE DIRECTIONS IN CATHETER-BASED ABLATION
HERAPY FOR ATRIAL FIBRILLATION (NEW SECTION)
or new or updated text, view the 2011 Focused Update. Text
pporting unchanged recommendations has not been updated.
.3.2. General Approach to Antiarrhythmic
rug Therapy
efore administering any antiarrhythmic agent, reversible
ecipitants of AF should be identified and corrected. Most
e related to coronary or valvular heart disease, hyperten-
on, or HF. Patients who develop HF in association with
cohol intake should abstain from alcohol consumption. andefinite antiarrhythmic treatment is seldom prescribed after
first episode, although a period of several weeks may help
abilize sinus rhythm after cardioversion. Similarly, patients
periencing breakthrough arrhythmias may not require a
ange in antiarrhythmic drug therapy when recurrences are
frequent and mild. Beta-adrenergic antagonist medication
ay be effective in patients who develop AF only during
ercise, but a single, specific inciting cause rarely accounts
r all episodes of AF, and the majority of patients do not
stain sinus rhythm without antiarrhythmic therapy. Selec-
on of an appropriate agent is based first on safety, tailored to
hatever underlying heart disease may be present, consider-
g the number and pattern of prior episodes of AF (742).
In patients with lone AF, a beta blocker may be tried first,
t flecainide, propafenone, and sotalol are particularly ef-
ctive. Amiodarone and dofetilide are recommended as
ternative therapies. Quinidine, procainamide, and disopyr-
ide are not favored unless amiodarone fails or is contra-
dicated. For patients with vagally induced AF, however, the
ticholinergic activity of long-acting disopyramide makes it
relatively attractive theoretical choice. In that situation,
ecainide and amiodarone represent secondary and tertiary
eatment options, respectively, whereas propafenone is not
commended because its (weak) intrinsic beta-blocking ac-
vity may aggravate vagally mediated paroxysmal AF. In
tients with adrenergically mediated AF, beta blockers
present first-line treatment, followed by sotalol and amio-
rone. In patients with adrenergically mediated lone AF,
iodarone represents a less appealing selection. Vagally
duced AF can occur by itself, but more typically it is part of
e overall patient profile. In patients with nocturnal AF, the
ssibility of sleep apnea should be considered (see Fig. 15).
When treatment with a single antiarrhythmic drug fails,
mbinations may be tried. Useful combinations include a
ta blocker, sotalol, or amiodarone with a class IC agent.
he combination of a calcium channel blocker, such as
ltiazem, with a class IC agent, such as flecainide or
opafenone, is advantageous in some patients. A drug that is
itially safe may become proarrhythmic if coronary disease
HF develops or if the patient begins other medication that
erts a proarrhythmic interaction. Thus, the patient should
alerted to the potential significance of such symptoms as
ncope, angina, or dyspnea and warned about the use of
ncardiac drugs that might prolong the QT interval. A useful
urce of information on this topic is the Internet site
tp://www.torsades.org.
The optimum method for monitoring antiarrhythmic drug
eatment varies with the agent involved as well as with
tient factors. Prospectively acquired data on upper limits of
ug-induced prolongation of QRS duration or QT interval
e not available. Given recommendations represent the
nsensus of the writing committee. With class IC drugs,
olongation of the QRS interval should not exceed 50%.
xercise testing may help detect QRS widening that occurs
ly at rapid heart rates (use-dependent conduction slowing).
or class IA or class III drugs, with the possible exception of
iodarone, the corrected QT interval in sinus rhythm should
kept below 520 ms. During follow-up, plasma potassiumd magnesium levels and renal function should be checked
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ulation and predisposes to proarrhythmia. In individual
tients, serial noninvasive assessment of LV function is
dicated, especially when clinical HF develops during treat-
ent of AF.
.3.3. Selection of Antiarrhythmic Agents in Patients
ith Cardiac Diseases
harmacological management algorithms to maintain sinus
ythm in patients with AF (see Figs. 13, 14, 15, and 16) and
plications in specific cardiac disease states are based on
ailable evidence and extrapolated from experience with
ese agents in other situations.
.3.3.1. HEART FAILURE
atients with HF are particularly prone to the ventricular
oarrhythmic effects of antiarrhythmic drugs because of
yocardial vulnerability and electrolyte imbalance. Random-
ed trials have demonstrated the safety of amiodarone and
fetilide (given separately) in patients with HF (501,743),
d these are the recommended drugs for maintenance of
nus rhythm in patients with AF in the presence of HF.
In a subgroup analysis of data from the Congestive Heart
ailure Survival Trial of Antiarrhythmic Therapy (CHF-
TAT) study (738), amiodarone reduced the incidence of AF
er 4 y in patients with HF to 4% compared with 8% with
acebo. Conversion to sinus rhythm occurred in 31% of
tients on amiodarone versus 8% with placebo and was
sociated with significantly better survival.
The Danish Investigations of Arrhythmias and Mortality
Dofetilide in Heart Failure (DIAMOND-CHF) trial ran-
mized 1518 patients with symptomatic HF. In a substudy
506 patients with HF and AF or atrial flutter (501,588),
fetilide (0.5 mg twice daily initiated in hospital) increased
e probability of sinus rhythm after 1 y to 79% compared
ith 42% with placebo. In the dofetilide group, 44% of
tients with AF converted to sinus rhythm compared with
% in the placebo group. Dofetilide had no effect on
ortality, but the combined endpoint of all-cause mortality
d HF hospitalization was lower in the treated group than
ith placebo (501,588). Torsades de pointes developed in 25
tients treated with dofetilide (3.3%), and three-quarters of
ese events occurred within the first 3 d of treatment.
Patients with LV dysfunction and persistent AF should be
eated with beta blockers and ACE inhibitors and/or angio-
nsin II receptor antagonists, because these agents help
ntrol the heart rate, improve ventricular function, and
olong survival (744–747). In patients with HF or LV
sfunction post-MI, ACE inhibitor therapy reduced the
cidence of AF (36,748,749). In a retrospective analysis of
tients with LV dysfunction in the SOLVD trials (38),
alapril reduced the incidence of AF by 78% relative to
acebo. In the CHARM and Val-HeFT studies, angiotensin
receptor antagonists given in combination with ACE
hibitors were superior to ACE inhibitors alone for preven-
on of AF. A post hoc analysis of the Cardiac Insufficiency
isoprolol Study (CIBIS II), however, found no impact of
soprolol on survival or hospitalization for HF in patients
ith AF (750). In the Carvedilol Post-Infarct Survival Con- mol in Left Ventricular Dysfunction (CAPRICORN) (751)
d Carvedilol Prospective Randomized Cumulative Survival
OPERNICUS) trials (752), AF and atrial flutter were more
mmon in the placebo groups than in patients treated with
rvedilol. Retrospective analysis of patients in the U.S.
arvedilol Heart Failure Trial program with AF complicating
F (753) suggested that carvedilol improved LV ejection
action. In a study by Khand et al (754), the combination of
rvedilol and digoxin reduced symptoms, improved ventric-
ar function, and improved ventricular rate control compared
ith either agent alone.
.3.3.2. CORONARY ARTERY DISEASE
stable patients with CAD, beta blockers may be considered
rst, although their use is supported by only 2 studies
83,587) and data on efficacy for maintenance of sinus
ythm in patients with persistent AF after cardioversion are
t convincing (583). When antiarrhythmic therapy beyond
ta blockers is needed for control of AF in survivors of acute
I, several randomized trials have demonstrated that sotalol
55), amiodarone (756,757), dofetilide (758), and azimilide
51) have neutral effects on survival. Sotalol has substantial
ta-blocking activity and may be the preferred initial anti-
rhythmic agent in patients with AF who have ischemic
art disease, because it is associated with less long-term
xicity than amiodarone. Amiodarone increases the risk of
adyarrhythmia requiring permanent pacemaker implanta-
on in elderly patients with AF who have previously sus-
ined MI (759) but may be preferred over sotalol in patients
ith HF (755–757). Neither flecainide nor propafenone is
commended in these situations, but quinidine, procain-
ide, and disopyramide may be considered as third-line
oices in patients with coronary disease. The Danish Inves-
gations of Arrhythmias and Mortality on Dofetilide in
yocardial Infarction (DIAMOND-MI) trial (758) involved
lected post-MI patients in whom the antiarrhythmic benefit
dofetilide balanced the risk of proarrhythmic toxicity,
aking this a second-line antiarrhythmic agent. In patients
ith coronary disease who have not developed MI or HF,
wever, it is uncertain whether the benefit of dofetilide
tweighs risk, and more experience is needed before this
ug can be recommended even as a second-line agent in such
tients.
.3.3.3. HYPERTENSIVE HEART DISEASE
ypertension is the most prevalent and potentially modifiable
dependent risk factor for the development of AF and its
mplications, including thromboembolism (760,761). Blood
essure control may become an opportune strategy for
evention of AF. Patients with LVH may face an increased
sk of torsades de pointes related to early ventricular after-
polarizations (742,762,763). Thus, class IC agents and
iodarone are preferred over type IA and type III antiar-
ythmic agents as first-line therapy. In the absence of
chemia or LVH, propafenone or flecainide is a reasonable
oice. Proarrhythmia with one agent does not predict this
sponse to another, and patients with LVH who develop
rsades de pointes during treatment with a class III agent
ay tolerate a class IC agent. Amiodarone prolongs the QT
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinesterval but carries a very low risk of ventricular proarrhyth-
ia. Its extracardiac toxicity relegates it to second-line
erapy in these individuals, but it becomes a first-line agent
the face of substantial LVH. When amiodarone and sotalol
ther fail or are inappropriate, disopyramide, quinidine, or
ocainamide represents a reasonable alternative.
Beta blockers may be the first line of treatment to maintain
nus rhythm in patients with MI, HF, and hypertension.
ompared with patients with lone AF, those with hyperten-
on are more likely to maintain sinus rhythm after cardio-
rsion of persistent AF when treated with a beta blocker
64). Drugs modulating the renin-angiotensin system reduce
ructural cardiac changes (765), and ACE inhibition was
sociated with a lower incidence of AF compared with
lcium channel blockade in patients with hypertension
ring 4.5 y of follow-up in a retrospective, longitudinal
hort study from a database of 8 million patients in a
anaged care setting (42). In patients at increased risk of
rdiovascular events, therapy with either the ACE inhibitor
mipril (766–768) or angiotensin receptor antagonist losar-
n (769,770) lowered the risk of stroke. A similar benefit has
en reported with perindopril in a subset of patients with AF
eated for prevention of recurrent stroke (771). New-onset
F and stroke were significantly reduced by losartan com-
red with atenolol in hypertensive patients with ECG-
cumented LVH, despite a similar reduction of blood
essure (41). The benefit of losartan was greater in patients
ith AF than those with sinus rhythm for the primary
mposite endpoint (cardiovascular mortality, stroke, and
I) and for cardiovascular mortality alone (772). Presum-
ly, the beneficial effects of beta blockers and drugs modu-
ting the renin-angiotensin system are at least partly related
lower blood pressure.
.3.4. Nonpharmacological Therapy for
trial Fibrillation
he inconsistent efficacy and potential toxicity of antiarrhyth-
ic drug therapies have stimulated exploration of a wide
ectrum of alternative nonpharmacological therapies for the
evention and control of AF.
.3.4.1. SURGICAL ABLATION
ver the past 25 y, surgery has contributed to understanding
both the anatomy and electrophysiology of commonly
countered arrhythmias, including the WPW syndrome, AV
dal reentry, ventricular tachycardia, and atrial tachycardia.
decade of research in the 1980s demonstrated the critical
ements necessary to cure AF surgically, including tech-
ques that entirely eliminate macroreentrant circuits in the
ria while preserving sinus node and atrial transport func-
ons. The surgical approach was based on the hypothesis that
entry is the predominant mechanism responsible for the
velopment and maintenance of AF (773), leading to the
ncept that atrial incisions at critical locations would create
rriers to conduction and prevent sustained AF. The proce-
re developed to accomplish these goals was based on the
ncept of a geographical maze, accounting for the term
aze” procedure used to describe this type of cardiac
eration (774). siSince its introduction, the procedure has gone through 3
erations (maze I, II, and III) using cut-and-sew techniques
at ensure transmural lesions to isolate the PV, connect these
viding lines to the mitral valve annulus, and create electrical
rriers in the RA that prevent macroentrant rhythms—atrial
utter or AF—from becoming sustained (775). Success rates
around 95% over 15 y of follow-up have been reported in
tients undergoing mitral valve surgery (776). Other studies
ggest success rates around 70% (777). Atrial transport
nction is maintained and, when combined with amputation
obliteration of the LAA, postoperative thromboembolic
ents are substantially reduced. Risks include death (less
an 1% when performed as an isolated procedure), the need
r permanent pacing (with right-sided lesions), recurrent
eeding requiring reoperation, impaired atrial transport func-
on, delayed atrial arrhythmias (especially atrial flutter), and
rioesophageal fistula.
Variations of the maze procedure have been investigated at
veral centers to determine the lesion sets necessary for
ccess. Studies in patients with persistent AF have demon-
rated the importance of complete lesions that extend to the
itral valve annulus; electrical isolation of the PV alone is
sociated with a lower success rate. Bipolar radiofrequency
78), cryoablation, and microwave energy have been used as
ternatives to the “cut-and-sew” technique. In one study,
aintenance of sinus rhythm following the maze procedure in
tients with AF was associated with improvement in some
pects of quality of life (348).
Despite its high success rate, the maze operation has not
en widely adopted other than for patients undergoing
rdiac surgery because of the need for cardiopulmonary
pass. A wide variety of less invasive modifications are
der investigation, including thoracoscopic and catheter-
sed epicardial techniques (777). If the efficacy of these
aptations approaches that of the endocardial maze proce-
re and they can be performed safely, they may become
ceptable alternatives for a larger proportion of patients with
F.
.3.4.2. CATHETER ABLATION
arly radiofrequency catheter ablation techniques emulated
e surgical maze procedure by introducing linear scars in the
rial endocardium (779). While the success rate was approx-
ately 40% to 50%, a relatively high complication rate
minished enthusiasm for this approach (105). The observa-
on that potentials arising in or near the ostia of the PV often
ovoked AF, and demonstration that elimination of these
ci abolished AF escalated enthusiasm for catheter-based
lation (105). Initially, areas of automaticity within the PV
ere targeted, and in a series of 45 patients with paroxysmal
F, 62% became free of symptomatic AF over a mean
llow-up of 8 mo, but 70% required multiple procedures
05). In another study, the success rate was 86% over a 6-mo
llow-up (780). Subsequent research has demonstrated that
tentials may arise in multiple regions of the RA and LA,
cluding the LA posterior wall, superior vena cava, vein of
arshall, crista terminalis, interatrial septum, and coronary
nus (109), and modification of the procedures has incorpo-
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lected patients (781).
The technique of ablation has continued to evolve from
rly attempts to target individual ectopic foci within the PV
circumferential electrical isolation of the entire PV mus-
lature. In a series of 70 patients, 73% were free from AF
llowing PV isolation without antiarrhythmic medications
ring a mean follow-up of 4 mo, but 29 patients required a
cond procedure to reach this goal. However, postablation
F may occur transiently in the first 2 mo (782). Advances
volving isolation of the PV at the antrum using a circular
apping catheter, guided by intracardiac echocardiography,
ve reportedly yielded approximately 80% freedom of
current AF or atrial flutter after the first 2 mo in patients
ith paroxysmal AF (783), but success rates were lower in
tients with cardiac dysfunction (784). Still another ap-
oach (785,786) uses a nonfluoroscopic guidance system and
diofrequency energy delivered circumferentially outside the
tia of the PV. In a series of 26 patients, 85% were free of
current AF during a mean follow-up of 9 mo, including
% taking no antiarrhythmic medications. The accumulated
perience involves nearly 4000 patients (786), with approx-
ately 90% success in cases of paroxysmal AF and 80% in
ses of persistent AF (784,787,788). Another anatomic
proach to radiofrequency catheter ablation targets complex
actionated electrograms (789), with 91% efficacy reported at
y. Restoration of sinus rhythm after catheter ablation for AF
gnificantly improved LV function, exercise capacity, symp-
ms, and quality of life (usually within the first 3 to 6 mo),
en in the presence of concurrent heart disease and when
ntricular rate control was adequate before ablation (790).
hile that study lacked a control group of patients with HF,
another study catheter ablation of AF was associated with
duced mortality and morbidity due to HF and thromboem-
lism (791).
In selected patients, radiofrequency catheter ablation of the
V node and pacemaker insertion decreased symptoms of AF
d improved quality-of-life scores compared with medica-
on therapy (363,387,388,792–794). Baseline quality-of-life
ores are generally lower for patients with AF or atrial flutter
an for those undergoing ablation for other arrhythmias
95). A meta-analysis of 10 studies of patients with AF (389)
und improvement in both symptoms and quality-of-life
ores after ablation and pacing. Although these studies
volved selected patients who remained in AF, the consistent
provement suggests that quality of life was impaired before
tervention. Two studies have described improvement in
mptoms and quality of life after radiofrequency catheter
lation of atrial flutter (796,797). New studies comparing
rict versus lenient rate control are under way to investigate
is issue further.
Despite these advances, the long-term efficacy of catheter
lation to prevent recurrent AF requires further study.
vailable data demonstrate 1 y or more free from recurrent
F in most (albeit carefully selected) patients (798–800). It
important to bear in mind, however, that AF can recur
ithout symptoms and be unrecognized by the patient or the
ysician. Therefore, it remains uncertain whether apparent bares represent elimination of AF or transformation into an
ymptomatic form of paroxysmal AF. The distinction has
portant implications for the duration of anticoagulation
erapy in patients with risk factors for stroke associated with
F. In addition, little information is yet available about the
te success of ablation in patients with HF and other
vanced structural heart disease, who may be less likely to
joy freedom from AF recurrence.
.3.4.2.1. Complications of Catheter-Based Ablation.
omplications of catheter ablation include the adverse events
sociated with any cardiac catheterization procedure in
dition to those specific to ablation of AF. Major complica-
ons have been reported in about 6% of procedures and
clude PV stenosis, thromboembolism, atrioesophageal fis-
la, and LA flutter (788). The initial ablation approach
rgeting PV ectopy was associated with an unacceptably
gh rate of PV stenosis (780,801), but the incidence has
amatically decreased as a result of changes in technique.
urrent approaches avoid delivering radiofrequency energy
ithin the PV and instead target areas outside the veins to
olate the ostia from the remainder of the LA conducting
ssue. Use of intracardiac echocardiographically detected
icrobubble formation to titrate radiofrequency energy has
so been reported to reduce the incidence of PV stenosis
83).
Embolic stroke is among the most serious complications of
theter-based ablation procedures in patients with AF. The
cidence varies from 0% to 5%. A higher intensity of
ticoagulation reduces the risk of thrombus formation dur-
g ablation (802). A comparison of 2 heparin dosing regi-
ens found LA thrombus in 11.2% of patients when the
tivated clotting time (ACT) was 250 to 300 s compared
ith 2.8% when the ACT was kept greater than 300 s. Based
these observations, it seems likely that more aggressive
ticoagulation may reduce the incidence of thromboembo-
sm associated with catheter-based ablation of AF.
Atrioesophageal fistula has been reported with both the
rcumferential Pappone approach (803,804) and the Haissa-
erre PV ablation techniques (804) but is relatively rare.
his complication may be more likely to occur when exten-
ve ablative lesions are applied to the posterior LA wall,
creasing the risk of atrial perforation. The typical manifes-
tions include sudden neurological symptoms or endocardi-
s, and the outcome in most cases is, unfortunately, fatal.
Depending on the ablation approach, LA flutter may
velop during treatment of AF (805), and this is typically
lated to scars created during catheter ablation. An incom-
ete line of ablation is an important predictor of postproce-
ral LA flutter, and extending the ablation line to the mitral
nulus may reduce the frequency of this complication. In
ost cases, LA flutter is amenable to further ablation (806).
3.4.2.2. Future Directions in Catheter-Based Ablation
herapy for Atrial Fibrillation. Catheter-directed ablation
AF represents a substantial achievement that promises
tter therapy for a large number of patients presently
sistant to pharmacological or electrical conversion to sinus
ythm. The limited available studies suggest that catheter-
sed ablation offers benefit to selected patients with AF, but
th
ca
Id
m
lo
so
of
su
tr
pr
ie
ra
as
fa
sh
ra
co
of
th
va
m
ti
pr
8
T
S
in
re
br
ve
ti
iz
u
m
w
br
pr
pa
ve
ti
W
av
ti
is
of
a
ti
A
st
re
at
ti
co
sy
ve
O
of
pe
lo
w
in
L
P
tr
pa
2
re
in
ag
bu
di
an
m
pr
ve
be
ex
an
ap
pe
be
va
de
re
cr
w
m
du
sw
an
de
W
or
on
ri
pa
va
re
8
In
de
co
cl
th
ni
ca
si
e165JACC Vol. 57, No. 11, 2011 Fuster et al.
March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinesese studies do not provide convincing evidence of optimum
theter positioning or absolute rates of treatment success.
entification of patients who might benefit from ablation
ust take into account both potential benefits and short- and
ng-term risks. Rates of success and complications vary,
metimes considerably, from one study to another because
patient factors, patterns of AF, criteria for definition of
ccess, duration of follow-up, and technical aspects. Regis-
ies of consecutive case series should incorporate clear and
ospectively defined outcome variables. Double-blind stud-
s are almost impossible to perform, yet there is a need for
ndomized trials in which evaluation of outcomes is blinded
to treatment modality. A comprehensive evaluation of the
vorable and adverse effects of various ablation techniques
ould include measures of quality of life and recurrence
tes compared with pharmacological strategies for rhythm
ntrol and, when this is not successful, with such techniques
rate control as AV node ablation and pacing. Generation of
ese comparative data over relatively long periods of obser-
tion would address the array of invasive and conservative
anagement approaches available for management of pa-
ents with AF and provide a valuable foundation for future
actice guidelines.
.3.4.3. SUPPRESSION OF ATRIAL FIBRILLATION
HROUGH PACING
everal studies have examined the role of atrial pacing, either
the RA alone or in more than one atrial location, to prevent
current paroxysmal AF. In patients with symptomatic
adycardia, the risk of AF is lower with atrial than with
ntricular pacing (807). In patients with sinus node dysfunc-
on and normal AV conduction, data from several random-
ed trials support atrial or dual-chamber rather than ventric-
lar pacing for prevention of AF (808 – 811). The
echanisms by which atrial pacing prevents AF in patients
ith sinus node dysfunction include prevention of
adycardia-induced dispersion of repolarization and sup-
ession of atrial premature beats. Atrial or dual-chamber
cing also maintains AV synchrony, preventing retrograde
ntriculoatrial conduction that can cause valvular regurgita-
on and stretch-induced changes in atrial electrophysiology.
hen ventricular pacing with dual-chamber devices is un-
oidable because of concomitant disease of the AV conduc-
on system, the evidence is less clear that atrial-based pacing
superior.
While atrial pacing is effective in preventing development
AF in patients with symptomatic bradycardia, its utility as
treatment for paroxysmal AF in patients without conven-
onal indications for pacing has not been proved (812). In the
trial Pacing Peri-Ablation for the Prevention of AF (PA3)
udy, patients under consideration for AV junction ablation
ceived dual-chamber pacemakers and were randomized to
rial pacing versus no pacing. There was no difference in
me to first occurrence of AF or total AF burden (812). In a
ntinuation of this study comparing atrial pacing with AV
nchronous pacing, patients were randomized to DDDR
rsus VDD node pacing after ablation of the AV junction.
nce again, there was no difference in time to first recurrence baAF or AF burden, and 42% of the patients lapsed into
rmanent AF by the end of 1 y (813).
It has been suggested that the incidence of AF may be
wer with atrial septal pacing or multisite atrial pacing than
ith pacing in the RA appendage (814). Pacing at right
teratrial septal sites results in preferential conduction to the
A via Bachmann’s bundle. Pacing from this site shortens
-wave duration and interatrial conduction time. Clinical
ials of pacing in the interatrial septum to prevent episodes of
roxysmal AF have yielded mixed results (815–817). While
small randomized trials found that atrial septal pacing
duced the number of episodes of paroxysmal AF and the
cidence of persistent AF at 1 y compared with RA append-
e pacing (815,816), a larger trial showed no effect on AF
rden despite reduction in symptomatic AF (817).
Both bi-atrial (RA appendage and either the proximal or
stal coronary sinus) and dual-site (usually RA appendage
d coronary sinus ostium) pacing have been studied as
eans of preventing AF. A small trial of biatrial pacing to
event recurrent AF found no benefit compared with con-
ntional RA pacing (818), and a larger trial revealed no
nefit from dual-site compared with single-site pacing,
cept in certain subgroups (819). The greater complexity
d more extensive apparatus required have limited the
peal of dual-site pacing.
Several algorithms have been developed to increase the
rcentage of atrial pacing time to suppress atrial premature
ats, prevent atrial pauses, and decrease atrial cycle length
riation in the hope of preventing AF. Prospective studies of
vices that incorporate these algorithms have yielded mixed
sults. In one large trial, these pacemaker algorithms de-
eased symptomatic AF burden, but the absolute difference
as small, and there was no gain in terms of quality of life,
ean number of AF episodes, hospitalizations, or mean
ration of AF detected by the pacemaker’s automatic mode-
itching algorithm (820). Other trials have failed to show
y benefit of atrial pacing in preventing AF (817,821).
In addition to pacing algorithms to prevent AF, some
vices are also capable of pacing for termination of AF.
hile efficacy has been shown for termination of more
ganized atrial tachyarrhythmias, there has been little dem-
strated effect on total AF burden (821,822).
In summary, atrial-based pacing is associated with a lower
sk of AF and stroke than ventricular-based pacing in
tients requiring pacemakers for bradyarrhythmias, but the
lue of pacing as a primary therapy for prevention of
current AF has not been proven.
.3.4.4. INTERNAL ATRIAL DEFIBRILLATORS
a sheep model of internal cardioversion of AF (354),
livery of synchronous shocks between the high RA and
ronary sinus effectively terminated episodes of AF. A
inical trial of a low-energy transvenous atrial cardioverter
at delivered a 3/3-ms biphasic waveform shock synchro-
zed to the R wave established the safety of internal atrial
rdioversion, but the energy required in patients with per-
stent AF was relatively high (mean 3.5 J) (355). Intense
sic and clinical research to find more tolerable shock
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both atrial sensing and cardioversion and ventricular
nsing and pacing in 290 patients with mean LV ejection
action greater than 50% who had not responded satisfacto-
ly to therapy with 4 antiarrhythmic drugs (355). In total, 614
isodes of AF were treated with 1497 shocks (mean 2.4
ocks per episode), and the rate of conversion to sinus
ythm was 93%. As spontaneous episodes were treated
ickly, the interval between episodes of AF lengthened.
Several available devices combining both atrial cardiover-
on and ventricular defibrillation capabilities with dual-
amber sensing and pacing have been designed to treat both
rial and ventricular arrhythmias by pacing before delivering
w- or high-energy shocks. A number of other techniques to
rminate AF by pacing are also under investigation, but
dications may be limited to atrial tachycardia and atrial
utter. Because these units accurately record the occurrence
AF, however, they provide valuable representation of AF
ntrol.
An important limitation of atrial defibrillators, unrelated to
ficacy, is that most patients find discharge energies over 1 J
comfortable without sedation requiring a medical setting,
d the mean cardioversion threshold is approximately 3 J,
aking such devices in their current form unacceptable for
ide clinical use. Optimal devices would use atrial pacing to
aintain sinus rhythm after cardioversion, and some patients
quire additional therapy to avoid frequent paroxysms of AF.
andidates for atrial cardioverters with infrequent episodes of
orly tolerated AF are typically also candidates for catheter
lation. As a result, implanted devices have limited utility,
cept for patients with LV dysfunction who are candidates
r implantable ventricular defibrillators.
.4. Special Considerations
.4.1. Postoperative AF
ECOMMENDATIONS
ASS I
Unless contraindicated, treatment with an oral beta blocker to
prevent postoperative AF is recommended for patients under-
going cardiac surgery. (Level of Evidence: A)
Administration of AV nodal blocking agents is recommended to
achieve rate control in patients who develop postoperative AF.
(Level of Evidence: B)
ASS IIa
Preoperative administration of amiodarone reduces the inci-
dence of AF in patients undergoing cardiac surgery and repre-
sents appropriate prophylactic therapy for patients at high risk
for postoperative AF. (Level of Evidence: A)
It is reasonable to restore sinus rhythm by pharmacological
cardioversion with ibutilide or direct-current cardioversion in
patients who develop postoperative AF as advised for nonsur-
gical patients. (Level of Evidence: B)
It is reasonable to administer antiarrhythmic medications in an
attempt to maintain sinus rhythm in patients with recurrent or
refractory postoperative AF, as recommended for other pa-
tients who develop AF. (Level of Evidence: B) 20It is reasonable to administer antithrombotic medication in
patients who develop postoperative AF, as recommended for
nonsurgical patients. (Level of Evidence: B)
ASS IIb
ophylactic administration of sotalol may be considered for
patients at risk of developing AF following cardiac surgery.
(Level of Evidence: B)
Although AF may occur after noncardiac surgery, the
cidence of atrial arrhythmias including AF after open-heart
rgery is between 20% and 50% (823–825), depending on
finitions and methods of detection. The incidence of
stoperative AF is increasing, perhaps more because of the
e of surgical patients than because of technical factors, and
is is associated with increased morbidity and costs.
.4.1.1. CLINICAL AND PATHOPHYSIOLOGICAL CORRELATES
ostoperative AF usually occurs within 5 d of open-heart
rgery, with a peak incidence on the second day. A number
studies have examined the predictors of AF, cost impact,
ngth of hospital stay, and the effects of various prophylactic
terventions aimed at reducing the incidence of AF
24,826–830), but many of these reflect earlier models of
tient management. In an observational study of 4657
tients undergoing coronary artery bypass graft (CABG)
rgery at 70 centers between 1996 and 2000, predictors of
F included age, a history of AF, COPD, valvular heart
sease, atrial enlargement, perioperative HF, and withdrawal
either beta blocker or ACE inhibitor medications before or
ter surgery (831) (Table 24). Many patients have none of
ese factors, however, and it is likely that the greater
llagen content of the atria in older patients or other factors
lated to the biology of aging are responsible (825) for the
eater propensity of elderly patients to develop AF after
rdiac surgery (832) (Table 24). Other contributing factors
e pericarditis (826) and increased sympathetic tone. In a
view of 8051 consecutive patients without previously doc-
ented AF (mean 64 y, 67% males) undergoing cardiac
rgery (84% involving CABG only) between 1994 and
BLE 24. Multivariate Predictors of Postoperative Atrial
rrhythmias in Patients Undergoing Myocardial
evascularization Surgery
Advanced age
Male gender
Digoxin
Peripheral arterial disease
Chronic lung disease
Valvular heart disease
Left atrial enlargement
Previous cardiac surgery
Discontinuation of beta-blocker medication
Preoperative atrial tachyarrhythmias
Pericarditis
Elevated postoperative adrenergic tone
Adapted with permission from the Society of Thoracic Surgeons (Creswell
, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial
rhythmias. Ann Thorac Surg 1993;56:539–49 (824).04, there was a strong, independent association between
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinesesity (body mass index over 30.1 kg/m2) and the develop-
ent of postoperative AF. During the index hospitalization,
F developed in 22.5% of all cases, and 52% of those over
e 85 y, compared with 6.2% of patients younger than 40 y.
mong the extremely obese, the relative risk of postoperative
F was 2.39. “Off-pump” CABG was associated with 39%
wer likelihood of developing AF than conventional on-
mp surgery, and the risk of AF correlated with the duration
cardiopulmonary bypass (833). The arrhythmia is usually
lf-correcting, and sinus rhythm resumes in more than 90%
patients by 6 to 8 wk after surgery (832), a rate of
ontaneous resolution higher than for other forms of AF.
atients with postoperative AF have a higher inpatient mor-
lity than patients without this arrhythmia (4.7% vs. 2.1%)
d longer hospital stay (median difference 2 d) (831). In
other study, postoperative AF was an independent predictor
long-term mortality (adjusted odds ratio [OR] 1.5, p less
an 0.001 in retrospective cohort, and OR 3.4, p 0.0018 in
case-control analysis) over 4 to 5 y (834).
.4.1.2. PREVENTION OF POSTOPERATIVE AF
meta-analysis of 13 randomized trials of prophylactic
tiarrhythmic therapy involving 1783 patients undergoing
rdiac surgery in which effects on hospital length of stay
ere addressed found that while these consistently showed
creases in the incidence of AF, the effects on hospital stay
ere less concordant and amounted to a 1.0 plus or minus
2 d overall decrease in length of hospital stay (p less than
001) (835). A systematic Cochrane database review found
studies with a total of 8565 participants in which inter-
ntions included amiodarone, beta blockers, solatol, and
cing. By meta-analysis, the effect size for prevention of
roke by prophylactic treatment for AF was not statistically
gnificant, nor was the effect on length or cost of hospital
ay. Beta blockers had the greatest magnitude of effect across
trials (4074 patients) (836). In a meta-analysis of 24 trials
25) limited to patients with ejection fraction greater than
% undergoing CABG, prophylactic administration of beta-
ocker medication protected against supraventricular tachy-
rdia (OR 0.28, 95% CI 0.21 to 0.36). In a meta-analysis of
trials including 3840 patients, sotalol (80 or 120 mg twice
ily) was more effective in reducing postoperative AF than
ther other beta-blocker medication or placebo (829), but the
sults were not confirmed in another study (491), in which
e difference between sotalol and beta-blocker treatment was
all.
When the prophylactic value of amiodarone, 600 mg per
y, initiated at least 7 d preoperatively, was evaluated in 124
tients undergoing cardiac surgery, the incidence of AF was
% in the treated group compared with 53% in patients
ndomized to placebo (p  0.003) (837). This approach is
practical unless patients are identified and treatment started
least 1 wk before surgery. The Amiodarone Reduction in
oronary Heart (ARCH) trial involving 300 patients found
at postoperative intravenous administration of amiodarone
g daily for 2 d) reduced the incidence of postoperative AF
om 47% to 35% compared with placebo (p  0.01). The
gher overall incidence of postoperative AF and less pro-
unced prophylactic effect than in other studies may have hien partly related to less-frequent use of beta blockers (838).
ore convincing evidence of the efficacy of amiodarone for
evention of AF in patients undergoing cardiac surgery
mes from the Prophylactic Oral Amiodarone for the Pre-
ntion of Arrhythmias that Begin Early after Revasculariza-
on, Valve Replacement, or Repair (PAPABEAR) trial, in
hich a 13-d perioperative course of oral amiodarone (10
g/kg daily beginning 6 d before and continuing for 6 d after
rgery) halved the incidence of postoperative atrial tachyar-
ythmias, including AF patients undergoing CABG, valve
placement, or valve repair surgery with or without CABG
rgery (839). Although efficacy was evident whether or not
ta-blocking medication was given concurrently, rates of
ta-blocker therapy withdrawal were not reported; hence,
fferential withdrawal of beta blockers from more patients in
e placebo group may have exaggerated the apparent effect
amiodarone (840).
Pretreatment with either digoxin or verapamil does not
liably prevent postoperative AF (825,841,842). Results
ith procainamide have been inconsistent, and this drug is
t widely used for prevention of postoperative AF (843).
ne report suggested that n-3 polyunsaturated fatty acids may
effective for prevention of AF in patients undergoing
ABG surgery (844).
There is limited evidence that single-chamber and biatrial
erdrive pacing prevents postoperative AF. In a randomized
ial involving 132 patients undergoing CABG, postoperative
atrial pacing significantly reduced the incidence of AF in
e biatrial pacing group by 12.5% compared with the other 3
oups (36% LA pacing, 33% RA pacing, and 42% without
cing; p  0.05). The length of hospital stay was also
gnificantly reduced in the biatrial pacing group (845). A
eta-analysis of 10 randomized trials comparing various
pes of atrial pacing to routine care after CABG surgery
und that AF was reduced by RA pacing (OR 0.68, 95% CI
39 to 1.19), LA pacing (OR 0.57, 95% CI 0.28 to 1.16), and
atrial pacing (OR 0.46, 95% CI 0.30 to 0.71), but the
mber of enrolled patients was small and the pacing sites
d protocols varied (846). Available data suggest that
atrial pacing may be superior to either LA or RA pacing for
evention of postoperative AF, but evidence is insufficient to
rmit firm conclusions or recommendations about this pro-
ylactic modality.
.4.1.3. TREATMENT OF POSTOPERATIVE AF
omorbidity including adrenergic stress often makes it diffi-
lt to control the ventricular rate in patients with postoper-
ive AF. Short-acting beta-blocker agents are particularly
eful when hemodynamic instability is a concern. Other AV
dal blocking agents, such as the nondihydropyridine cal-
um channel antagonist agents, can be used as alternatives,
t digoxin is less effective when adrenergic tone is high.
travenous amiodarone has been associated with improved
modynamics in this setting (379).
Given the self-limited course of postoperative AF, direct-
rrent cardioversion is usually unnecessary except when the
rhythmia develops in the early hypothermic period. In the
ghly symptomatic patient or when rate control is difficult to
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98hieve, cardioversion may be performed using the same
ecautions regarding anticoagulation as in nonsurgical cases.
variety of pharmacological agents, including amiodarone
37,838,847), procainamide (841), ibutilide, and sotalol,
ay be effective to convert AF to sinus rhythm. Although a
ass III agent (e.g., ibutilide) was more effective than placebo
r treatment of postoperative AF in one study (848), oral
talol is appealing in this situation because its beta-blocking
tion slows the ventricular rate and proarrhythmic toxicity is
latively infrequent, but this agent seems less effective than
hers for cardioversion of AF.
A number of studies have shown an increased risk of stroke
post-CABG patients. Accordingly, anticoagulation with hep-
in or oral anticoagulation is appropriate when AF persists
nger than 48 h (849,850). This entails special challenges
cause of the greater potential for bleeding in surgical patients.
he choice of drug, heparin and/or an oral anticoagulant, must
based on the individual clinical situation.
Atrial flutter is less common than AF after cardiac surgery
51), but pharmacological therapy is similar. Prevention of
stoperative atrial flutter is as difficult as prevention of AF,
t atrial overdrive pacing is generally useful for termination
atrial flutter when epicardial electrodes are in place.
.4.2. Acute Myocardial Infarction
ECOMMENDATIONS
ASS I
Direct-current cardioversion is recommended for patients with
severe hemodynamic compromise or intractable ischemia, or
when adequate rate control cannot be achieved with pharma-
cological agents in patients with acute MI and AF. (Level of
Evidence: C)
Intravenous administration of amiodarone is recommended to
slow a rapid ventricular response to AF and improve LV
function in patients with acute MI. (Level of Evidence: C)
Intravenous beta blockers and nondihydropyridine calcium
antagonists are recommended to slow a rapid ventricular
response to AF in patients with acute MI who do not display
clinical LV dysfunction, bronchospasm, or AV block. (Level of
Evidence: C)
For patients with AF and acute MI, administration of unfrac-
tionated heparin by either continuous intravenous infusion or
intermittent subcutaneous injection is recommended in a dose
sufficient to prolong the activated partial thromboplastin time
to 1.5 to 2.0 times the control value, unless contraindications
to anticoagulation exist. (Level of Evidence: C)
ASS IIa
travenous administration of digitalis is reasonable to slow a
rapid ventricular response and improve LV function in patients
with acute MI and AF associated with severe LV dysfunction
and HF. (Level of Evidence: C)
ASS III
e administration of class IC antiarrhythmic drugs is not recom-
mended in patients with AF in the setting of acute MI. (Level of
Evidence: C)
Estimates of the incidence of AF in patients with acute MI
ry depending on the population sampled. In the Coopera-ve Cardiovascular Project, 22% of Medicare beneficiaries
y or older hospitalized for acute MI had AF (270). In the
randolapril Cardiac Evaluation (TRACE) study of patients
ith LV dysfunction associated with acute MI, 21% had AF
52). Lower rates of AF were observed in patients selected
r other prospective trials, such as the Global Utilization of
treptokinase and Tissue Plasminogen Activator for Oc-
uded Coronary Arteries (GUSTO-I) study, in which the
cidence was 10.4% (853), but this may reflect the younger
e of patients presenting with acute MI associated with
T-segment elevation on the ECG. AF is more commonly
sociated with acute MI in older patients and those with
gher Killip class or LV dysfunction.
AF is associated with increased in-hospital mortality in the
tting of acute MI (25.3% with AF vs. 16.0% without AF),
-d mortality (29.3% vs. 19.1%), and 1-y mortality (48.3%
. 32.7%) (270). Patients who developed AF during hospi-
lization had a worse prognosis than those with AF on
mission (270). Stroke rates are also increased in patients
ith MI and AF compared with those without AF (853).
utcomes for patients with AF and acute MI have improved
the thrombolytic era compared with prior experience, but a
roke rate of 3.1% (853) emphasizes the importance of this
sociation in contemporary clinical practice.
Specific recommendations for management of patients
ith AF in the setting of acute MI are based primarily on
nsensus, because no adequate trials have tested alternative
rategies. The recommendations in this document are in-
nded to comply with the ACC/AHA Guidelines for the
anagement of Patients With ST-Elevation Myocardial In-
rction (854). Physicians should apply the guidelines for
anagement outlined elsewhere in this document with em-
asis on recognition of AF and risk stratification and
cognize the significance of the arrhythmia as an indepen-
nt predictor of poor long-term outcome in patients with
ute MI (855,856).
Urgent direct-current cardioversion is appropriate in acute
I patients presenting with AF and intractable ischemia or
modynamic instability. Intravenous administration of a
ta blocker is indicated for rate control in patients with acute
I to reduce myocardial oxygen demands. Digoxin is an
propriate alternative for patients with acute MI associated
ith severe LV dysfunction and HF. Anticoagulants are
dicated in those with large anterior infarcts and in survivors
acute MI who develop persistent AF. Treatment with ACE
hibitors appears to reduce the incidence of AF in patients
ith LV dysfunction after acute MI (857). In patients with
duced LV systolic function after MI, the placebo-controlled
APRICORN trial demonstrated a significant reduction in
e incidence of AF and/or atrial flutter in patients treated
ith carvedilol (5.4% vs. 2.3%) (858).
.4.3. Wolff-Parkinson-White (WPW)
reexcitation Syndromes
ECOMMENDATIONS
ASS I
Catheter ablation of the accessory pathway is recommended in
symptomatic patients with AF who have WPW syndrome,
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinesparticularly those with syncope due to rapid heart rate or those
with a short bypass tract refractory period. (Level of Evidence: B)
Immediate direct-current cardioversion is recommended to
prevent ventricular fibrillation in patients with a short antero-
grade bypass tract refractory period in whom AF occurs with a
rapid ventricular response associated with hemodynamic insta-
bility. (Level of Evidence: B)
Intravenous procainamide or ibutilide is recommended to re-
store sinus rhythm in patients with WPW in whom AF occurs
without hemodynamic instability in association with a wide
QRS complex on the ECG (greater than or equal to 120-ms
duration) or with a rapid preexcited ventricular response.
(Level of Evidence: C)
ASS IIa
travenous flecainide or direct-current cardioversion is reason-
able when very rapid ventricular rates occur in patients with AF
involving conduction over an accessory pathway. (Level of
Evidence: B)
ASS IIb
may be reasonable to administer intravenous quinidine, procain-
amide, disopyramide, ibutilide, or amiodarone to hemodynam-
ically stable patients with AF involving conduction over an
accessory pathway. (Level of Evidence: B)
ASS III
travenous administration of digitalis glycosides or nondihydro-
pyridine calcium channel antagonists is not recommended in
patients with WPW syndrome who have preexcited ventricular
activation during AF. (Level of Evidence: B)
Although the most feared complication of AF in patients
ith WPW syndrome is ventricular fibrillation and sudden
ath resulting from antegrade conduction of atrial impulses
ross a bypass tract, this actually occurs infrequently. The
cidence of sudden death ranges from 0% to 0.6% per year
patients with WPW syndrome (460,634,823,859). In con-
ast, a large population-based study in Olmsted County,
innesota, found 4 newly diagnosed cases of WPW syn-
ome per 100 000 people per year. There were only 2 sudden
aths over 1338 patient-y of follow-up, however. Among
3 patients with WPW syndrome, 6 had documented AF and
had atrial flutter. Patients with WPW syndrome at high risk
sudden death are those with short antegrade bypass tract
fractory periods (less than 250 ms) and short R-R intervals
ring preexcited AF (180 plus or minus 29 ms) (178,860). In
tients prone to ventricular fibrillation, there is also a higher
cidence of multiple pathways (178).
When a patient with a preexcited tachycardia is clinically
able, intravenous procainamide may be given to convert AF
sinus rhythm. It is critically important to avoid agents with
e potential to increase the refractoriness of the AV node,
hich could encourage preferential conduction over the
cessory pathway. Specifically, administration of AV nodal
ocking agents such as digoxin, diltiazem, or verapamil is
ntraindicated. Beta blockers are ineffective in this situation,
d their administration via the intravenous route may have
verse hemodynamic effects.
Flecainide can slow the ventricular rate in patients who
ve AF associated with a very rapid tachycardia due to an cocessory pathway and may terminate AF (861–864) by
olonging the shortest preexcited cycle length during AF.
ropafenone seems less effective in this respect (861).
For patients with preexcitation syndromes and AF who
ve syncope (suggesting rapid heart rate) or a short antero-
ade bypass tract refractory period, immediate direct-current
rdioversion followed by catheter ablation of the accessory
thway is the preferred therapy (865). Ablation of the bypass
act does not necessarily prevent AF, however, especially in
der patients, and additional pharmacological therapy may
required. Once the accessory pathway has been eliminated,
e selection of pharmacological therapy can parallel that for
tients without preexcitation.
.4.4. Hyperthyroidism
ECOMMENDATIONS
ASS I
Administration of a beta blocker is recommended to control
the rate of ventricular response in patients with AF complicat-
ing thyrotoxicosis, unless contraindicated. (Level of Evidence: B)
In circumstances when a beta blocker cannot be used, admin-
istration of a nondihydropyridine calcium channel antagonist
(diltiazem or verapamil) is recommended to control the ven-
tricular rate in patients with AF and thyrotoxicosis. (Level of
Evidence: B)
In patients with AF associated with thyrotoxicosis, oral anti-
coagulation (INR 2.0 to 3.0) is recommended to prevent
thromboembolism, as recommended for AF patients with other
risk factors for stroke. (Level of Evidence: C)
Once a euthyroid state is restored, recommendations for
antithrombotic prophylaxis are the same as for patients with-
out hyperthyroidism. (Level of Evidence: C)
AF occurs in 10% to 25% of patients with hyperthyroid-
m, more commonly in men and elderly patients than in
omen or patients younger than 75 y (866). Treatment is
rected primarily toward restoring a euthyroid state, which is
ually associated with a spontaneous reversion to sinus
ythm. Antiarrhythmic drugs and direct-current cardiover-
on are generally unsuccessful while the thyrotoxic condition
rsists (867,868). Beta blockers are effective in controlling
e ventricular rate in this situation, and aggressive treatment
ith intravenous beta blockers is particularly important in
ses of thyroid storm, when high doses may be required.
ondihydropyridine calcium channel antagonists may also be
eful (869). Although specific evidence is lacking in AF
used by hyperthyroidism, oral anticoagulation is recom-
ended to prevent systemic embolism (870).
Several reports suggest that patients with AF in the setting
thyrotoxicosis, which is often associated with decompen-
ted HF, are also at high risk (418,419,422), although the
echanism underlying this enhanced embolic potential is not
ear (203,416,423). The notion of increased thromboembolic
sk in thyrotoxic AF has been challenged on the basis of
mparison with patients in sinus rhythm, and logistic regres-
on analysis found age the only independent predictor of
rebral ischemic events (319). Although 13% of patients
ith AF had ischemic cerebrovascular events (6.4% per year)
mpared with 3% of those in normal sinus rhythm (1.7% per
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ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98ar) (203,268,320), there was no adjustment for duration of
servation or time to event. When TIAs are discounted, the
creased risk of stroke in patients with AF reached statistical
gnificance (p  0.03) (319). Although it remains contro-
rsial whether patients with AF associated with thyrotoxi-
sis are at increased risk of thromboembolic cerebrovascular
ents (421), the authors of these guidelines favor treatment
ith anticoagulant medication in the absence of a specific
ntraindication, at least until a euthyroid state has been
stored and HF has been cured.
.4.5. Pregnancy
ECOMMENDATIONS
ASS I
Digoxin, a beta blocker, or a nondihydropyridine calcium chan-
nel antagonist is recommended to control the rate of ventric-
ular response in pregnant patients with AF. (Level of Evidence: C)
Direct-current cardioversion is recommended in pregnant pa-
tients who become hemodynamically unstable due to AF.
(Level of Evidence: C)
Protection against thromboembolism is recommended
throughout pregnancy for all patients with AF (except those
with lone AF and/or low thromboembolic risk). Therapy (anti-
coagulant or aspirin) should be chosen according to the stage
of pregnancy. (Level of Evidence: C)
ASS IIb
Administration of heparin may be considered during the first
trimester and last month of pregnancy for patients with AF and
risk factors for thromboembolism. Unfractionated heparin may
be administered either by continuous intravenous infusion in a
dose sufficient to prolong the activated partial thromboplastin
time to 1.5 to 2 times the control value or by intermittent
subcutaneous injection in a dose of 10 000 to 20 000 units
every 12 h, adjusted to prolong the mid-interval (6 h after
injection) activated partial thromboplastin time to 1.5 times
control. (Level of Evidence: B)
Despite the limited data available, subcutaneous administra-
tion of low-molecular-weight heparin may be considered during
the first trimester and last month of pregnancy for patients
with AF and risk factors for thromboembolism. (Level of
Evidence: C)
Administration of an oral anticoagulant may be considered
during the second trimester for pregnant patients with AF at
high thromboembolic risk. (Level of Evidence: C)
Administration of quinidine or procainamide may be considered
to achieve pharmacological cardioversion in hemodynamically
stable patients who develop AF during pregnancy. (Level of
Evidence: C)
AF is rare during pregnancy and usually has an identifiable
derlying cause, such as mitral stenosis (875), congenital
art disease (876), or hyperthyroidism (877). A rapid ven-
icular response to AF can have serious hemodynamic
nsequences for both the mother and the fetus.
In a pregnant woman who develops AF, diagnosis and
eatment of the underlying condition causing the arrhythmia
e the first priorities. The ventricular rate should be con-
olled with digoxin, a beta blocker, or a nondihydropyridine mlcium channel antagonist (878–880). All currently avail-
le antiarrhythmic drugs have the potential to cross the
acenta and enter breast milk and should therefore be
oided if possible. Quinidine (879), sotalol (881), flecainide
81), and amiodarone (870,876–878) have all been used
ccessfully during pregnancy, however, in relatively small
mbers of cases. Quinidine has the longest record of safety
pregnant women and remains the agent of choice for
armacological cardioversion of AF in this situation
97,879). In the event of hemodynamic embarrassment,
rect-current cardioversion can be performed without fetal
mage (879).
The role of anticoagulation to prevent systemic arterial
bolism has not been systematically studied in pregnant
tients with AF, but the arrhythmia is frequently associated
ith conditions that carry a high risk of thromboembolism,
cluding congenital or valvular heart disease. Consideration
ould be given to avoiding warfarin because it crosses the
acental barrier and is associated with teratogenic embryop-
hy in the first trimester and with fetal hemorrhage in the
ter stages of pregnancy (880–886). Heparin is the preferred
ticoagulant because it does not cross the placenta. The
fety and efficacy of subcutaneous unfractionated heparin or
w-molecular-weight heparin in preventing ischemic stroke
patients with AF during pregnancy have not been proved,
d experience with these agents mainly involves patients
ith prosthetic heart valves or venous thromboembolism. In
tients with prosthetic valves who have AF, unfractionated
parin can be administered either by continuous intravenous
fusion or by twice-daily subcutaneous injections in a dose
tween 10 000 and 20 000 units adjusted to prolong the
id-interval activated partial thromboplastin time to 1.5
mes the control value. The same strategies are proposed for
tients without prosthetic valves who have AF and risk
ctors for thromboembolism (887,888).
.4.6. Hypertrophic Cardiomyopathy
ECOMMENDATIONS
ASS I
ral anticoagulation (INR 2.0 to 3.0) is recommended in patients
with hypertrophic cardiomyopathy who develop AF, as for other
patients at high risk of thromboembolism. (Level of Evidence: B)
ASS IIa
ntiarrhythmic medications can be useful to prevent recurrent AF
in patients with hypertrophic cardiomyopathy. Available data
are insufficient to recommend one agent over another in this
situation, but (a) disopyramide combined with a beta blocker
or nondihydropyridine calcium channel antagonist or (b) amio-
darone alone is generally preferred. (Level of Evidence: C)
Opinions differ regarding the clinical significance of AF in
e setting of HCM. In a retrospective series of 52 patients
udied between 1960 and 1985, 89% of those patients who
veloped AF experienced hemodynamic deterioration that
as ameliorated by restoration of sinus rhythm (889). In a
ultivariate analysis of a population-based cohort of 37
tients with HCM who experienced an annual cardiac
ortality rate of 5%, AF was associated with decreased
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinesrvival (402). A lower annual mortality rate (1.3%) was
served in a single-center retrospective study of 277 patients
ith HCM. The prevalence of AF was 18%. Among the 50
ses with AF, 15 deaths were recorded, a third of which were
tributed to stroke (890). The natural history of HCM is
tter defined by the combined experience of 3 large centers
llowing 717 cases for a mean of 8 plus or minus 7 y, during
hich there were 86 deaths (12%), 51% of which were
dden (mean age 45 plus or minus 20 y). Death was
tributable to HF in 36% of the patients (mean age 56 plus or
inus 19 y) and to stroke in 13% (mean age 73 plus or minus
y). Although most sudden deaths were attributed to
ntricular arrhythmias, cardiogenic embolism may have
en underestimated as a contributory mechanism. Ten of 11
tal strokes were associated with AF. In a study of 480
tients the prevalence of AF was 22% over 9 y. AF was
sociated with an increased risk of HCM-related death (odds
tio 3.7) due to excess HF-related mortality but not sudden
rdiac death. AF patients were at increased risk for stroke
dds ratio 17.7) and severe functional limitation (odds ratio
r NYHA Class III or IV 2.8) (891).
Studies of patients with HCM and AF (892) have consis-
ntly reported a high incidence of stroke and systemic
bolism (871–874). These retrospective longitudinal stud-
s report stroke or systemic embolism in 20% to 40% of
tients with HCM and AF followed up for a mean of 4 to
y, for a thromboembolism rate of 2.4% to 7.1% per year.
addition to AF, other factors associated with systemic
bolism in patients with HCM include advanced age (874),
pertension (872), mitral annular calcification, and LA
largement (872). By multivariate analysis, age and AF
ere independent predictors of thromboembolism (874).
lthough no randomized studies of anticoagulant therapy
ve been reported, the incidence of thromboembolism in
tients with HCM and AF is high, warranting consideration
anticoagulant medication when AF persists for longer than
h or when recurrence is likely.
There have been no systematic studies of the treatment of
F in patients with HCM, but various antiarrhythmic agents,
cluding disopyramide, propafenone, and amiodarone, have
en used. Deedwania et al (738) advocate administration of
iodarone both to prevent episodes of AF and to modulate
e rate of ventricular response. The use of electrical pacing
prevent AF has not been studied.
.4.7. Pulmonary Diseases
ECOMMENDATIONS
ASS I
Correction of hypoxemia and acidosis is the recommended
primary therapeutic measure for patients who develop AF
during an acute pulmonary illness or exacerbation of chronic
pulmonary disease. (Level of Evidence: C)
A nondihydropyridine calcium channel antagonist (diltiazem or
verapamil) is recommended to control the ventricular rate in
patients with obstructive pulmonary disease who develop AF.
(Level of Evidence: C) mDirect-current cardioversion should be attempted in patients
with pulmonary disease who become hemodynamically unsta-
ble as a consequence of AF. (Level of Evidence: C)
ASS III
Theophylline and beta-adrenergic agonist agents are not rec-
ommended in patients with bronchospastic lung disease who
develop AF. (Level of Evidence: C)
Beta blockers, sotalol, propafenone, and adenosine are not
recommended in patients with obstructive lung disease who
develop AF. (Level of Evidence: C)
Supraventricular arrhythmias, including AF, are common
patients with COPD (893,894). AF has adverse prognostic
plications in patients with acute exacerbations of COPD
95). Treatment of the underlying lung disease and correc-
on of hypoxia and acid-base imbalance are of primary
portance in this situation. Theophylline and beta-
renergic agonists, which are commonly used to relieve
onchospasm, can precipitate AF and make control of the
ntricular response rate difficult. Beta blockers, sotalol,
opafenone, and adenosine are contraindicated in patients
ith bronchospasm. Rate control can usually be achieved
fely with nondihydropyridine calcium channel antagonists
96); digoxin offers no advantage over calcium channel
tagonists in this situation. Pharmacological antiarrhythmic
erapy and direct-current cardioversion may be ineffective
ainst AF unless respiratory decompensation has been cor-
cted. Intravenous flecainide may be efficacious in restoring
nus rhythm in some patients (508), however, and direct-
rrent cardioversion may be attempted in hemodynamically
stable patients. In patients refractory to drug therapy, AV
dal ablation and ventricular pacing may be necessary to
ntrol the ventricular rate. Although anticoagulation has not
en studied specifically in patients with AF due to pulmo-
ry lung disease, the general recommendations for risk-
sed antithrombotic therapy apply.
.5. Primary Prevention
lthough measures aimed at the primary prevention of AF
ve not been widely investigated, it has been suggested that
rial or AV synchronous pacing may reduce the incidence of
bsequent AF in patients with bradycardia compared with
ntricular pacing (807,808). On the other hand, studies in
tients with intermittent atrial tachyarrhythmias failed to
lustrate a general benefit of atrial pacing (808,822,897).
nother potential avenue for primary prevention has been
ggested following secondary analysis of placebo-controlled
ials of treatment with ACE inhibitors (36,749). In the LIFE
1) and CHARM (898) trials, the angiotensin receptor
tagonists losartan and candesartan reduced the incidence of
F in hypertensive patients with LVH (41) and symptomatic
F (40,898), respectively. These results, together with their
vorable safety profile compared with antiarrhythmic agents,
ggest a role for ACE inhibitors or angiotensin receptor
tagonists for primary prevention of initial or recurrent
isodes of AF associated with hypertension, MI, HF, or
abetes mellitus. An overview of 11 clinical trials involving
ore than 56 000 patients with different underlying cardio-
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ceptor blockers may reduce the occurrence and recurrence
AF (43).
Yet inadequately explored, the use of statins has also been
ggested to protect against AF (335,899), and dietary lipid
mponents may influence the propensity of patients to
velop AF (900). In 449 patients with CAD followed for 5 y,
atin therapy reduced the incidence of AF—an effect not
served with other lipid-lowering drugs (899). In a canine
erile pericarditis model, atorvastatin prevented atrial
ectrophysiological and structural changes associated with
flammation and reduced the incidence of AF (119). Insuf-
cient data are available at this time to permit recommenda-
ons for primary prevention of AF in populations at risk
ing dietary interventions, pharmacological interventions, or
cing or other devices.
. Proposed Management Strategies
.1. Overview of Algorithms for Management
f Patients With Atrial Fibrillation
anagement of patients with AF requires knowledge of its
ttern of presentation (paroxysmal, persistent, or perma-
nt), underlying conditions, and decisions about restoration
d maintenance of sinus rhythm, control of the ventricular
te, and antithrombotic therapy. These issues are addressed
the various management algorithms for each presentation
AF (see Figs. 13, 14, 15, and 16).
.1.1. Newly Discovered Atrial Fibrillation
is not always clear whether the initial presentation of AF is
tually the first episode, particularly in patients with minimal
no symptoms related to the arrhythmia. In patients who
ve self-limited episodes of AF, antiarrhythmic drugs are
ually unnecessary to prevent recurrence unless AF is
sociated with severe symptoms related to hypotension,
yocardial ischemia, or HF. Regarding anticoagulation, the
sults of the AFFIRM study (296) indicate that patients with
F who are at high risk for stroke on the basis of identified
sk factors generally benefit from anticoagulation even after
nus rhythm has been restored. Therefore, unless there is a
ear reversible precipitating factor for AF, such as hyperthy-
idism that has been corrected, the diagnosis of AF in a
tient with risk factors for thromboembolism should prompt
ng-term anticoagulation.
When AF persists, one option is to accept progression to
rmanent AF, with attention to antithrombotic therapy and
ntrol of the ventricular rate. Although it may seem reason-
le to make at least one attempt to restore sinus rhythm, the
FFIRM study showed no difference in survival or quality of
fe with rate-control compared with rhythm-control strate-
es (296). Other trials that addressed this issue reached
milar conclusions (293,294,343,344). Hence, the decision to
tempt restoration of sinus rhythm should be based on the
verity of arrhythmia-related symptoms and the potential
sk of antiarrhythmic drugs. If the decision is made to
tempt to restore and maintain sinus rhythm, then anticoag-
ation and rate control are important before cardioversion.
lthough long-term antiarrhythmic therapy may not be ageded to prevent recurrent AF after cardioversion, short-
rm therapy may be beneficial. In patients with AF that has
en present for more than 3 mo, early recurrence is common
ter cardioversion. In such cases, antiarrhythmic medication
ay be initiated before cardioversion (after adequate antico-
ulation) to reduce the likelihood of recurrence, and the
ration of drug therapy would be brief (e.g., 1 mo).
.1.2. Recurrent Paroxysmal Atrial Fibrillation
patients who experience brief or minimally symptomatic
currences of paroxysmal AF, it is reasonable to avoid
tiarrhythmic drugs, but troublesome symptoms generally
ll for suppressive antiarrhythmic therapy. Rate control and
evention of thromboembolism are appropriate in both
tuations. In a given patient, several antiarrhythmic drugs
ay be effective, and the initial selection is based mainly on
fety and tolerability (see Fig. 15). For individuals with no
minimal heart disease, flecainide, propafenone, or sotalol is
commended as initial antiarrhythmic therapy because these
ugs are generally well tolerated and carry relatively little
sk of toxicity. For patients with recurrent episodes of
mptomatic AF who tolerate these agents, an as-needed,
ll-in-the-pocket approach may reduce the risk of toxicity
mpared with sustained therapy. When these drugs prove
effective or are associated with side effects, the second- or
ird-line choices include amiodarone, dofetilide, disopyr-
ide, procainamide, or quinidine, all of which carry greater
tential for adverse reactions. As an alternative to treatment
ith amiodarone or dofetilide when first-line antiarrhythmic
ugs fail or are not tolerated, PV isolation or LA substrate
odification may be considered. When a consistent initiating
enario suggests vagally mediated AF, drugs such as diso-
ramide or flecainide are appropriate initial agents, and a
ta blocker or sotalol is suggested for patients with adren-
gically induced AF. In particularly symptomatic patients,
npharmacological options such as LA ablation may be
nsidered when antiarrhythmic drug treatment alone fails to
ntrol the arrhythmia.
Many patients with organic heart disease can be broadly
tegorized into those with HF, CAD, or hypertension. Other
pes of heart disease can be associated with AF, and the
inician must determine which category best describes the
dividual patient. For patients with HF, safety data support
e selection of amiodarone or dofetilide to maintain sinus
ythm. Patients with CAD often require beta blocker medi-
tion, and sotalol, a drug with both beta-blocking activity
d primary antiarrhythmic efficacy, is considered first, un-
ss the patient has HF. Amiodarone and dofetilide are
nsidered secondary agents, and the clinician should con-
der disopyramide, procainamide, or quinidine on an indi-
dual basis.
The selection of antiarrhythmic drugs for patients with a
story of hypertension is confounded by the dearth of
ospective, controlled trials comparing the safety and effi-
cy of drug therapy for AF. In patients with hypertension
ithout LVH, drugs such as flecainide and propafenone,
hich do not prolong repolarization or the QT interval, may
fer a safety advantage and are recommended first. If these
ents either prove ineffective or produce side effects, then
am
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March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinesiodarone, dofetilide, or sotalol represents an appropriate
condary choice. Disopyramide, procainamide, and quini-
ne are considered third-line agents in this situation. Hyper-
ophied myocardium may be prone to proarrhythmic toxicity
d torsades de pointes ventricular tachycardia. Amiodarone
suggested as first-line therapy in patients with LVH
cause of its relative safety compared with several other
ents. Because neither ECG nor echocardiography reliably
tects LVH as defined by measurement of myocardial mass,
inicians may face a conundrum.
The scarcity of data from randomized trials of antiarrhyth-
ic medications for treatment of patients with AF applies
nerally to all patient groups. Accordingly, the drug-
lection algorithm presented here has been developed by
nsensus and is subject to revision as additional evidence
erges.
.1.3. Recurrent Persistent Atrial Fibrillation
atients with minimal or no symptoms referable to AF who
ve undergone at least one attempt to restore sinus rhythm
ay remain in AF after recurrence, with therapy for rate
ntrol and prevention of thromboembolism as needed. Al-
rnatively, those with symptoms favoring sinus rhythm
ould be treated with an antiarrhythmic agent (in addition to
edications for rate control and anticoagulation) before
rdioversion. The selection of an antiarrhythmic drug should
based on the same algorithm used for patients with
current paroxysmal AF. If patients remain symptomatic
ith heart rate control, and antiarrhythmic medication is
ther not tolerated or ineffective, then nonpharmacological
erapies may be considered. These include LA ablation, the
aze operation, and AV nodal ablation and pacing..1.4. Permanent Atrial Fibrillation
ermanent AF is the designation given to cases in which
nus rhythm cannot be sustained after cardioversion of AF or
hen the patient and physician have decided to allow AF to
ntinue without further efforts to restore sinus rhythm. It is
portant to maintain control of the ventricular rate and to
e antithrombotic therapy, as outlined elsewhere in this
cument, for all patients in this category.
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E angiotensin-converting enzyme
T activated clotting time
TIVE-W Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events
ONIS American-Australian Trial with Dronedarone in Atrial Fibrillation or Flutter Patients for Maintenance of Sinus Rhythm
atrial fibrillation
ASAK Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation
-CHF Atrial Fibrillation and Congestive Heart Failure
FIRM Atrial Fibrillation Follow-up Investigation of Rhythm Management
I Atrial Fibrillation Investigators
FA Etude en Activité Libérale sur la Fibrillation Auriculaire
P atrial naturetic peptide
T Ablate and Pace Trial
CH Amiodarone Reduction in Coronary Heart
RIA Anticoagulation and Risk Factors in Atrial Fibrillation
atrioventricular
ATAF Boston Area Anticoagulation Trial for Atrial Fibrillation
P B-type natriuretic peptide
BG coronary artery bypass
D coronary artery disease
FA Canadian Atrial Fibrillation Anticoagulation
PRICORN Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction trial
ADS2 Cardiac Failure, Hypertension, Age, Diabetes, Stroke [Doubled]
AMP Combined Hemotherapy and Mortality Prevention Study
ARM Candesartan in Heart failure, Assessment of Reduction in Mortality and morbidity
F-STAT Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure
confidence interval
BIS Cardiac Insufficiency Bisoprolol Study
MET Carvedilol Or Metoprolol European Trial
NSENSUS Co-operative North Scandinavian Enalapril Survival Study
PERNICUS Carvedilol Prospective Randomized Cumulative Survival
PD Chronic obstructive pulmonary disorder
P C-reactive protein
GF connective tissue growth factor
F-1 type 1 collagen volume fraction
AMOND Danish Investigations of Arrhythmias and Mortality on Dofetilide
AMOND-MI Danish Investigations of Arrhythmia and Mortality on Dofetilide–Myocardial Infarction
FT European Atrial Fibrillation Trial
G electrocardiogram
AT Embolism in the Left Atrial Thrombi
ERALD European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide study
electrophysiological
K-2-mRNA extracellular signal-regulated kinase messenger-RNA
P effective refractory period
PS II European Stroke Prevention Study II
RIDIS European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for Maintenance of Sinus Rhythm
AACS The French Fluindione-Aspirin Combination in High Risk Patients With AF
SICA Grupo Estudio de la Sobrevida en la Insufficienca Cardiaca en Argentina (V)
STO-1 Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
M hypertrophic cardiomyopathy
heart failure
T CAFÉ How to Treat Chronic Atrial Fibrillation
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011 Summary Table
EW SECTION)
ee the Summary Table in the 2011 Focused Update (Ap-
ndix 3) for a summary of evidence supporting the focused
ppendix III. Continued
V heart rate variability
P-2 atrial insulin-like growth factor-II
R international normalized ratio
AF immediate recurrence of atrial fib
C inferior vena cava
left atrium
A LA appendage
SAF Low-dose Aspirin, Stroke, Atrial F
FE Losartan Intervention For End Poi
WH low-molecular-weight heparin
left ventricle
ERIT-HF Metropolol CR/XL Randomized Int
I myocardial infarction
MP-2 matrix metalloproteinase 2
SPEAF National Study for Prevention of E
FAC Prevention of atrial fibrillation afte
PABEAR Prevention of Arrhythmias that Be
TAF Prevention of Arterial Thromboem
VE Post AV Node Ablation Evaluation
AF Pharmacological Intervention in A
pulmonary veins
right atrium
AS renin-angiotensin-aldosterone sys
CE Rate Control vs. Electrical cardiov
right ventricular
FE-T Sotalol Amiodarone Atrial Fibrillat
FIRE-D Symptomatic Atrial Fibrillation Inv
C spontaneous echo contrast
FA Studio Italiano Fibrillazione Atriale
LVD Studies of Left Ventricular Dysfun
PAT Suppression of paroxysmal atrial
AF Stroke Prevention in Atrial Fibrilla
INAF Stroke Prevention in Nonrheumat
ORTIF Stroke Prevention using an Oral D
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